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Maternal blood pressures are important arterial marker for hypertension and 
cardiovascular outcomes in the women and their offspring. While the 
determinants and consequences of hypertension in pregnancy are well studied 
in the literature, few have examined the components and the quantitative 
nature of blood pressures during pregnancy, particularly in Asian women. 
Therefore, the aims of this thesis are twofold: (1) to examine the influence of 
maternal lifestyle factors (adiposity and plasma polyunsaturated fatty acids 
[PUFAs]) on blood pressures and (2) the impact of blood pressures on 
offspring health outcomes (size at birth and early childhood blood pressures) 
in a cohort of Southeast-Asian Chinese, Malay and Indian women.  
Data were obtained from 1162 pregnant women who were recruited for 
the “Growing Up in Singapore Towards healthy Outcomes” (GUSTO). 
Maternal blood pressures (peripheral and central) were measured using 
automated oscillometric device and radial pulse wave analysis during GUSTO 
study follow-up at 26 - 28 weeks gestation. Anthropometric measures and 
blood samples were also taken at the same visit. Of the 1162 GUSTO study 
participants, 829 (71.3%) had evaluable peripheral and central blood 
pressures, and they were follow-up till delivery and at 36 months post-
delivery. These women were included in the analysis of the four studies 
included in this thesis. 
 In determining the influence of maternal lifestyle factors on blood 
pressures, cross-sectional analysis of GUSTO data on the respective influences 
of maternal adiposity and plasma PUFA levels on peripheral and central blood 
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pressures measured at 26 - 28 weeks gestation were performed. Findings 
showed positive maternal adiposity-blood pressure relations and inverse 
relations between maternal n-3 PUFA and blood pressures. An ethnic 
modification effect was also observed for the two relations, with stronger 
estimates observed in Chinese women than Malay or Indian women. 
 On the consequences of higher maternal blood pressures on health 
outcomes (size at birth and early childhood blood pressures) in the offspring, 
analysis of data on women with complete information at delivery and 36 
months post-delivery were performed. First, on the outcome of offspring size 
at birth, findings showed that higher maternal peripheral and central blood 
pressures were associated with smaller offspring and an increased risk of 
delivering offspring of low birth weight and small for gestational age. 
Maternal adiposity modified the relations, with stronger inverse association in 
normal weight women than overweight or obese women. Although the effect 
modification by maternal ethnicity was not statistically significant, Chinese 
women with higher blood pressures tended to have smaller offspring. Second, 
on the outcome of early childhood blood pressures, findings showed positive 
maternal-offspring blood pressure relations which persisted even in 
normotensive women who were free of hypertension during pregnancy. No 
significant effect modification by maternal ethnicity was observed. 
These findings suggest that maintaining blood pressure compliance during 
pregnancy is important to ensure optimal fetal growth and development. 
Therefore, preventive strategies incorporating healthy lifestyle during 
pregnancy, such as maintaining appropriate range of weight gain and healthy 
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diet with optimal n-3 fatty acids intake may be useful adjuncts to current 




LIST OF TABLES 
Table 2-1. Characteristics of GUSTO Study Participants……………………19 
Table 2-2. Type and Sequence of Information Collected in the  
GUSTO Study………………………………………………………………..20 
Table 3-1. Evidence Table for the Association between Maternal  
Body Mass Index (BMI) and Blood Pressures……………………………….26 
Table 3-2. Maternal Characteristics by Categories of Body Mass  
Index (BMI) at 2nd Trimester…………………………………………………35 
Table 3-3. Associations between 2nd Trimester Obesity Measures  
And Blood Pressures…………………………………………………………38 
Table 3-4. Associations between 2nd Trimester Obesity Measures  
and Blood Pressures: Stratified by Maternal Ethnicity ……………………...39 
Table 3-5. Associations between 2nd Trimester Obesity Measures  
and Blood Pressures: Stratified by Glycaemic Status ……………………….41 
Table 3-6. Association between 2nd Trimester Obesity Measures  
and Blood Pressures: Joint Stratification by Maternal Ethnicity and  
Glycaemic Status…………………………………………………….............43  
Supplemental Table 3-1. Maternal Characteristics by Study  
Inclusion to the Present Study……………………………………………….50 
Supplemental Table 3-2. Associations between 2nd Trimester BMI  
Categories (WHO International and Asian Classifications)  
and Blood Pressures………………………………………………………….51 
X 
 
Table 4-1: Evidence Table for the Association between n-3 and n-6  
PUFAs and Blood pressure Outcomes in Pregnancy (Randomised  
Controlled Trials)…………………………………………………………….55 
Table 4-2: Evidence Table for the Association between n-3 and n-6  
PUFAs and Blood pressure Outcomes in Pregnancy (Observational  
Studies)……………………………………………………………………….58 
Table 4-3. Characteristics of Women by Tertiles of Plasma PC n-3  
and n-6 Polyunsaturated Fatty Acids (PUFAs) at 26 – 28 Weeks 
Gestation……………………………………………………………………...68
      
Table 4-4. Composition of Maternal Plasma PC Fatty Acids (% of  
Total Fatty Acids) at 26 - 28 Weeks Gestation by Ethnicity…………………70   
Table 4-5. Multivariate Adjusted Association between Maternal  
Plasma PC n-3 PUFAs and Blood Pressures at 26 - 28 Weeks  
Gestation………………………………………………………….……. …….72 
Table 4-6. Multivariate Adjusted Association between Maternal  
Plasma PC n-6 PUFAs and Blood Pressures at 26 - 28 Weeks  
Gestation……………………………………………………………...............75 
Table 4-7. Multivariate Adjusted Relation of Maternal Plasma PC n-3  
and 6 PUFAs at 26 - 28 Weeks Gestation with Pregnancy Associated 
Hypertension…………………………………………………………………78 
Supplemental Table 4-1. Characteristics of Women Included and  
Excluded from the Analysis …………………………………………............85 
XI 
 
Supplemental Table 4-2. Composition of Maternal Plasma PC PUFAs 
 (% of Total Fatty Acids) at 26 – 28 Weeks Gestation by Fish Oil 
Supplementation Status………………………………………………............87 
Supplemental Table 4-3. Sensitivity Analysis for the Association  
between Maternal Plasma PC n-3 PUFAs and Blood Pressures at 26 – 28 
Weeks Gestation……………………………………………………………...88 
Supplemental Table 4-4. Association between Maternal Plasma PC  
n-3 PUFAs and Blood Pressures at 26 - 28 Weeks Gestation in Women 
without Fish Oil Supplementation………………………………….………...90 
Supplemental Table 4-5. Sensitivity Analysis for the Association  
between Maternal Plasma PC n-6 PUFAs and Blood Pressures at  
26 - 28 Weeks Gestation………………………………………………..........92 
Supplemental Table 4-6. Association between Maternal Plasma PC  
n-6 PUFAs and Blood Pressures at 26 - 28 Weeks Gestation in  
Women without Fish Oil Supplementation ………………………………….94 
Supplemental Table 4-7. Association between Maternal Plasma PC  
n-3 PUFA and Blood Pressures at 26 - 28 Weeks Gestation:  
Stratified by Ethnicity………………………………………………………..96 
Supplemental Table 4-8. Association between Maternal Plasma PC  
n-6 PUFAs and Blood Pressures at 26 - 28 Weeks Gestation:  
Stratified by Ethnicity………………………………………………..............99 
Table 5-1: Evidence Table for the Associations between Maternal  
Blood Pressures, Hypertension and Birth Weight ………………………….104 
XII 
 
Tale 5-2 Distribution of Maternal Blood Pressures by Maternal  
Characteristics…………………………………………………………........115 
Table 5-3 Associations between Blood Pressures (Per 1-SD Increase)  
and Size At Birth………………………………..…………….……………117 
Table 5-4 Associations between Blood Pressures (Per 1-SD Increase)  
and Size At Birth By Maternal Ethnicity…………………………………...119 
Table 5-5 Associations between Blood Pressures (Per 1-SD Increase)  
and Size at Birth by Maternal BMI…………………………………………121 
Table 5-6. The association between Maternal Blood Pressures  
(Per 1-SD Increase) and Low Birth Weight and Small for  
Gestational Age……………………………………………………………..124 
Supplemental Table 5-1. Maternal Characteristics by Study Inclusion  
to the Present Study…………………………………………………………130 
Supplemental Table 5-2. Sensitivity Analysis for Per 1-SD Increase in 
Maternal Blood Pressures and Size at Birth………………………………...132 
Supplemental Table 5-3. Per 1-SD Increase in Maternal Blood  
Pressures and Size at Birth by Maternal BMI in Tertiles……………… …..135 
Supplemental Table 5-4. Per 1-SD Increase in Maternal Blood  
Pressures and Gestational Age Adjusted SD Scores of Birth Size 
Outcomes………………………………………………………………. …..137 
Supplemental Table 5-5. Per 1-SD Increase in Maternal Blood  
Pressures and Gestational Age Adjusted SD Scores of Birth Size  
XIII 
 
outcomes by Maternal Ethnicity……………………………………............138 
Supplemental Table 5-6. Per 1-SD Increase in Maternal Blood  
Pressures and Gestational Age Adjusted SD Scores of Birth Size  
Outcomes by Maternal BMI According to WHO Classification…………...140 
Table 6-1. Evidence Table for the Associations between Maternal 
Hypertension and Offspring Blood Pressures………………………………145 
Table 6-2.Distribution of Maternal Blood Pressures by Maternal and  
Offspring’s Characteristics…………………………………………….. …..155 
Table 6-3. Maternal and Offspring Blood Pressures by Maternal  
Hypertension …………………………………………………………….....157 
Table 6-4. Estimated Increases in Offspring Peripheral Blood  
Pressures, Each 1-mmHg Increase in Maternal Blood Pressures…...……...158 
Supplemental Table 6-1. Characteristics of Women and Their Offspring, 
Comparing Those Included and Excluded From Analysis…........................166 
Supplemental Table 6-2. Partial Correlations between Maternal and  
Offspring’s Anthropometry and Blood Pressure Measures…….……..........167 
Supplementary Table 6-3. Estimated Increases in Offspring Peripheral  
Blood Pressures, Each 1-mmHg Increase in Maternal Blood Pressures in  
Chinese, Malay and Indian Women…………………………………...........168 
Supplementary Table 6-4. Estimated Increases in Offspring Peripheral  
Blood Pressures, Each 1-mmHg Increase in Maternal Blood Pressures in  
Male and Female Offspring………………………………………………...169 
XIV 
 
Supplemental Table 6-5. Estimated Increases in Offspring Peripheral  
Blood Pressures, Each 1-mmHg Increase in Maternal Blood Pressures in  
All Women and Non-Hypertensive Women………………………………..170 
Supplemental Table 6-6. Estimated Mean Difference in Offspring Peripheral 
Blood Pressures, Maternal Blood Pressures at 85th Percentile or Higher, in  





LIST OF FIGURES 
Figure 1-1. Aortic Pressure Waveform within a Cardiac Cycle….....................5 
Figure 1-2. Aortic Pressure Waveforms in Normotensive Person  
(A) Person with Arterial Stiffness (B)…………………………………. ……...7 
Figure 1-3. Conceptual Framework of Pathways for the Relations Between 
Maternal Adiposity, Plasma Polyunsaturated Fatty Acids (PUFA), Blood 
Pressures, Offspring Size at Birth and Blood Pressures at 3 years Old……...14 
Figure 2-1. Response Rates for GUSTO Study Measures …………………..21 
Figure 3-1.  Flow Chart of the GUSTO Study Sample Selected for  
Analysis………………………………………………………………………31 
Figure 4-1. Flow Chart of the GUSTO Study Sample Selected for  
Analysis ……………………………………………………………………...62 
Figure 4-2. Multivariate Adjusted Association between Maternal  
Plasma PC n-3 PUFAs (Tertiles) and Blood Pressures at 26 – 28  
Weeks Gestation ………………………………………..……………………71       
Figure 4-3. Multivariate Adjusted Association between Maternal  
Plasma PC n-6 PUFAs (Tertiles) and Blood Pressures at 26 – 28  
Weeks Gestation ………………………………………………………. …….74   
Figure 5-1. Flow Chart of the GUSTO Study Sample Selected for  
Analysis……………………………………………………………………..110 
Figure 6-1. Flow Chart of the GUSTO Study Sample Selected for  
Analysis……………………………………………………………………..150    
XVI 
 
Figure 6-2. Each 1-mmHg increase in Maternal Blood Pressures at  
26 – 28 Weeks Gestation and Offspring Blood Pressures …………………159 
Figure 6-3. Maternal Blood Pressures at 85th Percentile or Higher at  
26 – 28 Weeks Gestation and Offspring Blood Pressures………………….160 




LIST OF ABBREVIATIONS 
AA  Arachidonic acid  
ALA   α-linolenic acid 
ALSPAC Avon Longitudinal Study of Parents and Children  
BMI  Body mass index 
CI  Confidence interval 
DBP  Diastolic blood pressure 
DM  Diabetes mellitus 
DHA    Docosahexaenoic acid 
EPA   Eicosapentaenoic acid; 
GDM  Gestational diabetes 
GH  Gestational hypertension 
GUSTO Growing Up in Singapore Towards healthy Outcomes 
HUNT Study Helseundersøkelsen i Nord-Trøndelag) Study  
IOM  Institute of Medicine 
LBW  Low birth weight 
LA  Linoleic acid 
MAP  Mean arterial pressure 
XVIII 
 
MUFA  Monounsaturated fatty acids 
OR  Odds ratio 
PC  Phosphatidylcholine 
PE  Preeclampsia 
PP  Pulse pressure  
PUFA  Polyunsaturated fatty acids 
RCT  Randomised clinical trials 
RR  Risk ratio 
SBP  Systolic blood pressure 
SD  Standard deviation 
SFA  Saturated fatty acid 
SGA  Small for gestational age 




LIST OF APPENDICES 
Appendix 1: Recruitment Visit 1st Clinic Visit Questionnaire 
Appendix 2: Week 26 – 28 Clinic Visit Interviewer-administered 
Questionnaire (Mother) 
Appendix 3: Edinburgh Postnatal Depression Scale 
Appendix 4: Anthropometric Measurements for Participants (Parents and 
Children) 
Appendix 5: Procedures for using BPro and A-PULSE CASP 
Appendix 6: Measuring Blood Pressure by Dynamap CARESCAPETM V100 














Hypertension is a global public health issue, contributing to the burden of 
heart disease, stroke, kidney failure, premature disability and mortality among 
women,1-4 According to World Health Organization report in 2013, 
hypertension accounts for 45% of deaths from heart disease and 51% of deaths 
due to stroke.5 In women, hypertension during pregnancy has been shown to 
have higher risk to cardiovascular and metabolic outcomes later on in life.1, 2 
Metaanalysis from a systematic review of more than 43 studies has 
demonstrated that women with preeclampsia have a 2.3 fold increase risk to a 
clinical diagnosis of cardiovascular disease or a fatal outcome; and a 1.8 fold 
to hypertension and 2 fold to diabetes in later life.2  
In pregnancy, cardiovascular adaptation is one of the major physiological 
changes, occurring as early as 8 weeks gestation.6 In the pregnant women, 
reduction in blood pressures from systemic vasodilation and reduced vascular 
resistance are important physiological changes as it maintains the circulatory 
system during pregnancy,6, 7 while ensuring adequate fetal supply for optimal 
growth and development.8-10  
By convention, blood pressures from the brachial arm is often taken, as 
central blood pressures are not amenable to non-invasive measurement. But 
with the advent of non-invasive acquisition of pulse wave analysis, central 
blood pressures may be estimated with high reliability11-13 and 
reproducibility.14-16 In the literature, central systolic and pulse pressures, as 
indicators of cardiovascular adaptation, have been suggested to be surrogate 
markers of arterial stiffness.17 There are pressure differences between central 
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and peripheral sites, for example, between the aorta and brachial artery, and 
this is due to amplification effects which is influenced by aging and 
medication.18  
Blood pressure follows a normal distribution in the population and have a 
graded relationship to cardiovascular outcomes.19 Findings from 
epidemiological studies suggest that maternal blood pressures during 
pregnancy are associated with systemic disorders, genetic and environmental 
factors.20, 21 In turn, higher maternal blood pressures are also associated with 
adverse health outcomes in the women and their offspring.20, 22 However, 
findings from these studies are based on peripheral blood pressures, and few 
have evaluated central blood pressures. Moreover, few have examined the 
continuous distribution of maternal peripheral and central blood pressures. 
Study findings based on prevailing definitions of hypertension which depend 
on peripheral blood pressures thresholds for treatment benefits, may overlook 
the properties of systolic, diastolic or pulse pressures, and are of limited value 
for epidemiologic purposes.  
Given the public health importance of hypertension, targeting women 
early, before or during pregnancy through lifestyle modification measures may 
be a useful strategy in reducing maternal risk to hypertension during 
pregnancy and later on in life. Therefore, the focus of this thesis includes the 
influence of lifestyle factors on maternal adiposity and nutrition (plasma 
polyunsaturated fatty acids) as determinants of maternal blood pressures; and 
in turn, the consequences of maternal blood pressures on offspring size at birth 
and early childhood blood pressures. 
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1.2 The Arterial System in Pregnancy 
The arterial tree in the circulatory system is thought to be a static, elastic 
system, and the pressure along the arterial tree is determined by the physical 
factors, being the arterial blood volume and arterial compliance.23 These 
physical factors, in turn, are affected by the physiological factors which 
include cardiac output (as determined by heart rate and stroke volume) and 
peripheral resistance.23  During pregnancy, the cardiac chambers dilates,6, 24 
and the arterial tree undergoes structural changes rendering it to be more 
compliant.25 The structural changes include fragmentation of the reticular 
fibers, a reduction in acid mucopolysaccharides and normal corrugation of 
elastic fibers, hypertrophy and hyperplasia of smooth muscle cells,26 and 
increase in aortic diameter.27 Collectively, these changes enhance the arterial 
distensibility and capacitance,23, 28 thereby increasing arterial compliance.7  
1.2.1 Physiological Changes and Arterial Blood Pressures 
Cardiovascular changes in pregnancy are characterized by increased blood 
volume and cardiac output.6 Concurrent decrease in systemic vascular 
resistance and blood pressures occur in proportion to these increases.6, 20 
Overall, these shifts reflect the enhanced aortic distensibility modulated by the 
endothelium-dependent factors such as nitric oxide synthesis upregulated by 
oestradiaol and prostaglandins.6, 20, 24 It is well accepted that peripheral blood 
pressures start to decrease in early pregnancy till mid-trimester at 22-24 weeks 
gestation and gradually towards pre-pregnancy level until term.6, 29, 30 
Systolic and diastolic blood pressures reflect the peak and trough of the 
blood pressure at each cardiac cycle (Figure 1-1).31, 32 Pulse pressure, 
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measured as the difference between systolic and diastolic blood pressures, is 
dependent on the arterial blood volume and arterial capacitance. It is therefore 
function of arterial compliance.23  
 
Figure 1-1.  Aortic Pressure Waveform within a Cardiac Cycle 
Source32: Van Varik B, Rennenberg R, Reutelingsperger C, Kroon A, de 
Leeuw P, Schurgers LJ. Mechanisms of arterial remodeling: Lessons from 
genetic diseases. Frontiers in Genetics. 2012;3 
 
Due to pulse wave amplification effects, systolic and pulse pressures 
differ along the arterial tree,28, 33, 34  and therefore, they reflect the pulsatile 
components of blood pressure.35 Conversely, diastolic blood pressure reflects 
the tonic component of blood pressure as it is unaffected by amplification 
effects.36 Unlike systolic or pulse pressures, diastolic blood pressure is 
assumed to be constant along the arterial tree. 
During a cardiac cycle, pressure waves are amplified as they travel from 
the aorta to the periphery, and thereby augmenting the systolic and pulse 
pressures in the periphery.23, 37 Pressure wave amplification is more marked in 
healthy conduit arteries, particularly in the young, at a brachial to aortic pulse 
pressure ratio of 1 to 5.35 With aging or arterial diseases, pressure wave 
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amplification decreases and the gap between peripheral and central pressures 
narrows.23, 35   
Although physiological studies have found that blood pressures change 
continuously within a cardiac cycle, peripheral systolic and diastolic blood 
pressures taken from the brachial artery is thought to reflect the pressure 
throughout the large conduit arteries.30, 38-41  During pregnancy, changes 
central blood pressures occur in parallel with peripheral brachial blood 
pressures across pregnancy trimesters.29, 30 However, compared to peripheral 
brachial pressures, pregnancy associated changes in central aortic pressure are 
more marked due to pulse wave amplification effects.30, 41 
1.2.2 Basic Mechanisms in Arterial Hypertension 
Hypertension is essentially due to increased peripheral resistance and decrease 
in arterial distensibility.20, 23, 28 At higher blood pressures or hypertension, the 
central arteries are larger and stiffer, thereby leading to higher aortic 
impedance.28 The higher amplitude of the incident pressure wave at 
ventricular ejection and earlier return of the reflected pressure wave from the 
peripheral arteries contribute to a disproportionate increase in systolic blood 




Figure 1-2.  Aortic Pressure Waveforms in Normotensive Person (A) 
Person with Arterial Stiffness (B). 
 
Source43: Stoner L, Young JM, Fryer S. Assessments of arterial stiffness and 




In persistent hypertension, arterial degeneration occurs prematurely and 
accelerates as seen in aging.28 The central aorta becomes larger and stiffer to a 
greater extent, while the peripheral arteries undergoes intimal hyperplasia, 
atherosclerosis and impaired endothelial function.20, 28 Reactive vascular 
changes in the kidneys may also occur, leading to further vasoconstriction, salt 
retention and increase blood volume through the activation of the renal-
angiotensin aldosterone system.21, 28, 32 
In pregnancy, the key features underlying the development of 
preeclampsia, a severe form of pregnancy hypertension, are inadequate 
placentation, exaggerated inflammatory response and endothelial 
dysfunction.21, 44  To date, the pathophysiology underlying preeclampsia is 
unknown and various propositions from inadequate placentation, hypoxia, 
immune maladaptation, renin-angiotensin-aldosterone imbalance, excessive 
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oxidative stress to genetic susceptibility have been proposed.44, 45 As 
inadequate placentation is key to preeclampsia, there has been considerable 
focus on abnormal placentation and the development of preeclampsia.6, 21, 45, 46  
At the initial stage of disease development, inadequate placentation is 
observed in the first half of the pregnancy and thereafter, uteroplacental 
ischaemic changes is observed, causing abnormal placental perfusion. In turn, 
the ischaemic placenta leads to increase in cytokines release or deportation of 
syncytiotrophoblast particles into the maternal circulation.6, 46 These factors 
triggers a widespread microvascular damage and endothelium dysfunction in 
the pregnant women and consequently the overt presentation of hypertension 
and proteinuria.6, 45 
1.2.3 Classifications of Pregnancy Hypertension 
Current definitions for pregnancy hypertension based on guidelines from the 
Australasian Society for the Study of Hypertension in Pregnancy (ASSHP),47 
National Institute for Health and Clinical Excellence (NICE)48 and American’s 
College of Obstetricians and Gynaecologist (ACOG),49 is defined as systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; and 
it is differentiated by gestation, with hypertension occurring before 20 weeks 
gestation as chronic hypertension and those after as gestational hypertension 
(previously known as pregnancy induced hypertension). Preeclampsia, as 
defined by hypertension and proteinuria (≥ 0.3g protein in a 24-hour urine 
specimen) occurring after 20 weeks gestation, is a spectrum of disorder as it 
may be accompanied by other signs and symptoms involving the renal, liver, 
neurological, haematological and fetal growth restriction.47-49  
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Although these guidelines share similarities in the definition for 
gestational hypertension and preeclampsia, there are subtle differences. For 
example, the definition for preeclampsia by ASSHP47 included hypertension 
and any criteria from proteinuria to any other clinical signs and symptoms 
involving the renal, liver, neurological, haematological and fetal growth 
restriction; but not the NICE48 and ACOG49 guidelines. Moreover, past criteria 
such as edema and sudden increase in systolic or diastolic blood pressures 
based on the 30-15 mmHg rule were no longer included in the definition of 
preeclampsia but have been retained in the guidelines as important signs of 
preeclampsia. More specifically, (1) sudden or rapid development of edema is 
abnormal and women should be aware of the need to seek medical attention in 
the NICE48 and ASSHP47 guidelines and (2) sudden change in blood pressures 
is retained in the ACOG49 guideline only, with an emphasis on warranting 
further investigation. 
1.2.4 Methods of Measuring Arterial Blood Pressures 
By convention, blood pressures are taken from the non-dominant arm at the 
brachial artery using either a sphygmomanometer or an oscillometric device.50  
When blood pressures are determined using a sphygmomanometer, the 
systolic and diastolic blood pressures may be estimated by the palpatory or 
auscultatory method on the brachial artery based on the Korotkoff sounds.31, 50  
However, like all measuring devices, the sphygmomanometer requires 
calibration.50, 51 
In contrast to the sphygmomanometer, the oscillometric device measures 
blood pressures by utilizing a cuff with sensing and occluding functions.31, 50, 
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51 It is also simpler and less operator dependent.36 However, oscillometric 
devices are suitable only for persons with regular and stable pulse.51 
Depending on the size of the oscillation, blood pressures may be 
underestimated and in persons with very low blood pressures,31, 50 blood 
pressures may not be recordable51  For example, in elderly person with stiff 
arteries and wide pulse pressure, the mean arterial pressure will be 
underestimated.50 
Technological advances have enabled the estimation of central blood 
pressures through a non-invasive approach by measuring the carotid or radial 
artery pulse wave forms.18 From these wave forms, central blood pressures 
may be estimated through the general transfer functions, late systolic peak 
pressure or the n-point moving average technique.31, 52, 53 However, the non-
invasive measurement of central blood pressures is device dependent and 
requires calibration from peripheral blood pressures.38, 54-58 
Current methods in measuring blood pressures are susceptible to 
measurement errors compared to the gold standard of invasive measure of 
intra-arterial blood pressures.36, 50, 51, 59 In spite of the variation between 
brachial and intra-arterial blood pressures, brachial blood pressures continue to 
be an important marker for cardiovascular outcomes28, 50, 60 as it has been 
widely used in research and is well established in clinical practice. On the 
other hand, non-invasive measures of central blood pressures have shown 
good agreement with invasive measure of intra-arterial blood pressures.54 And 
over the last 15 years, non-invasive measures of central blood pressures are 
gaining widespread attention as there is evidence to suggest its role in 
prediction of cardiovascular outcomes.61-64  
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1.3 Literature on Arterial Blood Pressures during Pregnancy 
Blood pressures during pregnancy are known to be determined by socio-
demographic, lifestyle and systemic disorders.20, 28, 65-67 Among these factors, 
maternal lifestyle factors such as adiposity, diet, smoking, alcohol 
consumption and physical activity have important public health implications 
as they are modifiable risk factors for hypertension.28, 68 Amongst these 
lifestyle factors, maternal adiposity and diet (being the intake of fatty fish or n-
3 polyunsaturated fatty acids) have been commonly associated with pregnancy 
hypertension by way of inflammation, oxidative stress, dyslipidaemia, altered 
vascular and fibrinolytic functions.20, 21, 44 Therefore, a focus on the role of 
maternal adiposity and polyunsaturated fatty acids on blood pressures would 
be examined in this thesis and a brief review of literature would be presented 
accordingly in chapters 3 and 4. 
Hypertension in pregnancy is a well-established risk factor for adverse 
outcomes in the offspring, such as small for gestational age and higher blood 
pressures.20, 67 Particularly in Asian populations, these complications have 
large public health implications as the rate of small for gestational age69, 70 and 
hypertension is highest in Asia.71, 72 Although various risk factors have been 
associated with small for gestational age69, 73 and higher blood pressures in the 
offspring,65, 74 the focus in this thesis would be on the role of maternal blood 
pressures. A brief description on the current literature on the associations 
between maternal blood pressures and offspring size at birth and blood 




1.4 Current Gaps in Epidemiological Study of Arterial Blood Pressures in 
Pregnant Women 
Study on factors affecting maternal blood pressures during pregnancy is 
important as blood pressure is a known risk factor for cardiovascular risk in 
the women and her offspring later in life.20, 67 The focus on lifestyle factors, 
particularly for adiposity75-77 or diet,78, 79 have been very well studied, and 
findings from these studies have led to the development of health 
recommendations or policy changes to reduce risk of hypertension and 
cardiovascular outcomes.80, 81 Likewise for offspring health, pregnancy 
associated hypertension is strongly associated adverse outcomes such as low 
birth weight and hypertension in offspring later life. 65, 67, 74, 82 
However, the current literature in pregnant women is limited as maternal 
hypertension, instead of blood pressures are often examined, and few have 
concurrent examinations of maternal peripheral and central blood pressures. 
Moreover, the observed maternal blood pressure relations were based on 
studies that were conducted in predominantly white population and few were 
done in Asian population.  
Because blood pressure has a normal distribution and is known to vary 
between populations due to geographic and environmental factors,65 
differences in the magnitude or threshold for the lifestyle factors and blood 
pressure relations are likely to exist. For example, the lower body mass index 
(BMI) cut-offs for obesity in relation to cardiovascular risk in Asians 




Therefore, the present study is aimed to address the gaps identified from 
the review of literature. The study findings reported in this thesis will provide 
a deeper understanding on the blood pressure range and variation during 
pregnancy in relation to lifestyle factors and offspring outcomes. The study 
findings may also contribute to the health promotion and enable targeted 
monitoring or prevention programmes for Asian women and children. 
 
1.5 Study Aims and Objectives 
To address the gaps in the literature, the following studies are aimed to 
examine determinants and consequences of maternal blood pressures during 
pregnancy in an Asian birth cohort of Chinese, Malay and Indian women. The 
first aim of the study is to examine lifestyle modifiable factors that may be 
associated with blood pressures in pregnancy, and the specific study objectives 
are: 
1. To examine the relationship between maternal obesity, gestational 
diabetes and blood pressures during pregnancy. 
2. To examine the relationship between maternal plasma levels of 
polyunsaturated fatty acids and blood pressures during pregnancy. 
The 2nd aim of the study is to examine the influence of maternal blood 
pressures during pregnancy on offspring, and the specific study objectives are: 
1. To examine the relationship between maternal blood pressures during 
pregnancy and offspring size at birth. 
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2. To examine the relationship between maternal blood pressures and 
offspring blood pressures at 3 years old. 
 
Figure 1-3. Conceptual Framework of Pathways for the Relations 
Between Maternal Adiposity, Plasma Polyunsaturated Fatty Acids 
(PUFA), Blood Pressures, Offspring Size at Birth and Blood Pressures at 
3 Years Old 
As maternal adiposity, gestational diabetes, plasma PUFAs and blood 
pressures may be inter-correlated, a conceptual framework was developed to 
examine their pathways with respect to the blood pressure relations examined 
in this thesis (Figure 1-3). Maternal adiposity, gestational diabetes, plasma 
PUFAs may affect blood pressures during pregnancy, and  maternal blood 
pressures in turn, may affect offspring size at birth and blood pressures at 3 
years old. Maternal adiposity and gestational diabetes may also affect 
offspring weight and gestation at birth. Maternal ethnicity may modify the 
maternal adiposity, gestational diabetes, plasma PUFAs and blood pressure 
relations; and between maternal blood pressures and offspring size at birth and 
blood pressures at 3 years old.  
The study objectives would be addressed accordingly in the following 
chapters of this thesis. In Chapter 2, a general methodology on the overall 
study design, population and study measures would be presented. Chapters 3 
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and 4 would address the first aim of the study on the influence of maternal 
adiposity and polyunsaturated fatty acids (lifestyle modifiable factors) on 
maternal blood pressures during pregnancy. Chapters 5 and 6 would address 
the second aim of the study on the influence of maternal blood pressures on 
her offspring health in terms of weight at birth and subsequent blood pressures 
at 3 years old. Finally, in Chapters 7 and 8, the findings from the studies on 
lifestyle factors and offspring outcomes would be synthesized and discussed. 
An overall conclusion on the implications of these findings and future 














The Growing Up in Singapore Towards healthy Outcomes (GUSTO) is an 
ongoing prospective birth cohort study set up in 2009, with detailed follow-up 
of women and their offspring into early childhood.85 The GUSTO study was 
primarily designed to study epigenetic markers, and early life factors and the 
developmental pathways to metabolic disorders and altered body composition. 
The GUSTO study was conducted in Singapore, situated at the north of the 
equator (between latitudes 1o09'N and 1o29'N and longitudes 103o36'E and 
104o25'E), which is an urban city-state with a multi-ethnic society comprising 
predominantly of Chinese (76.2%), Malay (15.0%), Indian (7.4%) and others 
(1.4%).86 The study was reviewed and approved by the SingHealth and 
National Health Group Institutional and Domain Specific Review Boards. 
Written consent was also obtained from all women participating in the study. 
 
2.2 Study Design 
2.2.1 Overview 
 The GUSTO study is a prospective birth cohort study that measures exposures 
from fetal life to early childhood of the offspring. The GUSTO study 
incorporates a comprehensive measure of various phenotypic and epigenetic 
observations in the early years of the offspring. The study is conducted in two 
institutions (KK Women’s and Children’s Hospital and National University 
Hospital) that provide tertiary maternal and childcare services, with close 
collaborations with various scientists and clinicians. 
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2.2.2 Inclusion and Exclusion Criteria 
Between June 2009 and September 2010, pregnant women who were 
receiving antenatal care at KK Women’s and Children’s Hospital and National 
University Hospital at less than 14 weeks gestation were screened for study 
eligibility. Only women aged between 18 to 50 years old, citizens or 
permanent residents of Singapore with homogenous parental and spousal’s 
ethnic background (Chinese, Malay or Indian) and intending to reside in 
Singapore for the next 5 years were eligible for study participation. Women 
who were on chemotherapy, psychotropic drugs, have type 1 diabetes or 
unwilling to donate their birth tissues (umbilical cord, cord blood and 
placenta) would be excluded from the study. 
 
2.3 Study Population 
2.3.1 Pregnant Women 
From the 2034 eligible women who were screened at the two study sites, a 
total of 1162 women consented into the GUSTO main cohort. Briefly, the 
women in the main GUSTO cohort were enrolled into the study at a mean age 
30.3 ± 5.2 years old and they were predominantly Chinese (54.3%), followed 
by Malays (27.4%) and Indians (18.3%) (Table 2-1). About 32.1% of the 
women had completed tertiary education or higher. Women in the GUSTO 
cohort tended to be non-smokers and non-drinkers. About 28% of GUSTO 





Among the 1162 women in the main GUSTO cohort, 1097 (94.4%) had 
complete birth information at delivery, of which, 1087 women had singletons 
and 10 had twins. There were similar proportions of male (52.5%) and female 
(47.5%) singleton offspring. The mean gestation and weight at birth for the 
singleton offspring were 38.6 ± 1.6 weeks and 3.1 ± 0.4 kg, respectively. 
Table 2-1. Characteristics of GUSTO Study Participants 
Data are presented as mean ± SD or in column percentages (%) 
The variables with missing information for women in the GUSTO study are: 
age (n=2), ethnicity (n=2), education (n=17), parity (n=75), smoking status 
(n=66), alcohol intake (17), physical activity (n=65).  
Information on twin offspring is not included. 
Characteristics  Women Offspring 
 N=1162 N=1087 
Age at enrolment (years) 30.3 ± 5.2 - 
Ethnicity    
   Chinese 630 (54.3%) 576 (55.1%) 
   Malay 318 (27.4%) 281 (26.9%) 
   Indian 212 (18.3%) 189 (18.1%) 
Education    
   Primary to Secondary 371 (32.4%)  
   GCE/Vocational/Polytechnic 406 (35.5%)  
   Tertiary and above 368 (32.1%)  
Parity    
   Nulliparous 467 (42.9%)  
   Mulitparous 620 (57.1%)  
Smoking history    
   Non-smokers 941 (85.9%)  
   Ever smokers 155 (14.4%)  
Alcohol intake   
   None 691 (64.3%)  
   Yes 383 (35.7%)  
Physical activity    
   None to Light 809 (73.8%)  
   Moderate to Strenuous 288 (26.2%)  
Gestation at Delivery, weeks - 38.6 ± 1.6 
Birth weight, Kg - 3.1 ± 0.4 
Offspring Sex   
   Male - 571 (52.5%) 
   Female - 516 (47.4%) 
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2.4 Data Collection in the GUSTO Study 
The GUSTO study has incorporated a systematic and detailed collection of 
parental and offspring information from early pregnancy to early childhood of 
the offspring (Table 2-2). The information collected, is comprised of 
demographic, lifestyle, dietary, anthropometric, blood pressures, mental 
wellness and health outcomes such as hypertension and diabetes. A wide array 
of biological specimens from blood (maternal and cord blood), birth tissues 
(umbilical cord and placenta) and buccal smears (offspring) were collected. 
The following reflects a brief description of exposures, covariates and 
outcomes, which were examined in this thesis (Figure 2-1).  
Table 2-2. Type and Sequence of Information Collected in the GUSTO Study   
 Antenatal Visits Postnatal Visit 
 <14 weeks 26 – 28 weeks Delivery 36 months 
Women     
Questionnaires 
   Demographic 
   Socio-economic 
   Smoking 
   Alcohol 
   Physical activity 
   Dietary 
   Mental wellness 
   Medical history 
   Obstetric history 

























   Anthropometric 







   Glucose 






   Hypertension 
   Preterm birth 






Offspring     
Physical Measurements 
   Anthropometric 
   Blood pressures 


















Figure 2-1. Response Rates for GUSTO Study Measures 
2.4.1 Questionnaires 
The women in this study were interviewed by trained research coordinators at 
each GUSTO visit in early pregnancy at study enrolment and at mid-
pregnancy, between 26 – 28 weeks gestation. The questionnaires were 
designed to collect information on demographic, socio-economic, lifestyle, 
dietary, mental wellness, medical and obstetric history. The questionnaires 
were designed to collect information on demographic, socio-economic, 
Questionnaires  
 Demographic 99.8% (n=1160) 
 Socio-economic 99.8% (n=1160) 
 Medication 98.9% (n=1111) 
 
Questionnaires 
 Smoking 94.3% (n=1096) 
 Alcohol 92.4% (n=1074) 
 Physical activity 94.4% (n=1097) 
 Dietary 93.8% (n=1090) 
 Mental wellness 91.6% (n=1064) 
 Medical history 100% (n=1162) 
 Obstetric history 93.5% (n=1087)  
 Medication 80.9% (n=920) 
Physical Examination 
 Anthropometric 91.2% (n=1064) 
 Blood pressure 76.8% (n=893) 
Blood Biomarkers 
 Glucose 69.4% (n=807) 
 PUFA 85.0% (n=988) 
 
Pregnancy Outcomes 
 Hypertension 100% (n=1162) 
 Preterm birth 91.6% (n=1064) 
 Medication 100% (n=1162) 
Physical Measurements 
Anthropometric at Birth 94.3% (n=1087) 
Anthropometric at 36 Months Old 79.3% (n=862) 
Blood pressure 80.1% (n=923) 
Study Enrolment 
(< 14 Weeks Gestation) 
Offspring Follow-up 
(At Birth and at 36 Months Old) 
Mid-pregnancy Follow-up 




lifestyle, dietary, mental wellness, medical and obstetric history. In particular 
the women in the study were asked if they were ever diagnosed by a 
healthcare professional to have hypertension, diabetes, myopia. Information 
on antenatal use of medication or supplement were solicited from study 
participants at the first (<14 weeks gestation) and second (26-28 weeks 
gestation) GUSTO study visits. Overall, there were good responses (98.9% 
and 80.9%, respectively), and the information on medication collected during 
these study visits were on supplement use.  
These questionnaires were forward and backward translated into Chinese, 
Malay and Indian languages (Appendices 1-3: Recruitment Visit 1 and 26- 28 
Weeks GUSTO Visit Questionnaires; and Edinburgh Postnatal Depression 
Scale).   
2.4.2 Physical Examinations 
The physical examinations performed in the GUSTO study included 
anthropometric and blood pressures at the GUSTO mid-pregnancy study visit, 
between 26 – 28 weeks gestation. For the women, the anthropometric 
measures included were height, weight and skinfold thickness sites at biceps, 
triceps, supra-ailiac and subscapular (Appendix 4: Anthropometric 
Measurements for Participants [Parents and Children]). Peripheral blood 
pressures were taken from the brachial arm, and central blood pressures were 
estimated from radial pulse wave analysis (Appendix 5: Procedures for using 
BPro and A-PULSE CASP).  Similarly, offspring height, weight and blood 
pressures were taken at GUSTO visit at the age of 3 years old (Appendix 4 
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and 6: Measuring Blood pressures by Dynamap CARESCAPETM V100 
[General Instruction for Mother and Child]). 
2.4.3 Blood Biomarkers 
Maternal blood biomarkers were collected at GUSTO mid-pregnancy visit 
between 26 – 28 weeks gestation, in which plasma n-3 and n-6 
polyunsaturated fatty acids (PUFAs) from the fasting blood specimen, and 
glucose levels at fasting and 2-hour were determined.  
2.4.4 Pregnancy and Birth Outcomes 
Information on the offspring’s birth measurements and pregnancy 
complications were abstracted from medical records. The birth measures 
abstracted were offspring gestational age, birth weight, length and head 
circumference and placental weight. Other information included in the data 
abstraction was obstetrician’s diagnosis of preeclampsia, gestational 
hypertension and preterm birth. Information on medications prescribed during 
the intrapartum stage were also abstracted from medical records after delivery, 
and they include the use of intravenous antibiotics, intra-muscular steroids, 









MATERNAL OBESITY, GESTATIONAL DIABETES AND 
BLOOD PRESSURES DURING PREGNANCY IN SOUTH-
EAST ASIAN WOMEN  
 
This chapter was based on the paper published in J Hypertension: 
Wai-Yee Lim, Kenneth Kwek, Yap-Seng Chong, Yung-Seng Lee, 
Fabian Yap, Yiong-Huak Chan, Keith M. Godfrey, Peter D. Gluckman, 
Seang-Mei Saw and An Pan. Maternal adiposity and blood pressures in 
pregnancy: varying relations by ethnicity and gestational diabetes. J 






High blood pressure affects 10-12% of pregnancies and it is associated with 
adverse pregnancy outcomes including eclampsia, preterm birth and caesarean 
delivery.20, 22 The pathophysiology of hypertension in pregnancy is unclear, and 
a number of risk factors have been proposed, including older maternal age, 
smoking, nulliparity, previous abortions, multiple pregnancy, and obesity. 67, 87 
Previous studies have mainly focused on the relation between obesity and 
peripheral blood pressures in pregnancy (Table 3-1), 30, 77, 88-93 but less is known 
for central blood pressures, which is of interest because they reflect different 
cardiovascular adaptations compared to peripheral pressures. 94, 95  
Meanwhile, most studies of the obesity-blood pressure relation have been 
conducted in Caucasians, and studies in Asian women and particularly pregnant 
women are very limited. Furthermore, no study has specifically assessed 
differences in the obesity-blood pressure relation within Asian pregnant women 
of different ethnicities. The three major Asian ethnic groups, Chinese, Indian, 
and Malay, comprise of more than 43% of the total global population, and 
obesity has increasingly become a major public health problem in the three 
ethnicities,96, 97 with important implications for adverse pregnancy outcomes in 
the populations and potential long-term impact on the mothers and their 
offspring.75, 98 Some studies suggest that there are ethnic differences in 
predisposition to obesity within Asians,99 and obesity may be differentially 
related to insulin resistance and inflammatory markers among Chinese, Malays 




Table 3-1. Evidence Table for the Association between Maternal Body Mass Index (BMI) and Blood Pressures 
ID  Author 
/Year 
Study Design Sample size/ 
Country  










57/Norway At 14-16 weeks; 22-24; 





Pre-pregnant overweight women had higher SBP, 
DBP and MAP than those with normal pre-pregnant 
weight 
 
SBP: -6.0 (95%CI -11.4 to -0.5) mmHg;   
DBP: -4.7 (95%CI -8.8 to -0.6) mmHg;  
MAP: -4.8 (-95%CI -9.4 to -0.2) mmHg 
2 Fujime et al 







12 – 36 weeks   Central 
SBP 
 
Maternal BMI was correlated with central SBP  
(Pearson r=0.30; p<0.001) 
3 Gaillard  














Prepregnancy obesity is associated with blood 




1.03 (95%CI 0.95 to 1.10) mmHg in 1st trimester; 
0.98 (95%CI 0.91 to 1.04) mmHg in 2nd trimester;  






0.83 (95%CI 0.77 to 0.88) mmHg in 1st trimester; 
0.81 (95%CI 0.76 to 0.86) mmHg in 2nd trimester; 
0.74 (95%CI 0.69 to 0.79) mmHg in 3rd trimester. 













Overweight/ obese pre-pregnant women had higher 
SBP and DBP than pre-pregnant normal weight 
women.  
 
Overweight vs normal weight:  
9.9 mmHg (SBP); 7.5 mmHg (DBP);  
 
Obese vs normal weight:  
14.3 mmHg (SBP) and 7.9 mmHg (DBP) 
5 Thompson 















At any gestational age, mean SBP (or DBP) 
increased with increasing pre-pregnancy BMI; 
the increase however is attenuated with 
increasing pre-pregnancy BMI, particularly later 
in pregnancy 
6 Strevens 
et al/ 2002 
Prospective 
cohort 









Baseline  (early pregnancy) BMI influenced third 
trimester SBP significantly; but DBP levels were 














MAP Women with early pregnancy obesity had higher 
MAP than normal weight women 
 
Primiparous women:  
81.4(10.8) vs 88.7(12.5) mmHg at 39 weeks 
 
Multiparous women:  
79.9(9.2) vs  84.3(10.0) mmHg at 39 weeks 








Therefore, we examined the association of maternal adiposity with 
peripheral and central blood pressures as measures of arterial compliance in a 
large cohort of South Asian pregnant women in Singapore. Since the cohort 
members were from three major ethnic groups (Chinese, Malay and Indian), 
we also aimed to investigate whether the associations were modified by 
ethnicity. Lastly, as obesity and gestational diabetes are prevalent in Asian 
women,101 we assessed their independent and joint associations with blood 




The study subjects were drawn from the Growing Up in Singapore Towards 
healthy Outcomes (GUSTO) cohort study,85 which comprised of 1162 
pregnant women recruited from KK Women’s and Children’s Hospital (KKH) 
and National University Hospital (NUH) during 2009 and 2010. We recruited 
pregnant women who were Singapore citizens or permanent residents, and 
who conceived naturally and intended to deliver at the two hospitals. We only 
included pregnant women who were Chinese, Malay or Indian with 
homogenous parental ethnic background. Women with type 1 diabetes, on 
chemotherapy or psychotropic drugs were excluded. Among the 893 (76.8%) 
women who attended the GUSTO 2nd trimester study visit  for  blood 
pressures and radial pulse waves measurement, 64 women were excluded due 
to poor measurement of radial pulse wave forms and 30 women due to missing 
information on age, weight or height measurements. Therefore, data from 799 
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(89.5%) women were available for analysis (Figure 3-1). No significant 
differences in age and body mass index were found between women who were 
included and excluded from analysis because of poor measurement of radial 
pulse wave forms (Supplementary Table 3-1). The GUSTO study was 
approved by the SingHealth and National Health Group Institutional and 
Domain Specific Review Boards. 
Blood Pressure Measurement 
The blood pressures and anthropometric measurements were performed at 
mean 27 ± 1.2 weeks gestation during the GUSTO 2nd trimester study visit. 
Research coordinators were trained prior to commencement of fieldwork, and 
standard operating procedures were adopted. Participants were required to 
abstain from caffeine intake for at least 30 minutes prior to blood pressure 
measurement. Brachial systolic (SBP) and diastolic (DBP) pressures were 
measured thrice at 30–60 seconds intervals with an oscillometric device 
MC3100 (HealthSTATS International Pte Ltd, Singapore). We applied the A-
pulse tonometer (BPro®, HealthSTATS International Pte Ltd, Singapore) on 
the radial artery of the same arm, for continuous sampling of radial artery 
waveforms over 1 minute following standard procedures.12, 102 These 
waveforms were calibrated with the averaged brachial pressures to derive the 
central SBP. Central pulse pressure (PP) was calculated based on the 
difference between CASP and DBP.62 The BPro® device has shown high 










Women with BP and radial 
pulse measurement at 26 
weeks
(N=893)
Women with  BP and valid 
radial pulse wave 
measurement at 26 weeks 
(N=829)
Women with complete 
information on age, weight 
or height
(N=799)
Excluded women with 
missing  age (n=12); weight 
(n=19); height (n=11)
Excluded women with poor 
radial  waves recording 
(n=64)
Excluded those without BP 
and radial pulse 




Adiposity Measures (Body Mass Index and Skinfold Thickness)  
Maternal height and weight were measured during the 2nd trimester study visit. 
Height was measured twice to the nearest 0.1 cm, barefooted in the horizontal 
Frankfort plane using a Seca 213 Portable Stadiometer (SECA, Hamburg, 
Germany). Weight was measured to the nearest 0.1 kg using a calibrated 
weighing scale (SECA 803 electronic flat scale: SECA, Hamburg, Germany). 
Measurements were repeated if readings differed by more than 1 cm and 0.2 
kg respectively, and the average of all 3 readings were used. Body mass index 
(BMI, kg/m2) was calculated as weight in kg divided by square of height in 
meters. Skinfold thicknesses were measured at 4 sites (biceps, triceps, 
subscapular and suprailiac) following standard procedures103 using Holtain 
Tanner/Whitehouse skinfold calipers (Holtain Ltd, Crymych, United 
Kingdom). All measurements were made in triplicate to nearest 0.2 mm and 
the readings were averaged. The sum of skinfold thickness was derived by 
summating the averaged skinfold thicknesses of the 4 sites. 
Covariates 
Established risk factors for hypertension were assessed by questionnaire as 
potential confounders: maternal age, ethnicity, education, parity and pre-
existing chronic hypertension. Glycaemic status in pregnancy was ascertained 
using a 75mg oral glucose tolerance test performed at the same study visit; 
gestational diabetes was defined as fasting plasma glucose ≥7.0 mmol/l or 2 
hour glucose ≥11.1 mmol/l according to the World Health Organization 





Maternal BMI was categorized according to the WHO international 
classification105: underweight (<18.5 kg/m2), normal weight (18.5 to 24.9 
kg/m2), overweight (25.0 to 29.9 kg/m2) and obesity (≥30.0 kg/m2); and Asian 
classification 84: BMI <18.5, 18.5 to 22.9, 23.0 to 27.4, and ≥27.5 kg/m2, 
respectively. Because there were only 6 underweight women during the study 
visit and their BMIs were between 17.9 and 18.5 kg/m2, they were combined 
into the normal weight group. The sum of skinfold thickness was analysed as 
continuous and categorical (tertiles) variables. The unadjusted means and 
proportions of maternal characteristics according to BMI categories were 
compared using ANOVA and chi-square test for continuous and categorical 
variables respectively.  
We performed multivariate linear regression model to examine the 
independent relations of BMI and sum of skinfold thickness with peripheral 
and central blood pressures, adjusting for maternal age, ethnicity (Chinese, 
Malay, Indian), education (primary school or less, secondary school, tertiary 
school or more), parity (no, one, two or more live-births), current smoking 
status (yes, no), gestational diabetes (yes, no), maternal height and heart rate. 
Only 16 women had pre-existing chronic hypertension, so this variable was 
not included as a covariate due to problems with model convergence. A 
sensitivity analysis in women without pre-existing chronic hypertension 
revealed similar results (data not shown).  
Effect modification by ethnicity (Chinese, Malay, Indian) and gestational 
diabetes (yes, no) was evaluated from the multiplicative interaction term 
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between continuous BMI and the effect modifier added to the main effect 
model, and results were then stratified by ethnicity and gestational diabetes. 
We further explored these associations by joint stratification of ethnicity and 
gestational diabetes to assess their collective influences on the association 
between BMI and blood pressure outcomes. All tests performed were two-
tailed and statistical significance was set at 0.05 using Stata version 11.2 
(Statacorp, College Station, Texas). 
 
3.3 Results 
The mean BMI of the 799 women was 26.24 ± 4.44 kg/m2; 35% were 
overweight and 19% were obese (Table 3-2). Compared with normal weight 
women, obese women were more likely to have pre-existing chronic 
hypertension and gestational diabetes. The prevalence of obesity was higher in 
Malay women and those with low educational attainment. There were no 
differences in age and smoking status among obesity categories. Compared to 
normal weight women, obese women had higher skinfold thickness, pulse rate 










Table 3-2. Maternal Characteristics by Categories of Body Mass Index (BMI) at 2nd Trimestera 
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
a Data are represented as n (%) or mean ± SD where appropriate.  
P values derived from chi-squared tests for categorical variables and ANOVA for continuous variables. 
Missing values for variables: Education = 10; Parity = 32; Smoking history = 23; Gestational diabetes 
mellitus = 61 and Sum of skinfold thicknesses = 2. 
 
  
Maternal Characteristics  Overall 
2nd Trimester  Body Mass Index categories 








n 799 368 279 152  
Age  (years) 30.44 ± 5.16 30.29 ± 5.03 30.54 ± 5.32 30.59 ± 5.18 0.77 
Ethnicity      <0.001 
   Chinese 435 (54.4%) 243 (66.0%) 149 (53.4%) 43 (28.3%)  
   Malay 229 (28.7%) 75 (20.4%) 78 (27.9%) 76 (50.0%)  
   Indian 135 (16.9%) 50 (13.6%) 52 (18.7%) 33 (21.7%)  
Education      <0.001 
   Primary to secondary 256 (32.4%) 113 (31.2%) 87 (31.3%) 56 (37.6%)  
   GCE/Vocational/Polytechnic 276 (34.9%) 103 (28.4%) 112 (40.3%) 61 (40.9%)  
   Tertiary 257 (32.6%) 146 (40.3%) 79 (28.4%) 32 (21.5%)  
Parity      <0.001 
   Nulliparous 329 (42.9%) 170 (48.3%) 110 (41.0%) 49 (33.3%)  
   Multiparous 438 (57.1%) 182 (51.7%) 158 (59.0%) 98 (66.7%)  
Smoking history      0.47 
   Never smokers 673 (86.7%) 310 (86.8%) 244 (88.1%) 119 (83.8%)  
   Ever smokers 103 (13.3%) 47 (13.2%) 33 (11.9%) 23 (16.2%)  
Chronic hypertension      <0.001 
   No 773 (96.7%) 361 (99.7%) 275 (98.9%) 137 (91.9%)  
   Yes 16 (3.3%) 1 (0.3%) 3 (1.1%) 12 (8.05%)  
Gestational diabetes      0.01 
   No 602 (81.6%) 292 (86.1%) 205 (78.2%) 105 (76.6%)  
   Yes 136 (18.4%) 47 (13.9%) 57 (21.8%) 32 (23.4%)  
Sum of skinfold  
Thickness (mm)  
79.95 (19.63) 66.71 (13.35) 85.04 (14.51) 102.72 (14.83) <0.001 
Peripheral BP (mmHg)     
SBP 109.48 ± 11.21 104.62 ± 9.93 111.34 ± 9.92 117.82 ± 10.46 <0.001 
DBP 66.82 ± 8.45 63.81 ± 7.59 67.49 ± 7.87 72.93 ± 7.92 <0.001 
Central BP (mmHg)      
SBP 96.89 ± 10.09 92.81 ± 9.19 98.45 ± 8.97 103.89 ± 9.54 <0.001 
PP 30.06 ± 6.52 29.00 ± 6.29 30.96 ± 6.61 30.95 ± 6.57 <0.001 
Pulse rate (beats/minute) 104.01 ± 16.26 101.09 ± 15.96 104.20 ± 15.28 110.72 ± 16.80 <0.001 
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In a multivariable linear regression model, 2nd trimester BMI was 
significantly associated with all blood pressure outcomes (all P<0.001; Table 
3-3): the increases in blood pressures (mmHg) for each unit (kg/m2) increase 
in BMI were 1.19 [95% confidence interval (CI) 1.03-1.36] for peripheral 
SBP, 0.76 (95% CI 0.63-0.89) for peripheral DBP, 1.02 (95% CI 0.87-1.17) 
for central SBP and 0.26 (95% CI 0.16-0.37) for central PP. When we 
stratified BMI to three categories according to WHO international 
classification, overweight and obese women had significantly greater blood 
pressures compared with normal weight women. Similar trends were observed 
when maternal BMI was categorized according to the Asian classification 
(Supplemental Table 3-2). The results remained unchanged when we excluded 
the 6 underweight women from the analysis (data not shown). When using 
skinfold thickness as the adiposity measure, positive associations were 
observed with all four blood pressure outcomes (all P<0.001; Table 3-3). For 
example, each 10 mm increase in sum of skinfold thickness was associated 
with 2.17, 1.33, 2.03, and 0.69 mmHg higher peripheral SBP and DBP, central 
SBP and PP, respectively.  
We observed a significant interaction between BMI and ethnicity in 
relation to central PP (P = 0.03 for interaction; Table 3-4): each kg/m2 
increase in BMI was associated with 0.50 (95% CI 0.33-0.68) mmHg higher 
central PP in Chinese, while the corresponding point estimate was 0.15 (95% 
CI -0.01 to 0.30) in Malays and 0.06 (95% CI -0.21 to 0.32) in Indians. The 
relations of BMI with peripheral and central SBP were generally stronger in 
Chinese compared to Malays or Indians, although the interaction tests were 
not statistically significant. Similar patterns were observed when using 
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skinfold thickness as adiposity measure, but the interaction tests with ethnicity 
were not statistically significant. For example, each 10 mm increase in sum of 
skinfold thicknesses was associated with 1.01 (95% CI 0.67-1.35) mmHg 
higher central PP in Chinese, compared with 0.43 (95% CI 0.06-0.80) mmHg 
in Malays and 0.41 (95% CI -0.17 to 0.99) mmHg in Indians.  
We also found significant interactions between adiposity measures and 
gestational diabetes in relation to peripheral DBP and central SBP, with 
stronger associations in women with gestational diabetes compared to those 
without (both P<0.05 for interaction; Table 3-5). Interaction tests for 
peripheral SBP or central PP were not statistically significant, but trends for 
stronger associations were generally observed in women with gestational 
diabetes compared with normoglycaemic women.  
In the analysis jointly stratified by ethnicity and gestational diabetes, we 
found that the associations between BMI and blood pressure outcomes were 
strongest in Chinese women with gestational diabetes (Table 3-6). When 
stratified by ethnicity, interaction tests between BMI and gestational diabetes 
in relation to blood pressures (peripheral SBP, DBP and central SBP) were 
significant in Chinese women, but not in Malay or Indian women. Similarly, 
when stratified by gestational diabetes, interaction tests between BMI and 
ethnicity in relation to blood pressures (central SBP and PP) were significant 







Table 3-3. Associations between 2nd Trimester Obesity Measures and Blood Pressuresa  
 Peripheral Blood Pressures (mmHg)   Central Blood Pressures (mmHg)  
   
SBP DBP SBP PP 
N ß (95% CI) P  ß (95% CI) P  ß (95% CI)  P  ß (95% CI) P  
2nd Trimester BMI  (kg/m2)   799 1.19 (1.03 to 1.36) <0.001 0.76 (0.63 to 0.89) <0.001 1.02 (0.87 to 1.17) <0.001 0.26 (0.16 to 0.37) <0.001 
2nd Trimester BMI  (categories)           
Normal weight  (≤24.9 kg/m2) 368 Reference  Reference  Reference  Reference  
Overweight (25.0-29.9 kg/m2) 279 6.18 (4.60 to 7.76) <0.001 3.12 (1.91 to 4.33) <0.001 5.25 (3.79 to 6.71) <0.001 2.13 (1.14 to 3.12) <0.001 
Obese (≥30.0 kg/m2) 152 12.95 (10.94 to 14.95) <0.001 8.58 (7.04 to 10.11) <0.001 11.18 (9.33 to 13.02) <0.001 2.59 (1.34 to 3.86) <0.001 
          
Sum of skinfold thickness 
(per 10 mm  increase)     
797 2.17 (1.79 to 2.54) <0.001 1.33 (1.05 to 1.62) <0.001 2.03 (1.69 to 2.36) <0.001 0.69 (0.46 to 0.92) <0.001 
Sum of skinfold thickness (categories)           
First tertile (28.3-69.9 mm) 271 Reference  Reference  Reference  Reference  
Second tertile (70.0-87.2 mm) 252 2.99 (1.21 to 4.78) 0.001 1.52 (0.17 to 2.88) 0.028 2.99 (1.38 to 4.61) <0.001 1.47 (0.41 to 2.54) 0.007 
Third tertile (87.3-138.3 mm) 274 8.92 (7.08 to 10.76) <0.001 5.48 (4.09 to 6.88) <0.001 8.56 (6.89 to 10.24) <0.001 3.08 (1.98 to 4.18) <0.001 
BMI, body mass index; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure 
 
a The results were derived from multiple linear regression models with adjustment for maternal age, ethnicity, education level, parity status, smoking history, gestational 




Table 3-4. Associations between 2nd Trimester Obesity Measures and Blood Pressures: Stratified by Maternal Ethnicitya 
 Peripheral Blood Pressures (mmHg)   Central Blood Pressures (mmHg)  
   
SBP DBP SBP PP 
N ß (95% CI) P  ß (95% CI) P  ß (95% CI) P  ß (95% CI) P  
2nd Trimester BMI in Chinese women (kg/m2)  435 1.45 (1.16 to 1.74) <0.001 0.76 (0.53 to 0.98) <0.001 1.26 (0.99 to 1.53) <0.001 0.50 (0.33 to 0.68) <0.001 
2nd Trimester BMI category in Chinese women         
Normal weight  (≤24.9 kg/m2) 243 Reference  Reference  Reference  Reference  
Overweight (25.0-29.9 kg/m2) 149 6.09 (3.96 to 8.23) <0.001 2.92 (1.29 to 4.57) <0.001 5.26 (3.29 to 7.24) <0.001 2.33 (1.04 to 3.62) 
<0.00
1 
Obese (≥30.0 kg/m2) 43 14.49 (10.99 to 17.99) <0.001 8.14 (5.46 to 10.81) <0.001 12.68 (9.44 to 15.91) <0.001 4.54 (2.43 to 6.65) 
<0.00
1 
          
2nd Trimester BMI in Malay women (kg/m2)   229 0.98 (0.74 to 0.42) <0.001 0.75 (0.56 to 0.94) <0.001 0.89 (0.67 to 1.12) <0.001 0.15 (-0.01 to 0.30) 0.06 
2nd Trimester BMI category in Malay women         
Normal weight  (≤24.9 kg/m2) 75 Reference  Reference  Reference  Reference  
Overweight (25.0-29.9 kg/m2) 78 6.11 (2.92 to 9.30) <0.001 3.68 (1.25 to 6.11) 0.003 5.17 (2.26 to 8.08) 0.001 1.49 (-0.46 to 3.45) 0.13 
Obese (≥30.0 kg/m2) 76 12.06 (8.79 to 15.33) <0.001 9.13 (6.64 to 11.62) <0.001 11.07 (8.09 to 14.05) <0.001 1.94 (-0.06 to 3.94) 0.06 
          
2nd Trimester BMI in Indian women (kg/m2)   135 1.10 (0.73 to 1.48) <0.001 0.79 (0.50 to 1.08) <0.001 0.85 (0.51 to 1.19) <0.001 0.06 (-0.21 to 0.32) 0.66 
2nd Trimester BMI category  in Indian women          
Normal weight  (≤24.9 kg/m2) 50 Reference  Reference  Reference  Reference  
Overweight (25.0-29.9 kg/m2) 52 6.79 (2.84 to 10.73) 0.001 3.48 (0.42 to 6.64) 0.03 6.22 (2.65 to 9.78) 0.001 2.74 (0.03 to 5.45) 0.048 
Obese (≥30.0 kg/m2) 33 11.25 (6.83 to 15.67) <0.001 8.28 (4.85 to 11.69) <0.001 8.58 (4.59 to 12.58) <0.001 0.31 (-2.72 to 3.34) 0.84 
          
P for interaction (Ethnicity*BMI at 26 weeks)   0.17  0.92  0.31  0.03 
          
Sum of skinfold thicknesses in Chinese women 
(per 10 mm  increase)         
433 2.36 (1.78 to 2.94) <0.001 1.18 (0.74 to 1.62) <0.001 2.19 (1.66 to 2.72) <0.001 1.01 (0.67 to 1.35) 
<0.00
1 
Sum of skinfold thicknesses in Chinese women         
First tertile (28.3-69.9 mm) 170 Reference  Reference  Reference  Reference  
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Second tertile (70.0-87.2 mm) 154 2.36 (0.01 to 4.69) 0.049 1.44 (-0.34 to 3.21) 0.11 2.95 (0.81 to 5.09) 0.007 1.51 (0.16 to 2.87) 0.03 
Third tertile (87.3-138.3 mm) 109 9.18 (6.45 to 11.89) <0.001 4.14 (2.08 to 6.19) <0.001 8.72 (6.23 to 11.20) <0.001 4.58 (3.00 to 6.15) 
<0.00
1 
          
Sum of skinfold thicknesses in Malay women 
(per 10 mm  increase)         
229 1.87 (1.25 to 2.49) <0.001 1.44 (0.97 to 1.92) <0.001 1.88 (1.32 to 2.44) <0.001 0.43 (0.06 to 0.80) 0.02 
Sum of skinfold thicknesses in Malay women            
First tertile (28.3-69.9 mm) 63 Reference  Reference  Reference  Reference  
Second tertile (70.0-87.2 mm) 59 6.08 (2.38 to 9.78) 0.001 4.09 (1.29 to 6.91) 0.004 6.30 (2.98 to 9.62) <0.001 2.20 (0.05 to 4.35) 0.045 
Third tertile (87.3-138.3 mm) 107 8.79 (5.49 to 12.10) <0.001 6.89 (4.38 to 9.40) <0.001 8.86 (5.89 to 11.82) <0.001 1.96 (0.05 to 3.88) 0.045 
          
Sum of skinfold thicknesses in Indian women 
(per 10 mm  increase)         
135 2.12 (1.27 to 2.97) <0.001 1.43 (0.77 to 2.09) <0.001 1.84 (1.08 to 2.59) <0.001 0.41 (-0.17 to 0.99) 0.16 
Sum of skinfold thicknesses in Indian women           
First tertile (28.3-69.9 mm) 38 Reference  Reference  Reference  Reference  
   Second tertile (70.0-87.2 mm) 39 2.31 (-2.30 to 6.92) 0.32 -0.94 (-4.32 to 2.44) 0.58 0.12 (-3.84 to 4.09) 0.95 1.06 (-2.06 to 4.19) 0.50 
   Third tertile (87.3-138.3 mm) 58 9.03 (4.71 to 13.35) <0.001 6.98 (3.81 to 10.15) <0.001 8.38 (4.66 to 12.09) <0.001 1.39 (-1.53 to 4.33) 0.35 
          
P for interaction (Ethnicity*Sum of skinfold 
thickness) 
  0.79  0.52  0.96  0.17 
 BMI, body mass index; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure 
  a The results were derived from multiple linear regression models with adjustment for maternal age, education level, parity status, smoking history, gestational diabetes, 




Table 3-5. Associations between 2nd Trimester Obesity Measures and Blood Pressures: Stratified by Glycaemic Statusa 
 Peripheral Blood Pressures (mmHg)   Central Blood Pressures (mmHg)  
   
SBP DBP SBP PP 
N ß (95% CI) P  ß (95% CI) P  ß (95% CI) P  ß (95% CI) P  
2nd Trimester BMI in normoglycaemic 
women (kg/m2)     
602 1.16 (0.98 to 1.34) <0.001 0.70 (0.56 to 0.85) <0.001 0.98 (0.81 to 1.15) <0.001 0.27 (0.16 to 0.39) <0.001 
2nd Trimester BMI category in n 
ormoglycaemic women 
        
   Normal weight  (≤24.9 kg/m2) 292 Reference  Reference  Reference  Reference  
   Overweight (25.0-29.9 kg/m2) 205 5.43 (3.67 to 7.18) <0.001 2.73 (1.38 to 4.07) <0.001 4.46 (2.85 to 6.07) <0.001 1.73 (0.65 to 2.82) 0.002 
   Obese (≥30.0 kg/m2) 105 12.82 (10.51 to 15.12) <0.001 8.21 (6.44 to 9.97) <0.001 10.99 (8.89 to 13.11) <0.001 2.79 (1.36 to 4.22) <0.001 
          
2nd Trimester BMI in GDM women 
(kg/m2)       
136 1.31 (0.86 to 1.762) <0.001 1.04 (0.71 to 1.38) <0.001 1.19 (0.76 to 1.62) <0.001 0.15 (-0.13 to 0.43) 0.29 
2nd Trimester BMI category in GDM women          
   Normal weight  (≤24.9 kg/m2) 47 Reference  Reference  Reference  Reference  
   Overweight (25.0-29.9 kg/m2) 57 10.47 (6.43 to 14.51) <0.001 5.98 (2.91 to 9.06) <0.001 9.44 (5.62 to 13.27) <0.001 3.46 (0.93 to 5.99) 0.008 
   Obese (≥30.0 kg/m2) 32 14.85 (9.87 to 19.82) <0.001 11.65 (7.87 to 15.43) <0.001 13.82 (9.11 to 18.53) <0.001 2.17 (-0.95 to 5.29) 0.17 
          
P for interaction  
(GDM*BMI at 26 weeks) 
  0.21  0.030  0.046  0.77 
          
Sum of skinfold thicknesses in 
normoglycaemic women  
(per 10 mm  increase)         
601 1.98 (1.56 to 2.39) <0.001 1.14 (0.82 to 1.46) <0.001 1.84 (1.47 to 2.22) <0.001 0.70 (0.45 to 0.95) <0.001 
Sum of skinfold thickness in  
normoglycaemic women  
        
   First tertile (28.3-69.9 mm) 222 Reference  Reference  Reference  Reference  
   Second tertile (70.0-87.2 mm) 193 2.65 (0.69 to 4.61) 0.008 0.93 (-0.55 to 2.42) 0.22 2.59 (0.83 to 4.35) 0.004 1.66 (0.51 to 2.81) 0.005 
   Third tertile (87.3-138.3 mm) 186 8.31 (6.24 to 10.38) <0.001 4.69 (3.13 to 6.27) <0.001 7.89 (6.02 to 9.75) <0.001 3.19 (1.98 to 4.41) <0.001 
42 
 
          
Sum of skinfold thickness in GDM 
women (per 10 mm  increase)         
135 2.70 (1.61 to 3.79) <0.001 1.96 (1.14 to 2.77) <0.001 2.73 (1.72 to 3.73) <0.001 0.77 (0.12 to 1.42) 0.020 
Sum of skinfold thickness in GDM women         
   First tertile (28.3-69.9 mm) 30 Reference  Reference  Reference  Reference  
   Second tertile (70.0-87.2 mm) 42 1.51 (-3.85 to 6.88) 0.58 2.09 (-1.87 to 6.08) 0.29 2.53 (-2.42 to 7.47) 0.31 0.42 (-2.71 to 3.57) 0.79 
   Third tertile (87.3-138.3 mm) 63 9.36 (4.29 to 14.44) <0.001 7.40 (3.64 to 11.16) <0.001 10.12 (5.45 to 14.79) <0.001 2.72 (-0.24 to 5.69) 0.072 
          
P for interaction  
(GDM*Sum of skinfold thickness) 
  0.098  0.031  0.010  0.26 
BMI, body mass index; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure 
  a A total of 61 women were excluded from the analysis because of missing information on gestational diabetes status. The results were derived from multiple linear 
regression models with adjustment for maternal age, ethnicity, education level, parity status, smoking history, body height and heart rate.  
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Table 3-6. Association between 2nd Trimester Obesity Measures and Blood Pressures: Joint Stratification by Maternal Ethnicity and Glycaemic Statusa 
 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP DBP SBP PP 
Normo- 
glycaemic 
GDM Pb  
Normo- 
glycaemic 
GDM Pb  
Normo- 
glycaemic 
GDM Pb  
Normo- 
glycaemic 
GDM Pb  
BMI             
Chinese 
1.32 
(0.97 to 1.66) 
1.87 
(1.23 to 2.52) 
0.05 
0.63 
(0.36 to 0.89) 
1.14 
 (0.66 to 1.63) 
0.02 
1.07 
(0.75 to 1.39) 
1.83 
(1.22 to 2.43) 
0.003 
0.44 
(0.24 to 0.65) 
0.68 




(0.76 to 1.3) 
0.55 
(-0.80 to 1.91) 
0.66 
0.75 
(0.54 to 0.95) 
0.88 
(-0.29 to 2.05) 
0.54 
0.98 
(0.73 to 1.22) 
0.42 
(-0.75 to 1.59) 
0.31 
0.23 
(0.06 to 0.40) 
-0.46 




(0.70 to 1.54) 
0.66 
(-0.96 to 2.28) 
0.67 
0.69 
(0.38 to 1.01) 
0.53 
(-0.93 to 1.99) 
0.49 
0.80 
(0.46 to 1.15) 
0.55 
(-1.25 to 2.35) 
0.95 
0.11 
(-0.19 to 0.39) 
0.02 
(-0.97 to 1.00) 
0.39 




           
Chinese 
2.07 
(1.40 to 2.74) 
2.59 
(1.12 to 4.06) 
0.18 
0.87 
 (0.36 to 1.38) 
1.61 
(0.58 to 2.64) 
0.055 
1.87 
(1.26 to 2.48) 
2.76 
(1.41 to 4.10) 
0.03 
1.00 
(0.61 to 1.39) 
1.15 




(1.28 to 2.63) 
2.24 
(-1.76 to 6.24) 
0.66 
1.46 
(0.95 to 1.97) 
1.49 
(-2.33 to 5.31) 
0.36 
2.04 
(1.44 to 2.65) 
1.66 
(-1.84 to 5.15) 
0.87 
0.58 
(0.18 to 0.99) 
0.16 




(0.54 to 2.51) 
2.26 
(-1.13 to 5.66) 
0.39 
0.83 
(0.09 to 1.56) 
2.06 
(-0.98 to 5.10) 
0.13 
1.12 
(0.33 to 1.92) 
2.54 
(-1.17 to 6.26) 
0.09 
0.30 
(-0.32 to 0.92) 
0.48 
(-1.66 to 2.62) 
0.63 
Pd 0.76 0.95  0.14 0.68  0.28 0.51  0.21 0.19   
BMI, body mass index; GDM, gestational diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure 
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a A total of 61 women were excluded from the analysis because of missing information on gestational diabetes status. The results were derived from multiple linear regression 
models with adjustment for maternal age, education level, parity status, smoking history, body height and heart rate.  
b for interaction between GDM and BMI 
c for interaction between ethnicity and BMI 






In a large cohort of south Asian women of Chinese, Malay and Indian descent, 
we found positive associations between 2nd trimester adiposity (measured by 
BMI and sum of skinfold thickness) and peripheral and central blood 
pressures. The associations were generally stronger in Chinese women and 
women with gestational diabetes. Particularly, greater adiposity was associated 
with higher blood pressures among Chinese women with gestational diabetes.   
Our study is one of the few that has evaluated adiposity in relation to both 
peripheral and central blood pressures. The positive association is consistent 
with previous reports suggesting that obesity is a potential modifiable risk 
factor for elevated blood pressures in pregnancy30, 88-90, 93 and pregnancy 
hypertensive disorders (summarized in O’Brien et al77). For example, in  a 
longitudinal cohort study of 6902 pregnant women in the Netherlands, a one 
unit increase in pre-pregnancy BMI was associated with 0.89 and 0.74 mmHg 
higher SBP and DBP, respectively, at 30 weeks gestation88; our study 
estimates were similar at 1.19 and 0.74 mmHg for the corresponding blood 
pressures although both BMI and blood pressures were measured at the 2nd 
trimester. Our findings of positive associations between  maternal adiposity 
and central blood pressures are consistent with studies examining arterial 
stiffness and adiposity in adult population106-108 as well as in an earlier report 
by Fujime et al. 30 on 830 healthy Japanese women (crude Pearson’s 
correlation between pre-pregnancy BMI with CASP 0.31). Studies have 
suggested that central blood pressures may better reflect arterial stiffness and 
provide incremental value above and beyond brachial blood pressures.63, 109 
Thus, more investigations are needed to evaluate whether obesity is related to 
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central blood pressures and whether weight loss is linked to improvement in 
central blood pressures.  
To our knowledge, this is the first study to report the ethnic differences in 
the association between adiposity and blood pressures during pregnancy in 
Asian populations. Malay pregnant women had the highest prevalence of 
obesity, but the adiposity-blood pressure association was strongest in Chinese 
compared to Malay or Indian women. The ethnic disparity of the relation 
between maternal adiposity and blood pressures in our study is consistent with 
previous studies that examined this relationship in non-pregnant 
populations,83, 110-113 particularly, some studies have shown that the adiposity-
blood pressure association is stronger in Chinese than non-Chinese Asians.83, 
113 For example, Razak et al. 83 found that Chinese men and women had the 
highest blood pressures at the same BMI compared to South Asians and 
Europeans in 1078 non-pregnant adults in Canada. Similar results have been 
reported in another study in Canada, where Foulds et al. 113 found that East 
Asian women had significantly higher risk of hypertension than South Asian 
and European women at the same BMI level.  
The exact reasons for the ethnic difference in the association are unclear. 
But our findings are supported by a recent study where Khoo et al. 100 enrolled 
4804 Chinese, Malay, and Asian-Indian residents of Singapore and found that 
the increases in insulin resistance and C-reactive protein for each unit increase 
of BMI were greater in Chinese than that in Malay or Asian-Indian adults. 
Insulin resistance and inflammation have been implicated as potential 
mechanisms for high blood pressures: obesity may induce endothelial cell 
chronic inflammatory and oxidative stress, then cause insulin resistance 114 
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and eventually lead to impaired local and systemic vascular functions.76 As 
postulated by Khoo et al. 100, “Chinese may have a lower capacity for fat 
storage and an excess caloric intake may results in greater metabolic 
perturbations”. Genetic differences and various patterns of immigration and 
lifestyle between the ethnic groups may also play a role. However, we did not 
measure insulin resistance or C-reactive protein in our study population and 
we did not have information on immigration, lifestyle or genetic variations; 
thus, we are unable to directly test whether these mechanisms explains the 
ethnic disparity. Further investigations are strongly needed to explore the 
potential reasons. 
The greater associations between maternal adiposity and blood pressures 
observed in women with gestational diabetes suggest that the presence of 
gestational diabetes and high maternal BMI may have synergistic effects on 
arterial compliance in pregnancy as both are independent risk factors for 
hypertensive complications in pregnancy.87 Women with gestational diabetes 
have raised inflammatory markers and insulin resistance in early pregnancy or 
even before pregnancy,115, 116 and therefore, we speculate that obese women 
with gestational diabetes may have greater inflammation and insulin resistance 
than those with either condition or in isolation, leading to higher blood 
pressures. We further found that the interaction between obesity and 
gestational diabetes was only significant in Chinese women. There is some 
preliminary evidence to suggest ethnic differences in obesity related insulin 
resistance117 and gestational diabetes in pregnancy118, 119 and in adult 
population.100 For example, in a previous report by Retnakaran et al. 117, the 
correlation between maternal adiposity during pregnancy and insulin 
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resistance is greatest in Asian women and less apparent in South Asian 
women. Therefore, it is possible that the synergistic effect between obesity 
and gestational diabetes on blood pressures is greater in certain ethnic group. 
Our study is the first to examine interactions between maternal adiposity, 
ethnicity and gestational diabetes in relation to blood pressures in Asian 
women. We included both BMI and sum of skinfold thickness as adiposity 
measures, and the generally consistent results are reassuring. Standard 
operating procedures for measuring maternal anthropometry and blood 
pressures reduced the measurement errors in the exposures and outcomes. One 
strength of our study is that we included not only peripheral blood pressures 
but also central blood pressures to assess haemodynamic adaptation.  
This study has several limitations. First, due to the cross-sectional nature, 
we cannot establish temporality for the relationship between adiposity and 
blood pressures in the 2nd trimester. Future studies should incorporate multiple 
measurements on adiposity and blood pressures before and during pregnancy 
to capture trimester-specific temporal changes. Second, because we did not 
measure the adiposity before pregnancy, we could not evaluate the association 
between pre-pregnancy adiposity and weight gain during pregnancy with 
blood pressure outcomes.  The 2nd trimester BMI and skinfold thicknesses may 
not accurately reflect maternal adiposity due to the growing fetus and fluid 
accumulation; therefore, measurement error and misclassification is possible. 
Third, despite studying a large cohort of Asian women, we may still be under-
powered due to the smaller numbers of Malays and Indians. Lastly, residual 
confounding cannot be fully ruled out; for example, we did not have 
information on diet, physical activity and medication use.  
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In conclusion, our study provides supportive evidence that maternal 
adiposity is associated with higher central and peripheral blood pressures 
during pregnancy. The novel finding that the association varies by ethnicity 
and gestational diabetes requires further confirmation. Our observation that 
obesity has the strongest impact on blood pressures in Chinese women with 
gestational diabetes has substantial clinical and public health significance, 
suggesting that this group of women may need special attention on weight 
management. Our results also point to the need for urgent translational 
research to investigate whether weight reduction in obese pregnant women 















Supplemental Table 3-1. Maternal Characteristics by Study Inclusion to the Present Study 
BMI, body mass index; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; PP, pulse pressure 
Data are mean ± standard deviation or % as specified. 
*Using Student t test for continuous variables or χ2 test for categorical variables. 
Missing values for variables:; Education = 10; Parity = 32; Smoking history = 23; Gestational 
diabetes mellitus = 61 and Sum of skinfold thicknesses = 2. 
 
 







Age  (years) 799 30.4 ± 5.2 342 30.1 ± 5.3 0.27 
Ethnicity      0.25 
   Chinese 435 54.4% 186 54.4%  
   Malay 229 28.7% 86 25.2%  
   Indian 135 16.9% 70 20.5%  
Education      0.81 
   Primary to secondary 256 32.4% 110 31.9%  
   GCE/Vocational/Polytechnic 276 34.9% 127 36.9%  
   Tertiary 257 32.6% 107 31.1%  
Parity      0.99 
   Nulliparous 329 42.9% 129 43.3%  
   Multiparous 438 57.1% 169 56.7%  
Smoking history      0.36 
   Never smokers 673 86.7% 235 84.5%  
   Ever smokers 103 13.3% 43 15.5%  
Pre-existing chronic hypertension      0.75 
   No 773 98.0% 338 98.3%  
   Yes 16 2.0% 6 1.7%  
Gestational diabetes      0.25 
   No 602 81.6% 242 84.6%  
   Yes 136 18.4% 44 15.4%  
Second trimester BMI (kg/m2) 799 26.2 ± 4.4 280 26.0 ± 4.5 0.47 
Sum of skinfold thickness (mm)  797 79.9 ± 19.6 294 79.8 ± 19.4 0.91 
Peripheral BP (mmHg)     
   SBP 799 109.5 ± 11.2 30 109.9 ± 9.9 0.85 
   DBP 799 66.8 ± 8.4 30 65.5 ± 8.9 0.40 
Central BP (mmHg)      
   SBP 799 96.9 ± 10.1 30 96.9 ± 9.9 0.99 
    PP 799 30.0 ± 16.3 30 31.4 ± 7.0 0.27 
Pulse rate (beats/minute) 799 104.0 ± 16.3 30 106.1 ± 16.9 0.49 
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Supplemental Table 3-2. Associations between 2nd Trimester BMI Categories (WHO International and Asian Classifications) and Blood Pressuresa  
 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP DBP SBP PP 
N ß (95% CI) P ß (95% CI) P ß (95% CI) P ß (95% CI) P 
2nd Trimester BMI  (kg/m2)   799 1.19 (1.03 to 1.36) <0.001 0.76 (0.63 to 0.89) <0.001 1.02 (0.87 to 1.17) <0.001 0.26 (0.16 to 0.37) <0.001 
2nd Trimester BMI  (International classification)b          
   Normal weight  (≤24.9 kg/m2) 368 Reference  Reference  Reference  Reference  
   Overweight (25.0-29.9 kg/m2) 279 6.18 (4.60 to 7.76) <0.001 3.12 (1.91 to 4.33) <0.001 5.25 (3.79 to 6.71) <0.001 2.13 (1.14 to 3.12) <0.001 
   Obese (≥30.0 kg/m2) 152 12.95 (10.94 to 14.95) <0.001 8.58 (7.04 to 10.11) <0.001 11.18 (9.33 to 13.02) <0.001 2.59 (1.34 to 3.86) <0.001 
2nd Trimester BMI  (Asian classification)c         
   Normal weight  (≤22.9 kg/m2) 193 Reference  Reference  Reference  Reference  
   Overweight (23.0-27.4 kg/m2) 347 4.75 (2.97 to 6.53) <0.001 2.50 (1.12 to 3.88) <0.001 4.19 (2.55 to 5.84) <0.001 1.70 (0.58 to 2.81) 0.003 
   Obesity (≥27.5 kg/m2) 259 12.51 (10.54 to 14.49) <0.001 7.29 (5.75 to 8.82) <0.001 10.68 (8.85 to 12.50) <0.001 3.39 (2.16 to 4.63) <0.001 
BMI, body mass index; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure 
a Results were derived from multiple linear regression models with adjustment for maternal age, ethnicity, education level, parity status, smoking history, gestational 
diabetes, body height and heart rate.  
b BMI categorized according to WHO international classification. 










POLYUNSATURATED FATTY ACIDS AND BLOOD 
PRESSURES DURING PREGNANCY IN SOUTH-EAST 
ASIAN WOMEN 
This chapter was based on the paper published in Medicine: 
Wai-Yee Lim, Mary Chong, Philip C Calder, Kenneth Kwek, Yap-Seng 
Chong, Peter D Gluckman, Keith M Godfrey, Seang-Mei Saw and An 
Pan. Relations of plasma polyunsaturated fatty acids with blood 
pressures during the 26th and 28th week of gestation in women of 







Hypertensive disorders are major health concerns in pregnancy as they are 
associated with increased risks of maternal and fetal mortality and morbidity.20 
Therefore, strategies to prevent or limit pregnancy associated hypertension 
could be very important in reducing maternal and fetal complications. Recent 
reports on n-3 polyunsaturated fatty acids (PUFAs) supplementation during 
pregnancy have been shown to prolong pregnancy gestation and increase 
offspring birth weight,120, 121 and lower the risk of pregnancy complications,4,5 
although the precise mechanisms are unclear.  
Two meta-analyses of randomised trials have suggested that increasing 
dietary intake of long chain n-3 PUFAs lowers blood pressures, with stronger 
effects in hypertensive patients.79, 122 This hypotensive effect of n-3 PUFAs is 
likely due to several mechanisms including reduced inflammation, improved 
vascular endothelial function and increased nitric oxide production, effects 
that are well demonstrated in non-pregnant adult populations.81, 123 However it 
is unclear whether the effects persist on maternal blood pressures and 
pregnancy associated hypertension are less clear,120, 124-127 and only two trials 
have examined the effect of n-3 supplementation on maternal blood pressures 
(Table 4-1).128, 129 A number of observational studies have evaluated the 
relations of n-3 PUFAs and pregnancy associated hypertension, with some 
reporting inverse association,130-132 while others reporting null133, 134 or 
positive relations (Table 4-2).135-137 The results for n-6 PUFAs were also 
inconsistent.130-132, 134, 135, 137 Moreover, no observational study has examined 
the relations of n-3 and n-6 PUFAs with the continuous measures of maternal 
blood pressures during pregnancy, particularly in Asian women. Therefore, in 
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this study we aimed to evaluate the relations of maternal plasma 
concentrations of n-3 and n-6 PUFAs between 26 - 28 weeks gestation with 
maternal blood pressures and pregnancy associated hypertension in a birth 





Table 4-1: Evidence Table for the Association between n-3 and n-6 PUFAs and Blood pressure Outcomes in Pregnancy (Randomised 
Controlled Trials) 
ID Year/author Design Participants 
n/country/year enrolled 
Exposure(s) Outcome(s) Findings 
1 2006/Barden et al RCT (Fish oil vs 
none) 
Women with allergic disease 
98/Australia/ 
(40 treated vs 43 control) 
4 capsules/day – fish 
oil (27.7%EPA + 
56% DHA) 
Olive oil (67% oleic 
acid) 




No significant difference 
between SBP and DBP 
between groups. 
2 2000/Olsen et al RCT (fish oil vs 
olive oil) 
Women with previous 
preterm delivery, 
hypertension in pregnancy 
and growth restricted 
offspring 
4 prophylactic trials 
(232;280; 386; 579) + 2 
therapeutic trials (79 – 
preeclampsia; 63 – growth 
restriction)/ 19 centres in 
Denmark, Scotland, 
Sweden, England, Italy, The 
Netherlands, Norway, 
Belgium and Russia/ 
(?1991 to 1996) 
Prevention trial: 
4 capsules/day - fish 
oil (32% EPA + 23% 
DHA) vs olive oil 
(oleic acid 72% + 
linoleic acid 12%) 
Treated began about 
20 weeks gestation 
Therapeutic trial: 
9 capsules/day 










3 1996/Salvig et al RCT (Fish oil vs 
olive oil vs 
none) 
533/ Denmark/(1989-1990) 
266 treated with fish oil:136 
treated with olive oil:131 
control 
4 capsules/day - fish 
oil (32% EPA + 23% 
DHA) vs olive oil 
(oleic acid 72% + 
linoleic acid 12%) 




No significant difference 
between SBP and DBP 
between groups;  
Systolic Hypertension:105 
vs 53 vs 42 
Diastolic Hypertension:14 
vs 14 vs 5 
4 1995/ Onwude et 
al 




(113 treated vs 119 control) 
9 capsules - 2.7g 
Max EPA (Each 
capsule - EPA 180 
mg + DHA 120 mg) 





0.88 (95%CI 0.47 to 1.66) 
1.44 (95%CI 0.87 to 1.67) 
5 1994/ Blustra-
Ramakers et al 
RCT (EPA vs 
placebo-coconut 
oil) 
Women with history of 
growth restricted offspring 
63/The Netherlands/ (1987-
1990) 
(32 treated vs 31control) 





0.25 mg EPA 
Treated began 12-14 




EPA: 12/24 (50%) 
Placebo: 5/15 (33%) 
6 1990/Olsen & 
Secher (Main 
report 1946 ) 
RCT  
(fish oil vs 
control-none) 
5644/UK/(1938-1939) 
(2510 treated vs 2512 
control) 
(The People’s League of 
Health) 
EPA and DHA -
0.1g/d 
Mean length of 
treated 20 weeks 
gestation (<15 




OR 0.69 (95%CI 0.53 to 
0.89; p=0.0047) 









Table 4-2: Evidence Table for the Association between n-3 and n-6 PUFAs and Blood pressure Outcomes in Pregnancy (Observational 
Studies) 
ID Year/author Design Participants 
n/country/ 
year enrolled 
Exposure(s) Outcome(s) Findings 
1 2007/ 





Dietary PUFAs (FFQ) at first 
trimester 
n-3 PUFAs – ALA; EPA+DHA 







Preeclampsia :OR 0.84 (95%CI 0.69 
to 1.03)    
Gestational Hypertension: OR 1.01 
(95%CI 0.95 to 1.08)  
 
EPA+DHA/AA:  
Preeclampsia: OR 0.82 (95%CI 0.89 
to 1.01)  
Gestational Hypertension: OR 0.99 
(95%CI 0.93 to 1.07)  
 
n-3, n-6, n-3/n-6 not associated with 









Fish oil supplementation (Cod 





All: OR 4.7 (95%CI 1.8 to 12.6) 
Preeclampsia: OR 4.2 (95%CI 0.8 to 
20.9) 
Gestational Hypertension: OR 5.2 
(95%CI 1.5 to 17.8) 
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3 2001/  





Dietary n-3 and n-6 PUFAs at 





 tertiles of PUFA: 
OR 2.6 (95%CI 1.4 to 6.1) 
4 2010/  
Bakheit et al 
Case control 
(matched for 
age, parity & 
gestation) 
65 cases: 60 
controls/ 
Sudan/ 2008 
Erythrocyte n-3 and n-6 long 




Preeclampsia Cases vs controls for 
phosphatidylcholine PUFA (% total 
FA): 
EPA: 0.09 vs 0.07 (p<0.001) 
DHA: 1.37 vs 1.23 (p=0.05) 
AA: 8.18 vs 808 (p=0.67) 
5 2007/ 
Mahomed et al 




Erythrocyte n-3 and n-6 long 






 quartiles of PUFA: 
n-3: OR 0.42 (95%CI 0.20 to 0.87) 
n-6: OR 0.85 (95%CI 0.45 to 1.61) 
n-3/n-6: OR 0.96 (95%CI 0.45 to 
2.05) 
6 2006/Qiu et al Case control 100 cases: 100 
controls/Peru/ 
(1997-1998) 
Erythrocyte n-3 and n-6 long 
chain PUFAs non-fasting and 





 quartiles of PUFA: 
n-3: OR 3.3 (95%CI 1.2 to 9.5) 
n-6:  OR 1.5 (95%CI 0.6 to 3.8) 
7 1997/ 





184 and 189 
controls/ 
Denmark/  
Dietary n-3 PUFAs collected 6 








 categories of fish intake (for 
n-3 PUFAs): 




(1989-1991 Gestational Hypertension: OR 0.79 
(95%CI 0.27 to 2.34) 
8 1995/  
Williams et al 
Case control 22 cases:40 
controls/US/ 
1993 
Erythrocyte n-3 and n-6 long 






 tertiles of PUFA: 
n-3: OR 7.63 (95%CI 1.43 to 40.63) 
n-6: OR 0.10 (95%CI 0.01 to 0.97)  
PUFA, polyunsaturated fatty acids; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; AA, 






A birth cohort study on Asian women, known as the Growing Up in Singapore 
Towards healthy Outcomes (GUSTO) study, was initiated to recruit women in 
their early pregnancy from two public tertiary hospitals with maternity care in 
Singapore.85   From 2009 to 2012, the GUSTO study enrolled 1162 Singapore 
citizens or residents with homogenous parental ethnic Chinese, Malay or 
Indian background. Women were excluded if they received chemotherapy, 
psychotropic drugs or had type 1 diabetes. The study was approved by the 
SingHealth Centralised Institutional Review Board and National Healthcare 
Group Domain Specific Review Board. Written informed consent was 
obtained from each study participant. 
In the present analysis, we utilized information on maternal plasma 
phosphatidylcholine (PC) PUFAs and blood pressures measured during the 
GUSTO antenatal study visit between 26 - 28 weeks gestation. Women with 
incomplete information on plasma PC PUFAs (n=166) or blood pressures 
(n=245) were excluded, leaving a final sample of 751 (64.6% of the cohort) 
women for analysis. Women who were included and excluded from the study 
had similar ages, education levels and body mass index (BMI), but the 
excluded women were more likely to be smokers and alcohol drinkers before 
or during pregnancy than women who were included (17.2% versus 12.7%; 










Women with  information on 
polyunsaturated fatty acids at 26 weeks
(N=996)
Women with  BP and valid 
radial pulse wave measurement 
at 26 weeks (N=751)
Excluded women with poor or 
no radial waves recording 
(n=245)
Excluded those without information on 




Blood Pressure Measurements 
Maternal blood pressures and heart rates were taken by trained research 
coordinators based on a standardized protocol. Peripheral systolic (SBP) and 
diastolic (DBP) pressures were measured thrice from the brachial arm at 30-60 
second intervals with an oscillometric device MC3100 (HealthSTATS 
International Pte Ltd, Singapore). An average of the three readings was 
calculated if the difference between readings was less than 10 mmHg; 
otherwise, measurements were repeated. An A-pulse tonometer (BPro®, 
HealthSTATS International Pte Ltd, Singapore) was applied on the radial 
artery of the same arm for continuous sampling of radial artery pressure 
waveforms over 1 minute, and these waveforms were calibrated using the 
average of brachial SBP and DBP, respectively. Maternal heart rate and 
central SBP was then estimated from the calibrated radial artery pressure 
waveforms using the N-point moving average.12 Central pulse pressure was 
calculated as the difference between central SBP and peripheral DBP. 
Pregnancy Associated Hypertension 
Information on pregnancy associated hypertension, including gestational 
hypertension and preeclampsia, was ascertained from medical records. The 
abstracted information was cross-checked by another obstetrician who was 
involved with the study. In practice, the diagnosis of gestational hypertension 
included de novo hypertension (defined as peripheral SBP ≥140 mmHg or 
DBP ≥90 mmHg) without proteinuria after the 20th week of gestation, 
measured at two separate occasions with at least 4 hours apart.138 The 
definition for preeclampsia was hypertension with proteinuria after the 20th 
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week of gestation. As preeclampsia is a multi-organ disorder, and it may also 
include impairments in kidney, liver functions and low platelets.138 As there 
were only 16 incident cases of gestational hypertension and 12 incident cases 
of preeclampsia, they were collectively analysed as pregnancy associated 
hypertension. 
Plasma Phosphatidylcholine Fatty Acid Composition  
Fasting blood samples were taken between 26 - 28 weeks gestation. Plasma 
was prepared by centrifugation and was stored at -80°C until analysis. Total 
lipid extraction was carried out with chloroform/methanol (2:1 v/v) and PC, 
which contributes about 75% of plasma phospholipids, was isolated by solid 
phase extraction on aminopropylsilica catridges and eluted with 
chloroform/methanol (3:2 v/v). Fatty acid methyl esters were generated by 
reaction of purified PC with 2% sulfuric acid (v/v) at 50°C for 2 hours, 
extracted into hexane and separated by gas chromatography. A BPX-70 
column (30 m × 220 μm; film thickness 0.25 μm) fitted to a Hewlett-Packard 
HP6890 gas chromatograph was used for separation with helium as the 
running gas and detection of fatty acid methyl esters by flame ionisation 
before quantification using the ChemStation software in absolute 
concentration (µg/mL plasma). Plasma PC fatty acids were expressed as 
percentages of total plasma PC fatty acids, and the ratio of total n-3 to n-6 
PUFAs were calculated accordingly.   
Covariates 
Information on maternal age, ethnicity and education level, smoking status, 
alcohol intake before and during pregnancy, hypertension before pregnancy, 
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physical exercise and dietary supplements during pregnancy were obtained via 
standardized questionnaires. Maternal anthropometry (height and weight) was 
measured by trained investigators between 26 - 28 weeks gestation, and BMI 
was calculated as weight (kg) divided by the square of height (m2). Women 
with BMI <25.0 kg/m2 were categorized as normal weight, 25.0-29.9 kg/m2 as 
overweight and ≥30.0 kg/m2 as obese.105 Oral glucose tolerance test was 
performed and gestational diabetes was defined as fasting glucose ≥7.0 
mmol/L or 2-hour glucose ≥11.1 mmol/L. 
Statistical Analysis 
Crude trends of maternal baseline characteristics and pregnancy outcomes 
across tertiles of n-3 and n-6 PUFAs were done using Mantel-Haenszel test. 
The associations between plasma PC fatty acids and continuous measures of 
maternal peripheral and central blood pressures were examined using multiple 
linear regression analysis. The relation of fatty acids with pregnancy 
associated hypertension was examined using multiple logistic regression with 
exclusion of women with hypertension before pregnancy. All analyses were 
adjusted for maternal age, ethnicity, education level, exercise, smoking status 
and alcohol intake before or during pregnancy, BMI and height between 26 - 
28 weeks gestation, gestational diabetes, heart rate and the use of fish oil 
supplements. As there were only 14 women with hypertension before 
pregnancy, we did not adjust for this covariate in our main analysis. However, 
to test the robustness of our results, we adjusted for maternal hypertension 
before pregnancy or excluded them in our sensitivity analysis, and the results 
remained unchanged. We further adjusted for plasma monounsaturated fatty 
acids (MUFAs) in the sensitivity analysis. We also repeated our analysis for 
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the continuous measures of blood pressure outcomes in a subgroup of 383 
women who did not use fish oil supplements.  
Effect modification by maternal ethnicity was performed for the 
continuous measures of maternal blood pressures, but not for the binary 
outcomes of pregnancy associated hypertension due to the limited number of 
cases (n=28). To assess for ethnic modification, a multiplicative interaction 
term between ethnicity (Chinese, Malay, Indian) and plasma PC fatty acids 
(continuous variable) was added in the models. Ethnicity stratified analysis 
was performed and the likelihood ratio test was used to examine the 
interaction effects. Stata version 11.2 (Statacorp, College Station, Texas) was 




The women included in our analysis were predominantly Chinese (53.8%), 
followed by Malay (28.8%) and Indians (17.3%). Those with higher plasma 
PC n-3 PUFAs tended to have lower BMIs and were more physically active 
compared to those with higher plasma PC n-6 PUFAs (Table 4-2). The crude 
incidence of pregnancy associated hypertension was 3.9% (n=28) among 
women who were free from hypertension before pregnancy. Plasma PC n-3 
PUFAs were inversely correlated with gestational hypertension or 
preeclampsia (P for trend = 0.02), but for plasma PC n-6 PUFAs, a marginal 
trend of positive correlation was observed instead (P for trend = 0.05) 
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PUFAs accounted for about 40% of plasma PC fatty acids, with 6.4% as 
total n-3 PUFAs and 34.2% as total n-6 PUFAs (Table 4-3). The n-3 PUFAs 
identified were α-linolenic acid (ALA, 18:3n-3; 0.2%), long chain n-3 
[eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3) and 
docosahexanoic acid (22:6n-3); 5.9%], whereas the n-6 PUFAs included 
linoleic acid (18:2n-6; 21.7%), dihomo-ƴ-linolenic acid (20:3n-6; 3.9%) and 
arachidonic acid (20:4n-6; 7.9%). Chinese women had the highest total n-3 
PUFAs (6.7%), whereas, Indian women had the highest total n-6 PUFAs 
(35.2%). Furthermore, women who took fish oil supplements tended to have 
higher total n-3 PUFAs (6.8% versus 6.0%), higher long chain n-3 PUFAs 
(6.4% versus 5.7%) and lower n-6 PUFAs (33.9% versus 34.4%) compared to 















Table 4-3. Characteristics of Women by Tertiles of Plasma PC n-3 and n-6 Polyunsaturated Fatty Acids (PUFAs) at 26 - 28 Weeks 
Gestation      
    n-3 PUFAs P   
(Trend) 
n-6 PUFAs P   
(Trend)   n 1st Tertile 2nd Tertile 3rd Tertile 1st Tertile 2nd Tertile 3rd Tertile 
Age (year) 751 29.9 ± 5.2 30.0 ± 5.2 31.7 ± 4.8 <0.001 31.1 ± 5.1 30.4 ± 5.1 30.1 ±  5.2 0.04 
Ethnicity (%)         
<0.001 
      
<0.001 
   Chinese 404 114 (45.8%) 122 (48.4%) 168 (67.2%) 152 (61.8%) 133 (50.2%) 119 (49.6%) 
   Malay 217 82 (32.9%) 82 (32.5%) 53 (21.2%) 64 (26.0%) 88 (33.2%) 65 (27.1%) 
   Indian 130 53 (21.3%) 48 (19.0%) 29 (11.6%) 30 (12.2%) 44 (16.6%) 56 (23.3%) 
Education (%)         
<0.001 
      
0.49 
   Primary to secondary 232 94 (38.4%) 82 (33.1%) 56 (22.5%) 71 (29.1%) 86 (32.9%) 75 (31.6%) 
   GCE/Vocational/Polytechnic 265 81 (33.1%) 90 (36.3%) 94 (37.8%) 88 (36.1%) 92 (35.2%) 85 (35.9%) 
   Tertiary 245 70 (28.6%) 76 (30.6%) 99 (39.8%) 85 (34.8%) 83 (31.8%) 77 (32.5%) 
Exercise (%)         
0.16 
      
0.01    None to gentle exercise 547 188 (75.8%) 184 (73.0%) 175 (70.3%) 162 (66.1%) 202 (76.5%) 183 (76.2%) 
   Moderate to strenuous exercise 202 60 (24.2%) 68 (26.9%) 74 (29.7%) 83 (33.9%) 62 (23.5%) 57 (23.8%) 
Body Mass Index (kg/m2) 737 26.7 ±4.5  26.5 ± 4.6  25.5 ±  3.9  0.001 25.6 ± 4.1 26.3 ± 4.5 26.7 ± 4.2 0.02 
Height (cm) 744 157.8 ± 5.4 158.5 ±5.7 158.7 ± 5.8 0.03 157.8 ±5.6 158.5 ± 5.3 158.8 ± 6.0 0.14 
Smoking status (%)         
0.006 
      
0.33    Non-smoker 653 212 (85.8%) 206 (82.1%) 235 (94.0%) 212 (86.2%) 228 (86.7%) 213 (89.1%) 
   Ever smoker 95 35 (14.2%) 45 (17.9%) 15 (6.0%) 34 (13.8%) 35 (13.3%) 26 (10.9%) 
Alcohol Intake (%)         
0.61 
      
0.007    No 486 163 (67.9%) 164 (65.9%) 159 (65.7%) 141 (58.8%) 179 (70.2%) 166 (70.3%) 
   Yes    245 77 (32.1%) 85 (34.1%) 83 (34.3%) 99 (41.2%) 76 (29.8%) 70 (29.7%) 
Gestational Diabetes (%)         
0.33 
      
0.33    No 577 194 (83.6%) 197 (82.8%) 186 (80.2%) 196 (82.4%) 207 (85.2%) 174 (78.7%) 
   Yes 125 38 (16.4%) 41 (17.2%) 46 (19.8%) 42 (17.6%) 36 (14.8%) 47 (21.3%) 
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Hypertension before pregnancy 
(%) 
         
   No 722 238 (97.5%) 243 (98.4%) 241 (98.4%) 
0.50 
239 (98.4%) 255 (98.5%) 228 (97.4%) 
0.47 
   Yes 14 6 (2.5%) 4 (1.6%) 4 (1.6%) 4 (1.6%) 4 (1.5%) 6 (2.6%) 
Pregnancy Associated 
Hypertension * (%) 
         
   Normotensive pregnancy 694 224 (94.1%) 233 (95.9%) 237 (98.4%) 
0.02 
233 (97.5%) 247 (96.9%) 214 (93.9%) 
0.05    Gestational hypertension 16 8 (3.4%) 5 (2.1%) 3 (1.2%) 4 (1.7%) 4 (1.6%) 8 (3.5%) 
   Preeclampsia 12 6 (2.5%) 5 (2.1%) 1 (0.4%) 2 (0.8%) 4 (1.6%) 6 (2.6%) 
Fish Oil Supplementation     
<0.001 
   
0.002    No 383 146 (65.5%) 129 (58.4%) 108 (45.9%) 111 (49.3%) 130 (55.8%) 142 (64.2%) 
   Yes 296 77 (34.5%) 92 (41.6%) 127 (54.0%) 114 (50.7%) 103 (44.2%) 79 (35.8%) 
PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids.  
Data are presented in n (column %) or mean ± SD. 
*Incident cases were reported having excluded 14 women with hypertension before pregnancy. 
P values were derived from Cochran-Mantel-Haenszel test. Variables with missing information: education (n=9), exercise (n=2), body mass   
index (n=14), height (n=7), smoking status (n=3), alcohol intake (n=20), gestational diabetes (n=49), hypertension before pregnancy (n=15) and 





Table 4-4. Composition of Maternal Plasma PC Fatty Acids (% of Total Fatty Acids) at 26 - 28 Weeks Gestation by Ethnicity   
Plasma Fatty Acids Overall Chinese Malay Indian P   
n 751 404 217 130  
SFAs 45.8 ± 3.2  46.0 ± 3.1  45.1 ± 3.1  46.5 ± 3.4  <0.001 
MUFAs 13.6 ± 2.3  13.5 ± 2.1  14.6 ± 2.3  12.3 ± 2.0  <0.001 
PUFAs 40.5 ± 3.3 40.5 ± 3.4  40.2 ± 3.1  41.1 ± 3.6  0.05 
Total n-3 PUFAs  6.3 ± 1.9  6.7 ± 1.9  6.0 ± 1.7  5.9 ± 1.8  <0.001 
α-linolenic acid [18:3n-3] 0.2 ± 0.1  0.2 ± 0.1  0.2 ± 0.1  0.2 ± 0.1  0.12 
Long chain n-3 PUFAs  5.9 ± 1.8  6.3 ± 1.9  5.6 ± 1.6  5.6 ± 1.8  <0.001 
Total n-6 PUFAs 34.2 ± 3.2  33.8 ± 3.1  34.2 ± 3.0  35.2 ± 3.7 <0.001 
Linoleic acid [18:2n-6] 21.7 ± 3.3  21.6 ± 3.2  22.1 ± 3.4  21.2 ± 3.2  0.02 
Dihomo-ƴ-linolenic acid [20:3n-6] 3.9 ± 1.2  3.7 ± 1.2  4.1 ± 1.2  4.4 ± 1.3  <0.001 
Arachidonic acid [20:4n-6] 7.9 ± 1.7  7.8 ± 1.5  7.3 ± 1.5  8.9 ± 1.9  <0.001 
n-3/n-6 ratio 0.19 ± 0.06  0.20 ± 0.06  0.18 ± 0.06  0.17 ± 0.06  <0.001 
   PC= phosphatidylcholine, SFAs =saturated fatty acids, MUFAs= monounsaturated fatty acids, PUFAs= polyunsaturated fatty acids.  
 




Relation of Plasma n-3 PUFAs to Maternal Blood Pressures  
After multivariate adjustment, higher total and long chain n-3 PUFAs and n-
3/n-6 ratio was associated with lower peripheral SBP (Table 4-4 and Figure 4-
2): the mean (95% confidence interval [CI]) was -0.51 (-0.89 to -0.13) mmHg 
for a one-percent increase in total n-3 PUFAs, and -0.52 (-0.92 to -0.13) 
mmHg for a one-percent increase in long chain n-3 PUFAs, and -1.51 (-2.63 to 
-0.38) mmHg for a 0.1-unit increase in the n-3/n-6 ratio. Total and long chain 
n-3 PUFAs and n-3/n-6 ratio were marginally associated with central SBP and 
PP, but not with DBP. The results were not materially changed in the 
sensitivity analyses: (1) further adjustment or exclusion of women with 
hypertension before pregnancy (Supplemental Table 4-3); (2) further 
adjustment for plasma MUFAs (Supplemental Table 4-3); and (3) in women 
without fish oil supplementation (Supplemental Table 4-4). 
Figure 4-2. Multivariate Adjusted Association between Maternal Plasma PC n-3 
PUFAs (Tertiles) and Blood Pressures at 26 - 28 Weeks Gestation        
*P for trend ≤0.05; **P for trend <0.001.
** ** **
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Table 4-5. Multivariate Adjusted Association Between Maternal Plasma PC n-3 PUFAs and Blood Pressures at 26 - 28 Weeks 
Gestation. 
Fatty Acids (%) 
Blood Pressure Outcomes 
Model 1 Model 2 Model 3 
β (95% CI) P   β (95% CI) P    β (95% CI) P   
Peripheral SBP  
Total n-3 PUFAs -0.65 (-1.08 to -0.23) 0.003 -0.48 (-0.86 to -0.11) 0.01 -0.51 (-0.89 to -0.13) 0.008 
α-linolenic acid -2.95 (-8.81 to 2.91) 0.32 -0.02 (-5.18 to 5.14) 0.99 -0.11 (-5.28 to 5.06) 0.97 
Long chain n-3 PUFAs -0.68 (-1.13 to -0.24) 0.003 -0.50 (-0.89 to -0.11) 0.01 -0.52 (-0.92 to -0.13) 0.01 
n-3/n-6 ratio* -2.17 (-3.43 to -0.91) 0.001 -1.44 (-2.55 to -0.33) 0.01 -1.51 (-2.63 to -0.38) 0.009 
Peripheral DBP       
Total n-3 PUFAs -0.23 (-0.56 to 0.09) 0.15 -0.09 (-0.39 to 0.20) 0.52 -0.08 (-0.38 to 0.21) 0.58 
α-linolenic acid -3.43 (-7.83 to 0.97) 0.13 -0.81 (-4.79 to 3.17) 0.69 -1.03 (-5.01 to 2.95) 0.61 
Long chain n-3 PUFAs -0.23 (-0.57 to 0.10) 0.17 -0.09 (-0.39 to 0.21) 0.55 -0.07 (-0.38 to 0.23) 0.63 
n-3/n-6 ratio* -0.83 (-1.78 to 0.12) 0.09 -0.23 (-1.08 to 0.63) 0.60 -0.19 (-1.05 to 0.68) 0.67 
Central SBP       
Total n-3 PUFAs -0.49 (-0.88 to -0.11) 0.01 -0.30 (-0.65 to 0.05) 0.09 -0.31 (-0.67 to 0.04) 0.09 
α-linolenic acid -3.63 (-8.96 to 1.69) 0.18 -1.15 (-5.96 to 3.66) 0.64 -1.33 (-6.15 to 3.48) 0.59 
Long chain n-3 PUFAs -0.50 (-0.90 to -0.09) 0.02 -0.29 (-0.65 to 0.08) 0.12 -0.30 (-0.67 to 0.07) 0.12 
n-3/n-6 ratio* -1.60 (-2.74 to -0.46) 0.01 -0.89 (-1.93 to 0.15) 0.09 -0.91 (-1.96 to 0.13) 0.09 
Central PP       
Total n-3 PUFAs -0.26 (-0.51 to 0.00) 0.05 -0.12 (-0.45 to 0.04) 0.10 -0.13 (-0.48 to 0.02) 0.07 
α-linolenic acid -0.20 (-3.69 to 3.28) 0.91 -0.34 (-3.69 to 3.01) 0.84 -0.30 (-3.66 to 3.06) 0.86 
Long chain n-3 PUFAs -0.26 (-0.52 to 0.00) 0.05 -0.20 (-0.45 to 0.06) 0.13 -0.22 (-0.48 to 0.04) 0.09 
n-3/n-6 ratio* -0.77 (-1.53 to -0.02) 0.04 -0.66 (-1.38 to 0.06) 0.07 -0.73 (-1.46 to 0.00) 0.05 
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PC= phosphatidylcholine, CI= confidence interval, PUFA= polyunsaturated fatty acids, SBP= systolic blood pressure, DBP= diastolic blood 
pressure, PP= pulse pressure.  
*The values were β (95% CI) for blood pressures in 0.1-unit increase of the n-3/n-6 ratio. 
Model 1: adjusted for age and ethnicity using multiple linear regression;  
Model 2: adjusted for age, ethnicity, education, exercise, alcohol intake, smoking status, BMI and height at 26 – 28 weeks gestation, 
gestational diabetes and heart rate;  




Relation of Plasma n-6 PUFAs to Blood Pressures 
The relations of total n-6 PUFAs, linoleic acid and arachidonic acid to blood 
pressure outcomes were not statistically significant, but dihomo-ƴ-linolenic 
acid was marginally positively associated with peripheral SBP [0.58 (-0.02 to 
1.18); P=0.06] and central SBP [0.52 (-0.04 to 1.07); P=0.07] (Table 4-5 and 
Figure 4-3). The results were not materially different with further adjustment 
for maternal hypertension before pregnancy or plasma MUFAs (Supplemental 
Table 4-5), and in subgroup analysis of women who were not supplemented 
with fish oil (Supplemental Table 4-6). 
 
Figure 4-3. Multivariate Adjusted Association between Maternal Plasma PC n-
6 PUFAs (Tertiles) and Blood Pressures at 26 - 28 Weeks Gestation      
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Table 4-6. Multivariate Adjusted Association Between Maternal Plasma PC n-6 PUFAs and Blood Pressures at 26 - 28 Weeks 
Gestation. 
Fatty Acids (%) 
Blood Pressure Outcomes 
Model 1 Model 2 Model 3 
β (95% CI) P   β (95% CI) P   β (95% CI) P   
Peripheral SBP  
Total n-6 PUFAs 0.35 (0.10 to 0.59) 0.006 0.18 (-0.04 to 0.40) 0.11 0.18 (-0.04 to 0.40) 0.11 
Linoleic acid  0.03 (-0.21 to 0.27) 0.80 0.14 (-0.07 to 0.35) 0.19 0.14 (-0.07 to 0.35) 0.19 
Dihomo-ƴ-linolenic acid  1.42 (0.76 to 2.08) <0.01 0.58 (-0.02 to 1.17) 0.06 0.58 (-0.02 to 1.18) 0.06 
Arachidonic acid  0.45 (-0.05 to 0.94) 0.08 -0.22 (-0.66 to 0.22) 0.33 -0.22 (-0.66 to 0.23) 0.34 
Peripheral DBP       
Total n-6 PUFAs 0.23 (0.05 to 0.42) 0.01 0.09 (-0.08 to 0.25) 0.32 0.08 (-0.09 to 0.25) 0.35 
Linoleic acid  -0.03 (-0.22 to 0.15) 0.71 0.02 (-0.15 to 0.18) 0.85 0.02 (-0.14 to 0.18) 0.83 
Dihomo-ƴ-linolenic acid  0.92 (0.42 to 1.41) <0.001 0.33 (-0.12 to 0.79) 0.15 0.29 (-0.17 to 0.75) 0.21 
Arachidonic acid  0.47 (0.10 to 0.84) 0.01 0.00 (-0.34 to 0.34) 0.99 0.00 (-0.34 to 0.34) 0.99 
Central SBP       
Total n-6 PUFAs 0.25 (0.02 to 0.47) 0.03 0.13 (-0.07 to 0.34) 0.20 0.13 (-0.07 to 0.33) 0.22 
Linoleic acid  -0.08 (-0.30 to 0.14) 0.46 0.05 (-0.15 to 0.24) 0.64 0.05 (-0.15 to 0.24) 0.63 
Dihomo-ƴ-linolenic acid  1.22 (0.62 to 1.81) <0.001 0.54 (-0.02 to 1.09) 0.06 0.52 (-0.04 to 1.07) 0.07 
Arachidonic acid  0.55 (0.10 to 1.00) 0.02 -0.03 (-0.44 to 0.38) 0.89 -0.03 (-0.44 to 0.38) 0.89 
Central PP       
Total n-6 PUFAs 0.01 (-0.13 to 0.16) 0.85 0.05 (-0.10 to 0.19) 0.52 0.05 (-0.09 to 0.19) 0.50 
Linoleic acid  -0.05 (-0.19 to 0.09) 0.51 0.03 (-0.10 to 0.17) 0.65 0.03 (-0.11 to 0.17) 0.66 
Dihomo-ƴ-linolenic acid  0.30 (-0.10 to 0.69) 0.14 0.20 (-0.18 to 0.59) 0.30 0.22 (-0.16 to 0.61) 0.26 
Arachidonic acid 0.08 (-0.22 to 0.37) 0.62 -0.03 (-0.32 to 0.26) 0.84 -0.03 (-0.31 to 0.26) 0.85 
PC= phosphatidylcholine, CI= confidence interval, PUFA= polyunsaturated fatty acids, SBP= systolic blood pressure, DBP= diastolic blood 
pressure, PP= pulse pressure.   
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Model 1: adjusted for age and ethnicity using multiple linear regression;  
Model 2: adjusted for age, ethnicity, education, exercise, alcohol intake, smoking status, BMI and height at 26 - 28 Weeks gestation, 
gestational diabetes and heart rate;  




Relations between Plasma PUFAs and Pregnancy Associated 
Hypertension 
The relations of total and long chain n-3 PUFAs to pregnancy associated 
hypertension were statistically significant (Table 4-6). The adjusted odds ratio 
(95% CI) for pregnancy associated hypertension from one-percent increase in 
total n-3 PUFAs was 0.76 (0.60 to 0.97) and 0.77 (0.60 to 0.98) in long chain 
n-3 PUFAs. No significant associations were found between n-6 PUFAs and 




Table 4-7. Multivariate Adjusted Relation of Maternal Plasma PC n-3 and 6 PUFAs at 26 - 28 Weeks Gestation with Pregnancy 
Associated Hypertension  
 Pregnancy Associated Hypertension* 
 Model 1 Model 2 Model 3 
Fatty Acids (%) OR (95% CI) P  OR (95% CI) P    OR (95% CI) P   
n-3 PUFAs       
   Total n-3 PUFAs 0.69 (0.54 to 0.89) 0.004 0.69 (0.53 to 0.90) 0.007 0.76 (0.60 to 0.97) 0.03 
   Long chain n-3 PUFAs 0.69 (0.54 to 0.90) 0.006 0.69 (0.53 to 0.92) 0.01 0.77 (0.60 to 0.98) 0.04 
n-6 PUFAs       
   Total n-6 PUFAs 1.14 (1.01 to 1.29) 0.04 1.10 (0.97 to 1.26) 0.15 1.09 (0.97 to 1.22) 0.16 
   Linoleic acid  1.05 (0.94 to 1.18) 0.40 1.09 (0.96 to 1.24) 0.17 0.82 (0.56 to 1.19) 0.29 
   Dihomo-ƴ-linolenic acid  1.09 (0.81 to 1.49) 0.55 0.85 (0.57 to 1.26) 0.42 1.05 (0.82 to 1.34) 0.70 
   Arachidonic acid 1.23 (1.02 to 1.48) 0.03 1.10 (0.87 to 1.40) 0.42 1.07 (0.95 to 1.22) 0.26 
PC= phosphatidylcholine, CI= confidence interval, PUFA= polyunsaturated fatty acids, SBP= systolic blood pressure, DBP= diastolic blood 
pressure, PP= pulse pressure.    
 
Results for α-linolenic acid and ratio of n-3 to n-6 PUFAs were not reported as their plasma concentrations were very low, leading to unstable 
estimates and large confidence intervals in the regression analysis.  
*Pregnancy associated hypertension (n=28) included gestational hypertension (n=16) and preeclampsia (n=12).  A total of 14 women with 
hypertension before pregnancy were excluded from analysis. 
Model 1: adjusted for age and ethnicity using multiple logistic regression;  
Model 2: adjusted for age, ethnicity, education, exercise, alcohol intake, smoking status, BMI and height at 26 - 28 weeks gestation, gestational 
diabetes and heart rate;  




Relations between Plasma PUFAs and Blood Pressures in Different 
Ethnic Groups 
The relations of total and long chain n-3 PUFAs and n-3/n-6 ratio to peripheral 
SBP, DBP and central SBP varied across maternal ethnic groups (P values for 
interaction ranged from 0.02 to 0.07). The inverse associations tended to be 
stronger in Chinese women and weaker in Indian women, but non-
significantly positive in Malay women (Supplemental Table 4-7).  
The positive relations of linoleic acid with SBP and total n-6 PUFAs with 
DBP were stronger in Indian women compared to Chinese or Malay women 
(P for interaction = 0.02 and 0.05, respectively; Supplemental Table 4-8). In 
Indian women, higher tertiles of total n-6 PUFAs and linoleic acid were 
associated with higher peripheral SBP, DBP and central SBP (P for trend 
ranged from 0.002 to 0.09), and higher tertiles of dihomo-ƴ-linoleic acid with 






Plasma PC PUFAs reflect both intake of those fatty acids139 and levels of 
those fatty acids in various cells and tissues.140 Thus, they are good markers of 
maternal PUFA status. The main findings from this cohort of Asian women 
are: (1) total and long chain n-3 PUFAs and n-3/n-6 ratio were all inversely 
associated with peripheral SBP and central SBP and PP between 26 - 28 
weeks gestation, whereas dihomo-ƴ-linolenic acid was marginally positively 
associated with peripheral and central SBP; (2) higher n-3 PUFAs were 
associated with lower odds of pregnancy associated hypertension; (3) maternal 
ethnicity modified the relations  between plasma PC PUFAs and blood 
pressures, with stronger inverse associations for n-3 PUFAs in Chinese 
women, and stronger but positive associations for n-6 PUFAs in Indian 
women.  
Our findings on the inverse relations between plasma PC n-3 PUFAs and 
maternal blood pressures and pregnancy associated hypertension are consistent 
with evidence from clinical78, 123, 141 and epidemiological studies8,24,25 on the 
direct and indirect mechanisms of action of n-3 PUFAs81, 142 and they lend 
support to the potentially beneficial role of long chain n-3 PUFAs in 
pregnancy. Although the earlier two trials in pregnant women reported no 
significant findings,128, 129 trials in the general population have found 
consistent hypotensive and cardioprotective effects from n-3 
supplementation,6,7,9 and this has led to the development of several national 
and international guidelines for their consumption.81 Further trials on n-3 
supplementation are still needed as hypertension in pregnancy is a major 
complication in pregnancy, and as demonstrated in the general population,81, 
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143 fish oil supplementation may be a useful adjunct to prevent or limit 
hypertension disorders and associated complications in pregnancy. 
 This study is one of the few that has comprehensively examined the 
relations between PUFA status and blood pressures in pregnant Asian women. 
Our findings are consistent with a recent meta-analysis of 70 randomised 
clinical trials in non-pregnant populations,79 that n-3 PUFA provision reduces 
blood pressures (SBP, -1.52 mmHg; DBP, -0.99 mmHg) compared with 
placebo. Other studies have found that higher n-3 PUFA concentrations in the 
blood stream were associated with lower cardiovascular risk.144 Data from 
observational studies in non-pregnant populations support the hypotensive 
effects of n-3 PUFAs measured from dietary intake145 or plasma 
phospholipid145 or serum.146  For example, plasma phospholipid n-3 PUFAs 
was inversely associated with hypertension in a cross-sectional study among 
1154 Chinese men and women,145 and serum n-3 PUFAs was inversely 
associated with peripheral SBP and PP in 778 healthy Finnish men and 
women.146  
In contrast to our findings, reports from randomised trials of n-3 PUFA 
supplementation during pregnancy did not find significant blood pressure 
reduction128, 129 or prevention of pregnancy hypertension.120, 147 This may 
possibly be due to baseline variation across study populations such as 
inclusion of women with high risk of pregnancy complications, or differences 
in the timing and duration of fish oil supplementation. Reports on dietary n-3 
PUFAs measured from food frequency questionnaires were inconsistent, with 
some studies reporting increased risk to preeclampsia from higher dietary n-3 
PUFAs intake at mid-trimester135 or fish oil supplementation at first 
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trimester.136 However, other studies reported a lower risk of preeclampsia with 
higher mean n-3 PUFA intake during the first and second trimesters130 or null 
findings with retrospective recall of pregnancy diet.133 The discrepant findings 
may be due to the varying gestation period when diet was assessed as well as 
measurement errors from questionnaires, leading to misclassification of n-3 
PUFA status. As for the biomarker assessment of erythrocyte n-3 PUFAs were 
associated with lower risk to preeclampsia131, 132 and a lower risk but not 
statistically significant in another report.134  
As to the overall positive but not statistically significant associations 
between plasma PC n-6 PUFAs and maternal blood pressures, the findings are 
broadly consistent with two observational studies which reported an increased 
risk of hypertension in pregnancy with higher erythrocyte134 or plasma n-6 
PUFAs.148 Other reports, however, found null relations with higher dietary130 
or plasma n-6 PUFA levels.131  
 Ethnic differences were found in plasma PC fatty acid composition and 
in the relations of plasma PC fatty acids to blood pressures. Chinese women 
had higher plasma PC n-3 PUFAs, possibly because of their higher intake of 
foods rich in n-3 PUFAs such as eggs, meat (poultry and non-poultry) and 
fish, whereas the higher plasma PC n-6 PUFAs amongst the Indians may be 
due to their higher use of n-6 PUFA-rich oils for cooking.149 We postulate that 
the greater consumption of dietary n-3 PUFAs among the Chinese women 
may be linked with lower blood pressures,145 whereas in Indian women, the 
high intake of n-6 PUFAs may lead to higher blood pressures.123, 148 Further 
investigations into the influences of genetic, dietary and lifestyle factors on n-
3 PUFAs and blood pressures in Asian women are needed. 
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Our study has several strengths. First, as data was acquired from a 
prospective birth cohort study, we were able to account for important 
confounders. Second, the blood pressure measurements were performed by 
trained research personnel, following a standard protocol. Lastly, our study 
sample of Chinese, Malay and Indian women enabled us to examine the 
ethnicity related variations in the relations of plasma PC n-3 and 6 PUFAs 
with blood pressures. However, the results should be interpreted cautiously 
because of the small sample size in the stratified analysis. 
Limitations include the cross sectional nature of our study and therefore 
we are unable to establish causality of the association between PUFAs and 
blood pressures. We were also unable to examine maternal blood pressure 
changes during pregnancy as they were measured between 26 - 28 weeks 
gestation only. Our findings on the relations of PUFAs with pregnancy 
associated hypertension were constrained by the lack of study power as there 
were only 28 cases of pregnancy associated hypertension. Although we have 
excluded a total of 409 (35.4%) women in the GUSTO study, it is unlikely that 
selection bias would affect our results as most baseline characteristics between 
women who were included and excluded in the study were not materially 
different. Our effect estimates may be affected by residual confounding from 
imperfectly self-reported measures such as physical activity and supplement 
use. Lastly, we did not measure dietary intake of PUFAs, and this may have 
limited the interpretation of our study findings. However, plasma PC n-3 
PUFAs have been found to be good markers of n-3 PUFA dietary intake139, 140 
and a dose response relation  has been demonstrated recently in a randomized 
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trial on the dose and time-dependent response of eicosapentaenoic acid and 
docosahexanoic acid incorporation into various biosamples.139  
In conclusion, plasma PC n-3 PUFAs were inversely related to peripheral 
and central SBP and central PP in pregnancy with stronger inverse relations of 
plasma PC n-3 in Chinese women, but positive relations with plasma PC n-6 
PUFAs in Indian women.  Higher plasma n-3 PUFAs between 26 - 28 weeks 













P   
Age (year) 751 30.5 ± 5.2 409 29.9 ± 5.3 0.07 
Ethnicity (%) 
   Chinese 
   Malay 



















   Primary to secondary 
   GCE/Vocational/Polytechnic 



















   None to gentle exercise 














Body Mass Index (kg/m2) 737 26.2 ±4.4 343 26.0 ±4.7 0.49 
Height (cm) 744 158.4 ±5.6 346 157.9 ±5. 7 0.27 
Smoking status (%) 
   Non-smoker 














Alcohol Intake (%) 
   No  
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Hypertension before pregnancy (%) 
   No 














Pregnancy Associated Hypertension* (%) 
   Normotensive Pregnancy  
   Gestational Hypertension 

























45.8 ± 3.2 
13.6 ± 2.3 




45.8 ± 3.9 
13.6 ± 2.3 




    Total n-3 PUFAs 
       α-linolenic acid   
       Long chain n-3 PUFAs 
    Total n-6 PUFAs 
       Linoleic acid   
       Dihomo-gamma-linolenic acid  
       Arachidonic acid   









6.4 ± 1.9 
0.2 ± 0.1 
5.9 ± 1.8 
34.2 ± 3.2 
21.7 ± 3.3 
3.9 ± 1.2 
7.9 ± 1.7 









6.3 ± 1.8 
0.2 ± 0.2 
5.9 ± 1.7 
34.3 ± 4.0 
21.9 ± 3.9 
3.9 ± 1.4 
7.9 ± 1.7 









   PC= phosphatidylcholine, SFAs= saturated fatty acid, MUFAs= 
monounsaturated fatty acids, PUFAs= polyunsaturated fatty acids.  
 
   Data are presented in % or mean ± SD. P values were derived from chi-





  * Incident cases were reported having excluded 14 women with 
hypertension before pregnancy. 
 
   A total of 751 women were included for analysis. Variables with missing 
information: education (n=9), exercise (n=2), body mass index (n=14), height 
(n=7), smoking status (n=3), alcohol intake (n=20), gestational diabetes 
(n=49), hypertension before pregnancy (n=15) and fish oil supplementation (n 




Supplemental Table 4-2. Composition of Maternal Plasma PC PUFAs (% of Total Fatty Acids) 
at 26 - 28 Weeks Gestation by Fish Oil Supplementation Status 
 Not Supplemented Supplemented P   
n 383 296  
Total n-3 PUFAs  
    α-linolenic acid [18:3 (n3)] 
    Long chain n-3 PUFAs 
Total n-6 PUFAs 
    Linoleic acid [18:2 (n6)] 
    Dihomo-ƴ-linolenic acid [20:3 (n6)] 
    Arachidonic acid [20:4 (n6)] 
n-3/n-6 ratio 
6.06  ± 1.79 
0.22  ± 0.15 
5.66  ± 1.73 
34.37  ± 3.35 
21.58  ± 3.39 
4.15  ± 1.22 
7.94  ± 1.74 
0.17  ± 0.06 
6.82  ± 1.91 
0.21  ± 0.12 
6.44  ± 1.83 
33.90  ± 3.14 
21.77 ± 3.19 
3.68  ± 1.16 
7.84  ± 1.63 









   PC= Phosphatidylcholine, PUFAs= polyunsaturated fatty acids.  






















Supplemental Table 4-3. Sensitivity Analysis for the Association between Maternal Plasma PC n-3 PUFAs and Blood Pressures at 26 - 28 Weeks 
Gestation 
Fatty Acids (%) 
Blood Pressure Outcomes 
Final Model 
Final Model Adjusted  
for Hypertension  
Before Pregnancy  
Final Model (Exclusion of  
Hypertension Before 
Pregnancy Cases)  
Final Model Adjusted for 
MUFAs 
β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P 
Peripheral SBP     
Total n-3 PUFAs -0.51 (-0.89 to -0.13) 0.008 -0.51 (-0.89 to -0.13)  0.008 -0.50 (-0.89 to -0.12 0.01 -0.48 (-0.88 to -0.09) 0.02 
α-linolenic acid -0.11 (-5.28 to 5.06) 0.97 -0.11 (-5.28 to 5.05) 0.97 0.24 (-5.00 to 5.49) 0.93 0.27 (-4.94 to 5.48) 0.92 
Long chain n-3 PUFAs -0.52 (-0.92 to -0.13) 0.01 -0.53 (-0.92 to -0.13) 0.009 -0.53 (-0.93 to -0.12) 0.01 -0.50 (-0.91 to -0.08) 0.02 
n-3/n-6 ratio* -1.51 (-2.63 to -0.38) 0.009 -1.52 (-2.64 to -0.39) 0.008 -1.49 (-2.64 to -0.34) 0.01 -1.44 (-2.58 to -0.29) 0.01 
Peripheral DBP         
Total n-3 PUFAs -0.08 (-0.38 to 0.21) 0.58 -0.08 (-0.37 to 0.21) 0.58 -0.09 (-0.39 to 0.20) 0.52 -0.02 (-0.32 to 0.29) 0.91 
α-linolenic acid -1.03 (-5.01 to 2.95) 0.61 -0.99 (-4.95 to 2.97) 0.62 -1.18 (-5.22 to 2.85) 0.56 -0.65 (-4.65 to 3.35) 0.75 
Long chain n-3 PUFAs -0.07 (-0.38 to 0.23) 0.63 -0.07 (-0.38 to 0.23) 0.63 -0.09 (-0.41 to 0.22) 0.55 -0.01 (-0.32 to 0.31) 0.97 
n-3/n-6 ratio* -0.19 (-1.05 to 0.68) 0.67 -0.19 (-1.05 to 0.68) 0.67 -0.23 (-1.11 to 0.66) 0.62 -0.07 (-0.95 to 0.81) 0.88 
Central SBP         
Total n-3 PUFAs -0.31 (-0.67 to 0.04) 0.09 -0.31 (-0.66 to 0.04) 0.09 -0.32 (-0.68 to 0.04) 0.08 -0.28 (-0.65 to 0.10) 0.15 
α-linolenic acid -1.33 (-6.15 to 3.48) 0.59 -1.26 (-6.06 to 3.53) 0.60 -0.97 (-5.85 to 3.92) 0.69 -1.00 (-5.85 to 3.84) 0.68 
Long chain n-3 PUFAs -0.30 (-0.67 to 0.07) 0.12 -0.29 (-0.66 to 0.07) 0.12 -0.32 (-0.69 to 0.06) 0.10 -0.26 (-0.64 to 0.13) 0.19 
n-3/n-6 ratio* -0.91 (-1.96 to 0.13) 0.09 -0.91 (-1.95 to 0.13) 0.09 -0.94 (-2.01 to 1.30) 0.08 -0.83 (-1.89 to 0.23) 0.12 
Central PP         
Total n-3 PUFAs 0.13 (-0.48 to 0.02) 0.07 -0.23 (-0.48 to 0.02) 0.07 -0.22 (-0.47 to 0.03) 0.08 0.13 (-0.52 to 0.00) 0.05 
α-linolenic acid -0.30 (-3.66 to 3.06) 0.86 -0.27 (-3.64 to 3.09) 0.87 0.22 (-3.19 to 3.62) 0.90 -0.35 (-3.74 to 3.03) 0.84 
Long chain n-3 PUFAs -0.22 (-0.48 to 0.04) 0.09 -0.22 (-0.48 to 0.04) 0.09 -0.22 (-0.48 to 0.04) 0.09 -0.25 (-0.52 to 0.02) 0.07 
n-3/n-6 ratio* -0.73 (-1.46 to 0.00) 0.05 -0.72 (-1.46 to 0.01) 0.05 -0.71 (-1.46 to 0.03) 0.06 -0.76 (-1.51 to -0.02) 0.04 
   CI= confidence interval, PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids, MUFAs= monounsaturated fatty acids, SBP= systolic blood 
pressure, DBP= diastolic blood pressure, PP= pulse pressure.  
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*The values were β (95% CI) for blood pressures in 0.1-unit increase of the n-3/n-6 ratio. 
   There were 14 women with hypertension before pregnancy. The final model was derived from multiple linear regression with adjustment for maternal age, 





Supplemental Table 4-4. Association Between Maternal Plasma PC n-3 PUFAs and Blood Pressures at 26 - 28 Weeks Gestation in Women without 
Fish Oil Supplementation   
  
Fatty Acids (%) 
1st Tertile 
2nd Tertile 3rd Tertile  
P   
(Trend) 
per 1% Increase 
β (95% CI) P   β (95% CI) P   β (95% CI) P   
Peripheral SBP                 
Total n-3 PUFAs Reference -0.35 (-2.66 to 1.95) 0.76 -1.88 (-4.35 to 0.59) 0.14 0.19 -0.45 (-0.99 to 0.09) 0.11 
α-linolenic acid Reference 1.59 (-0.84 to 4.03) 0.19 -0.04 (-2.46 to 2.38) 0.97 0.96 -2.08 (-8.57 to 4.40) 0.53 
Long chain n-3 PUFAs Reference -0.20 (-2.53 to 2.12) 0.86 -1.52 (-3.96 to 0.91) 0.22 0.24 -0.46 (-1.02 to 0.11) 0.12 
n-3/n-6 ratio* Reference -0.11 (-0.34 to 0.13) 0.36 -0.23 (-0.47 to 0.01) 0.06 0.06 -1.49 (-3.09 to 0.04) 0.07 
Peripheral DBP          
Total n-3 PUFAs Reference -0.34 (-2.22 to 1.53) 0.72 0.24 (-1.77 to 2.25) 0.81 0.86 0.16 (-0.28 to 0.60) 0.48 
α-linolenic acid Reference 1.13 (-0.84 to 3.11) 0.26 0.00 (-1.96 to 1.97) 0.99 0.99 -2.26 (-7.52 to 3.00) 0.39 
Long chain n-3 PUFAs Reference -0.34 (-0.22 to 1.55) 0.72 0.88 (-1.10 to 2.86) 0.38 0.43 0.21 (-0.26 to 0.67) 0.38 
n-3/n-6 ratio* Reference -0.11 (-0.30 to 0.08) 0.26 0.02 (-0.18 to 0.21) 0.86 0.96 0.49 (-0.81 to 1.79) 0.46 
Central SBP          
Total n-3 PUFAs Reference 0.23 (-1.92 to 2.39) 0.83 -1.19 (-3.51 to 1.12) 0.31 0.35 -0.10 (-0.61 to 0.41) 0.69 
α-linolenic acid Reference 1.99 (-0.28 to 4.26) 0.08 -0.32 (-2.58 to 1.93) 0.78 0.75 -2.21 (-8.28 to 3.85) 0.47 
Long chain n-3 PUFAs Reference 0.16 (-2.02 to 2.34) 0.89 -0.40 (-2.68 to 1.88) 0.73 0.75 -0.06 (-0.59 to 0.47) 0.82 
n-3/n-6 ratio* Reference -0.07 (-0.29 to 0.15) 0.55 -0.13 (-0.35 to 0.09) 0.26 0.26 -0.47 (-1.97 to 1.03) 0.54 
Central PP          
Total n-3 PUFAs Reference 0.58 (-0.89 to 2.06) 0.44 -1.44 (-3.03 to 0.15) 0.08 0.11 -0.26 (-0.62 to 0.09) 0.14 
α-linolenic acid Reference 0.86 (-0.71 to 2.42) 0.28 -0.33 (-1.89 to 1.23) 0.68 0.66 0.05 (-4.14 to 4.23) 0.98 
Long chain n-3 PUFAs Reference 0.49 (-0.99 to 1.99) 0.51 -1.28 (-2.84 to 0.29) 0.11 0.15 -0.27 (-0.64 to 0.09) 0.15 
n-3/n-6 ratio* Reference 0.04 (-1.09 to 1.96) 0.58 -0.14 (-0.29 to 0.01) 0.06 0.09 -0.96 (-1.99 to 0.07) 0.07 
   CI= confidence interval, PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids, MUFAs= monounsaturated fatty acids, SBP= systolic blood 
pressure, DBP= diastolic blood pressure, PP= pulse pressure. 
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*The values were β (95% CI) for blood pressures in 0.1-unit increase of the n-3/n-6 ratio. 
Subgroup analysis was performed in 383 women without fish oil supplementation. Results were derived from multiple linear regression with adjustment for 




Supplemental Table 4-5. Sensitivity Analysis for the Association between Maternal Plasma PC n-6 PUFAs and Blood Pressures at 26 - 28 Weeks 
Gestation  
Fatty Acids (%) 
Blood Pressure Outcomes 
Final Model 
Final Model Adjusted  
for Hypertension  
Before Pregnancy  
Final Model (Exclusion of  
Hypertension Before 
Pregnancy Cases)  
Final Model Adjusted for 
MUFAs 
β (95% CI) P   β (95% CI) P   β (95% CI) P β (95% CI) P 
Peripheral SBP      
Total n-6 PUFAs 0.18 (-0.04 to 0.40) 0.11 0.17 (-0.05 to 0.39) 0.12 0.16 (-0.06 to 0.38) 0.16 0.23 (0.00 to 0.45) 0.05 
Linoleic acid  0.14 (-0.07 to 0.35) 0.19 0.13 (-0.08 to 0.34) 0.21 0.13 (-0.08 to 0.34) 0.23 0.19 (-0.03 to 0.42) 0.08 
Dihomo-ƴ-linolenic acid  0.58 (-0.02 to 1.18) 0.06 0.57 (-0.02 to 1.17) 0.06 0.57 (-0.04 to 1.18) 0.06 0.52 (-0.11 to 1.14) 0.10 
Arachidonic acid  -0.22 (-0.66 to 0.23) 0.34 -0.20 (-0.64 to 0.24) 0.36 -0.24 (-0.68 to 0.21) 0.29 -0.19 (-0.63 to 0.25) 0.40 
Peripheral DBP         
Total n-6 PUFAs 0.08 (-0.09 to 0.25) 0.35 0.07 (-0.09 to 0.24) 0.38 0.07 (-0.10 to 0.24) 0.42 0.12 (-0.05 to 0.30) 0.17 
Linoleic acid  0.02 (-0.14 to 0.18) 0.83 0.01 (-0.15 to 0.17) 0.42 -0.00 (-0.16 to 0.16) 0.99 0.07 (-0.09 to 0.24) 0.40 
Dihomo-ƴ-linolenic acid  0.29 (-0.17 to 0.75) 0.21 0.29 (-0.17 to 0.74) 0.22 0.33 (-0.14 to 0.79) 0.17 0.21 (-0.27 to 0.69) 0.40 
Arachidonic acid  0.00 (-0.34 to 0.34) 0.99 0.01 (-0.32 to 0.35) 0.93 0.01 (-0.33 to 0.36) 0.94 0.03 (-0.31 to 0.37) 0.88 
Central SBP         
Total n-6 PUFAs 0.13 (-0.07 to 0.33) 0.22 0.12 (-0.08 to 0.33) 0.23 0.12 (-0.09 to 0.33) 0.26 0.17 (-0.04 to 0.38) 0.11 
Linoleic acid  0.05 (-0.15 to 0.24) 0.63 0.04 (-0.15 to 0.24) 0.68 0.04 (-0.16 to 0.24) 0.69 0.10 (-0.10 to 0.31) 0.34 
Dihomo-ƴ-linolenic acid  0.52 (-0.04 to 1.07) 0.07 0.51 (-0.04 to 1.06) 0.07 0.54 (-0.03 to 1.10) 0.06 0.46 (-0.12 to 1.04) 0.12 
Arachidonic acid  -0.03 (-0.44 to 0.38) 0.89 -0.01 (-0.42 to 0.39) 0.97 -0.04 (-0.46 to 0.37) 0.83 0.00 (-0.42 to 0.41) 0.99 
Central PP         
Total n-6 PUFAs 0.05 (-0.09 to 0.19) 0.50 0.05 (-0.09 to 0.19) 0.50 0.05 (-0.09 to 0.19)  0.50 0.05 (-0.10 to 0.20) 0.52 
Linoleic acid  0.03 (-0.11 to 0.17) 0.66 0.03 (-0.11 to 0.17) 0.67 0.04 (-0.10 to 0.18) 0.57 0.03 (-0.12 to 0.17) 0.70 
Dihomo-ƴ-linolenic acid  0.22 (-0.16 to 0.61) 0.26 0.22 (-0.16 to 0.61) 0.26 0.21 (-0.18 to 0.60) 0.29 0.26 (-0.15 to 0.66) 0.21 
Arachidonic acid  -0.03 (-0.31 to 0.26) 0.85 -0.02 (-0.31 to 0.26) 0.87 -0.06 (-0.35 to 0.23) 0.69 -0.03 (-0.32 to 0.26) 0.83 
   CI= confidence interval, PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids, MUFAs= monounsaturated fatty acids, SBP= systolic blood 




   There were 14 women with hypertension before pregnancy. Final model was derived from multiple linear regression with adjustment for maternal age, 





Supplemental Table 4-6. Association Between Maternal Plasma PC n-6 PUFAs and Blood Pressures at 26 - 28 Weeks Gestation in Women without Fish 
Oil Supplementation  
  
Fatty Acids (%) 
1st Tertile 
2nd Tertile 3rd Tertile P   
(Trend) 
per 1% Increase 
β (95% CI) P   β (95% CI) P   β (95% CI) P   
Peripheral SBP                 
Total n-6 PUFAs Reference 0.24 (-2.18 to 2.67) 0.84 1.54 (-0.86 to 3.94) 0.21 0.19 0.24 (0.04 to 0.53) 0.10 
Linoleic acid  Reference 0.97 (-1.37 to 3.32) 0.42 0.24 (-2.22 to 2.70) 0.85 0.83 0.13 (-0.16 to 0.43) 0.37 
Dihomo-ƴ-linolenic acid  Reference 4.52 (1.99 to 7.04) <0.001 3.94 (1.45 to 6.34) 0.002 0.005 0.78 (-0.05 to 1.61) 0.06 
Arachidonic acid  Reference 1.85 (-0.51 to 4.22) 0.12 1.43 (-1.13 to 3.99) 0.27 0.25 -0.01 (-0.61 to 0.59) 0.97 
Peripheral DBP          
Total n-6 PUFAs Reference 1.08 (-0.89 to 3.05) 0.28 1.38 (-0.56 to 3.33) 0.16 0.17 0.08 (-0.16 to 0.31) 0.53 
Linoleic acid  Reference 1.01 (-0.89 to 2.91) 0.29 -0.01 (-2.01 to 1.99) 0.99 0.97 -0.02 (-0.25 to 0.22) 0.89 
Dihomo-ƴ-linolenic acid  Reference 2.67 (0.59 to 4.74) 0.01 1.52 (-0.52 to 3.56) 0.14 0.22 -0.01 (-0.68 to 0.67) 0.98 
Arachidonic acid  Reference 2.23 (0.32 to 4.15) 0.02 1.83 (-0.24 to 3.90) 0.08 0.07 0.30 (-0.19 to 0.79) 0.23 
Central SBP          
Total n-6 PUFAs Reference 0.25 (-2.02 to 2.52) 0.83 1.29 (-0.96 to 3.54) 0.26 0.25 0.19 (-0.08 to 0.47) 0.16 
Linoleic acid  Reference 1.49 (-0.69 to 3.67) 0.18 -0.64 (-2.93 to 1.66) 0.59 0.63 0.04 (-0.24 to 0.31) 0.79 
Dihomo-ƴ-linolenic acid  Reference 3.82 (1.45 to 6.19) 0.002 3.36 (1.03 to 5.69) 0.005 0.01 0.62 (-0.16 to 1.39) 0.12 
Arachidonic acid  Reference 2.80 (0.60 to 4.99) 0.01 2.29 (-0.09 to 4.68) 0.06 0.05 0.28 (-0.28 to 0.84) 0.32 
Central PP          
Total n-6 PUFAs Reference -0.83 (-2.40 to 0.74) 0.29 -0.09 (-1.64 to 1.45) 0.90 0.97 0.12 (-0.07 to 0.31) 0.21 
Linoleic acid  Reference 0.47 (-1.04 to 1.98) 0.54 -0.63 (-2.22 to 0.96) 0.44 0.46 0.05 (-0.14 to 0.24) 0.58 
Dihomo-ƴ-linolenic acid  Reference 1.15 (-0.50 to 2.79) 0.17 1.84 (0.22 to 3.47) 0.03 0.03 0.63 (0.09 to 1.16) 0.02 




   CI= confidence interval, PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids, MUFAs= monounsaturated fatty acids, SBP= systolic 
blood pressure, DBP= diastolic blood pressure, PP= pulse pressure. 
 
   Subgroup analysis was performed in 383 women without fish oil supplementation. Results were derived from multiple linear regression with 
adjustment for maternal age, ethnicity, education, exercise, alcohol intake, smoking status, BMI and height at 26 - 28 weeks gestation, 
gestational diabetes and heart rate.  
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2nd Tertile 3rd Tertile 
P   
(Trend) 
per 1% Increase 
P   
(Interaction) 
β (95% CI) P   β (95% CI) P   β (95% CI) P   
Peripheral SBP                    
Total n-3 
PUFAs 
Chinese Reference -3.84 (-6.35 to -1.34) 0.003 -3.15 (-5.53 to -0.77) 0.01 0.02 -0.66 (-1.17 to -0.15) 0.01 
0.06 Malay Reference 0.07 (-2.98 to 3.12) 0.96 -0.43 (-4.03 to 3.16) 0.81 0.83 0.21 (-0.60 to 1.01) 0.61 
Indian Reference -4.46 (-8.21 to -0.71) 0.02 -3.44 (-7.68 to 0.80) 0.11 0.07 -0.85 (-1.76 to 0.06) 0.07 
α-linolenic 
acid 
Chinese Reference 1.60 (-0.87 to 4.07) 0.20 -0.44 (-2.81 to 1.92) 0.71 0.69 -1.63 (-9.13 to 5.86) 0.67 
0.69 Malay Reference 1.96 (-1.25 to 5.18) 0.23 2.29 (-1.24 to 5.84) 0.20 0.18 3.64 (-7.07 to 14.35) 0.50 




Chinese Reference -3.29 (-5.78 to -0.80) 0.01 -3.62 (-5.99 to -1.25) 0.003 0.004 -0.65 (-1.18 to -0.13) 0.02 
0.07 Malay Reference 0.72 (-2.33 to 3.77) 0.64 1.50 (-2.11 to 5.08) 0.42 0.41 0.20 (-0.65 to 1.05) 0.64 
Indian Reference -4.29 (-8.19 to -0.39) 0.03 -2.49 (-6.67 to 1.69) 0.24 0.18 -0.90 (-1.85 to 0.05) 0.06 
n-3/n-6 
ratio* 
Chinese Reference -1.80 (-4.32 to 0.72) 0.16 -2.69 (-5.1 to -0.28) 0.03 0.03 -1.84 (-3.38 to -0.31) 0.02 
0.02 Malay Reference -0.94 (-3.98 to 2.11) 0.55 -0.54 (-4.09 to 3.02) 0.77 0.71 0.57 (-1.72 to 2.86) 0.62 
Indian Reference -3.10 (-7.09 to 0.89) 0.13 -4.76 (-8.93 to -0.60) 0.03 0.02 -3.45 (-6.17 to -0.82) 0.01 
Peripheral DBP                    
Total n-3 
PUFAs 
Chinese Reference -2.00 (-3.94 to -0.06) 0.04 -1.36 (-3.20 to 0.48) 0.15 0.18 -0.27 (-0.67 to 0.12) 0.17 
0.03 Malay Reference 0.97 (-1.33 to 3.26) 0.41 1.02 (-1.68 to 3.73) 0.46 0.41 0.51 (-0.10 to 1.11) 0.10 
Indian Reference -1.56 (-4.54 to 1.42) 0.30 -1.34 (-4.71 to 2.03) 0.43 0.38 -0.39 (-1.11 to 0.33) 0.28 
α-linolenic 
acid 
Chinese Reference 1.59 (-0.30 to 3.48) 0.10 -0.70 (-2.51 to 1.11) 0.45 0.42 -3.75 (-9.49 to 2.00) 0.20 
0.19 Malay Reference -0.29 (-2.71 to 2.14) 0.82 1.44 (-1.24 to 4.11) 0.29 0.33 3.99 (-4.08 to 12.06) 0.33 






Chinese Reference -1.60 (-3.53 to 0.33) 0.10 -1.58 (-3.41 to 0.26) 0.09 0.11 -0.26 (-0.66 to 0.15) 0.22 
0.04 Malay Reference 0.56 (-1.73 to 2.85) 0.63 2.42 (-0.27 to 5.12) 0.08 0.09 0.51 (-0.13 to 1.14) 0.12 
Indian Reference -1.80 (-4.89 to 1.28) 0.25 -1.14 (-4.44 to 2.17) 0.50 0.44 -0.41 (-1.15 to 0.34) 0.28 
n-3/n-6 
ratio* 
Chinese Reference -1.06 (-3.00 to 0.88) 0.29 -0.99 (-2.85 to 0.87) 0.30 0.32 -0.54 (-1.73 to 0.64) 0.37 
0.03 Malay Reference -0.09 (-2.39 to 2.21) 0.94 0.92 (-1.77 to 3.60) 0.50 0.55 1.42 (-0.29 to 3.14) 0.10 
Indian Reference -2.31 (-5.44 to 0.81) 0.15 -3.16 (-6.42 to 0.10) 0.06 0.05 -1.82 (-3.94 to 0.29) 0.09 
Central SBP                    
Total n-3 
PUFAs 
Chinese Reference -2.79 (-5.12 to -0.46) 0.02 -2.56 (-4.78 to -0.35) 0.02 0.03 -0.49 (-0.97 to -0.02) 0.04 
0.02 Malay Reference 1.05 (-1.76 to 3.87) 0.46 0.38 (-2.93 to 3.70) 0.82 0.74 0.46 (-0.28 to 1.2) 0.23 
Indian Reference -3.76 (-7.22 to -0.29) 0.03 -2.99 (-6.90 to 0.93) 0.13 0.09 -0.67 (-1.51 to 0.17) 0.12 
α-linolenic 
acid 
Chinese Reference 1.53 (-0.75 to 3.82) 0.19 -1.10 (-3.29 to 1.09) 0.32 0.31 -3.63 (-10.57 to 3.31) 0.30 
0.42 Malay Reference 1.67 (-1.30 to 4.64) 0.27 1.89 (-1.39 to 5.16) 0.26 0.24 3.67 (-6.22 to 13.56) 0.47 




Chinese Reference -2.44 (-4.76 to -0.12) 0.04 -2.85 (-5.06 to -0.64) 0.01 0.01 -0.46 (-0.95 to 0.04) 0.07 
0.03 Malay Reference 1.12 (-1.69 to 3.93) 0.43 2.52 (-0.78 to 5.82) 0.13 0.13 0.47 (-0.31 to 1.25) 0.23 
Indian Reference -3.77 (-7.36 to -0.17) 0.04 -2.20 (-6.05 to 1.66) 0.26 0.20 -0.72 (-1.60 to 0.16) 0.11 
n-3/n-6 
ratio* 
Chinese Reference -1.04 (-3.38 to 1.30) 0.38 -2.01 (-4.25 to 0.23) 0.08 0.08 -1.36 (-2.79 to 0.06) 0.06 
0.02 Malay Reference 0.06 (-2.76 to 2.88) 0.97 0.62 (-2.66 to 3.91) 0.71 0.73 1.14 (-0.97 to 3.25) 0.29 
Indian Reference -2.61 (-6.30 to 1.07) 0.16 -4.00 (-7.85 to -0.15) 0.04 0.04 -2.57 (-5.06 to -0.08) 0.04 
Central PP                    
Total n-3 
PUFAs 
Chinese Reference -0.79 (-2.35 to 0.76) 0.32 -1.20 (-2.68 to 0.28) 0.11 0.11 -0.22 (-0.54 to 0.09) 0.17 
0.67 Malay Reference 0.09 (-1.79 to 1.96) 0.93 -0.64 (-2.85 to 1.57) 0.57 0.61 -0.05 (-0.55 to 0.45) 0.84 
Indian Reference -2.20 (-5.13 to 0.73) 0.14 -1.65 (-4.96 to 1.67) 0.33 0.27 -0.28 (-0.99 to 0.43) 0.43 
α-linolenic 
acid 
Chinese Reference -0.06 (-1.58 to 1.47) 0.94 -0.40 (-1.86 to 1.06) 0.59 0.59 0.11 (-4.49 to 4.72) 0.96 
0.91 Malay Reference 1.96 (-0.01 to 3.92) 0.05 0.45 (-1.72 to 2.62) 0.68 0.56 -0.32 (-6.92 to 6.28) 0.92 






Chinese Reference -0.84 (-2.39 to 0.70) 0.28 -1.27 (-2.75 to 0.20) 0.09 0.09 -0.20 (-0.53 to 0.13) 0.23 
0.70 Malay Reference 0.56 (-1.32 to 2.44) 0.56 0.10 (-2.12 to 2.31) 0.93 0.87 -0.04 (-0.56 to 0.49) 0.89 
Indian Reference -1.96 (-5.01 to 1.09) 0.21 -1.06 (-4.33 to 2.21) 0.52 0.45 -0.31 (-1.05 to 0.43) 0.41 
n-3/n-6 
ratio* 
Chinese Reference 0.02 (-1.53 to 1.57) 0.98 -1.02 (-2.51 to 0.46) 0.18 0.15 -0.82 (-1.76 to 0.12) 0.09 
0.66 Malay Reference 0.16 (-1.72 to 2.03) 0.87 -0.29 (-2.48 to 1.90) 0.79 0.83 -0.28 (-1.69 to 1.13) 0.69 
Indian Reference -0.30 (-3.45 to 2.85) 0.85 -0.84 (-4.13 to 2.44) 0.61 0.62 -0.74 (-2.86 to 1.37) 0.49 
CI= confidence interval, PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids, MUFAs= monounsaturated fatty acids, SBP= systolic blood 
pressure, DBP= diastolic blood pressure, PP= pulse pressure. 
*The values were β (95% CI) for blood pressures in 0.1-unit increase of the n-3/n-6 ratio.  
Results were derived from multiple linear regression with adjustment for maternal age, education, exercise, alcohol intake, smoking status, BMI and height at 













2nd Tertile 3rd Tertile 
P   
Trend 
per 1% Increase 
P   
Interaction 
β (95% CI) P   β (95% CI) P   β (95% CI) P   
Peripheral SBP                    
Total n-6 
PUFAs 
Chinese Reference -0.68 (-3.03 to 1.68) 0.57 1.22 (-1.26 to 3.70) 0.33 0.36 0.11 (-0.21 to 0.44) 0.49 
0.14 Malay Reference -3.09 (-6.28 to 0.09) 0.06 0.41 (-3.01 to 3.83) 0.81 0.79 0.13 (-0.30 to 0.57) 0.55 
Indian Reference 3.73 (-0.62 to 8.09) 0.09 5.33 (1.24 to 9.42) 0.01 0.01 0.52 (0.09 to 0.95) 0.02 
Linoleic 
acid 
Chinese Reference 1.45 (-0.92 to 3.83) 0.23 1.34 (-1.06 to 3.75) 0.27 0.27 0.04 (-0.26 to 0.35) 0.78 
0.02 Malay Reference -0.82 (-4.33 to 2.68) 0.64 0.24 (-3.05 to 3.54) 0.88 0.83 0.11 (-0.29 to 0.50) 0.59 




Chinese Reference 2.63 (0.33 to 4.93) 0.03 1.63 (-0.88 to 4.16) 0.20 0.14 0.47 (-0.41 to 1.33) 0.30 
0.97 Malay Reference 1.73 (-1.76 to 5.23) 0.33 2.53 (-0.95 to 6.00) 0.15 0.16 0.83 (-0.36 to 2.02) 0.17 
Indian Reference 1.26 (-3.90 to 6.41) 0.63 2.99 (-1.65 to 7.63) 0.21 0.16 0.35 (-0.92 to 1.61) 0.59 
Arachidonic 
acid 
Chinese Reference 1.17 (-1.17 to 3.51) 0.33 0.97 (-1.55 to 3.48) 0.45 0.44 -0.05 (-0.70 to 0.60) 0.88 
0.71 Malay Reference -0.70 (-3.72 to 2.33) 0.65 -2.96 (-6.74 to 0.83) 0.13 0.15 -0.54 (-1.49 to 0.42) 0.27 
Indian Reference -1.15 (-6.50 to 4.20) 0.67 0.04 (-4.52 to 4.59) 0.99 0.84 -0.24 (-1.06 to 0.58) 0.56 
Peripheral DBP                    
Total n-6 
PUFAs 
Chinese Reference -0.42 (-2.23 to 1.39) 0.65 -0.13 (-2.04 to 1.78) 0.89 0.87 -0.06 (-0.32 to 0.19) 0.61 
0.05 Malay Reference -0.56 (-2.98 to 1.87) 0.65 1.28 (-1.33 to 3.88) 0.34 0.33 0.07 (-0.26 to 0.40) 0.68 
Indian Reference 2.22 (-1.20 to 5.64) 0.20 3.52 (0.31 to 6.73) 0.03 0.03 0.37 (0.03 to 0.71) 0.03 
Linoleic 
acid 
Chinese Reference 0.06 (-1.77 to 1.89) 0.95 0.10 (-1.75 to 1.96) 0.91 0.91 -0.07 (-0.30 to 0.16) 0.56 
0.13 Malay Reference 1.42 (-1.21 to 4.05) 0.29 -0.09 (-2.56 to 2.38) 0.94 0.84 0.06 (-0.24 to 0.36) 0.68 






Chinese Reference 1.66 (-0.11 to 3.43) 0.07 1.16 (-0.78 to 3.10) 0.24 0.18 0.22 (-0.45 to 0.89) 0.51 
0.49 Malay Reference 0.76 (-1.88 to 3.41) 0.57 1.32 (-1.31 to 3.95) 0.32 0.32 0.17 (-0.74 to 1.07) 0.72 
Indian Reference 2.44 (-1.55 to 6.43) 0.23 3.37 (-0.22 to 6.97) 0.07 0.07 0.60 (-0.38 to 1.58) 0.23 
Arachidonic 
acid 
Chinese Reference 1.54 (-0.25 to 3.33) 0.09 0.02 (-1.90 to 1.94) 0.98 0.95 -0.15 (-0.65 to 0.35) 0.55 
0.60 Malay Reference 0.02 (-2.27 to 2.32) 0.98 -0.87 (-3.74 to 2.01) 0.55 0.61 -0.19 (-0.92 to 0.53) 0.60 
Indian Reference 2.21 (-1.94 to 6.36) 0.29 1.96 (-1.58 to 5.49) 0.28 0.37 0.27 (-0.36 to 0.91) 0.40 
Central SBP                    
Total n-6 
PUFAs 
Chinese Reference -0.70 (-2.89 to 1.48) 0.53 0.58 (-1.72 to 2.88) 0.62 0.66 0.05 (-0.25 to 0.36) 0.73 
0.26 Malay Reference -2.34 (-5.30 to 0.61) 0.12 0.67 (-2.50 to 3.84) 0.68 0.66 0.17 (-0.24 to 0.57) 0.42 
Indian Reference 1.37 (-2.70 to 5.44) 0.51 3.21 (-0.61 to 7.03) 0.10 0.09 0.30 (-0.10 to 0.70) 0.14 
Linoleic 
acid 
Chinese Reference 1.21 (-0.99 to 3.42) 0.28 0.44 (-1.79 to 2.67) 0.69 0.69 -0.02 (-0.30 to 0.26) 0.89 
0.11 Malay Reference -0.17 (-3.40 to 3.06)  0.92 -0.43 (-3.46 to 2.61) 0.78 0.78 0.08 (-0.29 to 0.45) 0.68 




Chinese Reference 2.11 (-0.02 to 4.25) 0.05 1.79 (-0.55 to 4.13) 0.13 0.10 0.40 (-0.40 to 1.21) 0.33 
0.99 Malay Reference 1.19 (-2.04 to 4.41) 0.47 2.50 (-0.70 to 5.71) 0.13 0.12 0.79 (-0.31 to 1.89) 0.16 
Indian Reference 2.41 (-2.32 to 7.14) 0.32 3.48 (-0.78 to 7.74) 0.11 0.12 0.37 (-0.79 to 1.54) 0.53 
Arachidonic 
acid 
Chinese Reference 1.56 (-0.60 to 3.72) 0.16 0.83 (-1.49 to 3.16) 0.48 0.47 0.03 (-0.57 to 0.63) 0.93 
0.93 Malay Reference -0.13 (-2.93 to 2.68) 0.93 -1.37 (-4.88 to 2.15) 0.44 0.50 -0.19 (-1.07 to 0.70) 0.68 
Indian Reference -0.19 (-5.12 to 4.74) 0.94 0.36 (-3.83 to 4.56) 0.86 0.81 -0.11 (-0.86 to 0.65) 0.78 
Central PP                     
Total n-6 
PUFAs 
Chinese Reference -0.28 (-1.73 to 1.16) 0.70 0.71 (-0.81 to 2.24) 0.36 0.39 0.12 (-0.08 to 0.32) 0.25 
0.83 Malay Reference -1.79 (-3.76 to 0.19) 0.08 -0.61 (-2.73 to 1.51) 0.57 0.59 0.10 (-0.17 to 0.37) 0.48 
Indian Reference -0.84 (-4.30 to 2.61) 0.63 -0.31 (-3.55 to 2.94) 0.85 0.93 -0.07 (-0.41 to 0.27) 0.69 





Malay Reference -1.59 (-3.74 to 0.55) 0.14 -0.34 (-2.34 to 1.67) 0.74 0.86 0.01 (-0.23 to 0.26) 0.91 




Chinese Reference 0.45 (-0.97 to 1.87) 0.53 0.63 (-0.93 to 2.19) 0.43 0.41 0.18 (-0.36 to 0.71) 0.51 
0.29 Malay Reference 0.43 (-1.73 to 2.58) 0.70 1.18 (-0.96 to 3.33) 0.28 0.27 0.62 (-0.11 to 1.35) 0.09 
Indian Reference -0.03 (-4.04 to 3.98) 0.99 0.10 (-3.51 to 3.71) 0.96 0.94 -0.23 (-1.21 to 0.75) 0.64 
Arachidonic 
acid 
Chinese Reference 0.02 (-1.41 to 1.46) 0.98 0.81 (-0.73 to 2.35) 0.30 0.31 0.18 (-0.22 to 0.58) 0.38 
0.42 Malay Reference -0.15 (-2.02 to 1.72) 0.87 -0.50 (-2.84 to 1.85) 0.68 0.69 0.01 (-0.58 to 0.60) 0.98 
Indian Reference -2.39 (-6.50 to 1.71) 0.25 -1.59 (-5.09 to 1.90) 0.37 0.54 -0.38 (-1.01 to 0.25) 0.23 
   CI= confidence interval, PC= phosphatidylcholine, PUFAs= polyunsaturated fatty acids, MUFAs= monounsaturated fatty acids, SBP= systolic blood 
pressure, DBP= diastolic blood pressure, PP= pulse pressure. 
   Results were derived from multiple linear regression with adjustment for maternal age, education, exercise, alcohol intake, smoking status, BMI and height 

















MATERNAL BLOOD PRESSURES DURING PREGNANCY 
AND OFFSPRING SIZE AT BIRTH  
 
This chapter was based on the paper published in BMC Pregnancy and 
Childbirth: 
Wai-Yee Lim, Yung-Seng Lee, Chuen-Seng Tan, Kenneth Kwek, Yap-
Seng Chong, Peter D Gluckman, Keith M Godfrey, Seang-Mei Saw and 
An Pan. The association between maternal blood pressures and offspring 
size at birth in Southeast Asian women. BMC Pregnancy Childbirth. 





Birth weight is an important measure of intra-uterine growth. Various 
maternal and fetal factors are known to influence size at birth. 69, 73 Amongst 
these factors, maternal blood pressures have been considered as an important 
determinant. Various epidemiological studies have suggested that maternal 
hypertension is associated with an increased risk of lower birth weight.150, 151 
Reduced utero-placental function has been suggested as one possible 
mechanism because this has been found to occur in women with concurrent 
pre-eclampsia and fetal growth restriction.73 
Several studies have investigated the associations between offspring’s 
birth weight and maternal peripheral 9, 118, 150, 152-165 and central blood 
pressures,155, 159, 160 with inverse relations reported in most studies,9, 150, 152-155, 
159-165 but not all (Table 5-1).156-158 Some studies have also suggested that the 
relation between maternal central blood pressures and size at birth may be 
more pronounced than peripheral blood pressures.159, 160 However, studies that 
compared maternal peripheral and central blood pressures concurrently were 
fewer and smaller in sample size, ranging around 40-50 women, compared to 






Table 5-1: Evidence Table for the Associations between Maternal Blood Pressures, Hypertension and Birth Weight 


















At 26 – 33 
weeks gestation 





DBP and PP 
Central SBP and augmentation index were inversely 
associated with birth weight (r=-0.26, p<0.01 and r=-0.33, 
p<0.01, respectively).  
Peripheral SBP, DBP and PP were not associated with birth 
weight. 
2 











Central augmentation index, measured at 22 and 34 weeks 
gestation was inversely correlated with birth weight centile  
(r=-0.36, p=0.01 and r=-0.42, p=0.05, respectively) 
3 














Third trimester DBP is inversely associated with birth weight, 
length and head circumference, whereas third trimester SBP is 
inversely associated with lower birth weight only. Second 
trimester blood pressure is not associated with any birth 
measures 
4 











Significant interaction between DBP and composite stress 
(p<0.04); In high stress – negative association between DBP 
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and birth weight (p=0.05); no significant association in low 
stress.  
No significant association observed in SBP 
5 
Elvan-












Pulse wave velocity and central pulse pressure are associated 
with birth weight (centiles) [ß(SD): -17.6(7.0); p=0.016 and -
1.8(0.4); p<0.001, respectively]; and only pulse wave velocity 
is associated with catch up growth at 6 months [22.3(8.7); 
p=0.015] 
6 








35.6 ± 3.5 weeks 
Ambulatory 
peripheral DBP 
Day time blood pressure: 
SBP: -7.6 (95%CI -15.8 to 0.60) g 
DBP: -13.5 (95%CI -23.4 to -3.60) g 
 
Night time blood pressure: 
SBP: -4.6 (95%CI -13.5 to 4.30) g  













18 weeks gestation: 
SBP: 0·7 (-9·4 to 10·8) g 
DBP: -8·1 (-23·3 to 6·9) g 
28 weeks gestation: 
SBP: -4·0 (-14·5 to 6·6) g 
DBP: -21·5 (-35·7 to -7·2) g 
38 weeks gestation: 
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SBP: -10·8 (-18·4 to -3·2) g 
DBP: -24·1 (-33·7 to -14·5) g 
8 












Mothers with SBP < 110 mmHg or >130 mmHg had higher 
risk to LBW compared to those with SBP 110 – 130 mmHg 
(OR 1.2 and 1.4 respectively) 
 
Mothers with DBP <75 mmHg or >85 mmHg had higher risk 
to LBW compared to those with DBP 75-85 mmHg (OR 1.2 













Positively associated with birth weight (z scores) for South 
Asians only, p<0.001 
10 











>34 weeks gestation, Inverted u shaped association between 
DBP and birth weight. Highest birth weight was observed in 
DBP between 70-90mmHg 
11 








From prenatal at 




High DBP at baseline and excessive rise ≥15mmHg is 
associated with twice the risk of having a small baby 
12 













Significant difference in birth weight between women with 
severe preeclampsia vs normotensive women when delivered 





Women with gestational hypertension/ preeclampsia had 
higher risk to delivering small for gestational age offspring 












Risk of SGA was 4 times higher in women with preeclampsia 
(RR 4.2 95%CI 2.2 – 8.0) 
14 











Women with preeclampsia had higher risk to smaller 
offspring (birth weight < 2kg);  
In whites: RR 2.8 (95%CI 1.6 – 5.0) 
In blacks: RR 2.8 (95%CI 1.7 – 4.5) 
In Indo-Asians: RR 5.6 (95%CI 3.8 – 8.2) 
15 












Severe PIH were associated with significant lowering of birth 
weight.  
SBP ≥160 mm of Hg : Birth weight reduced by 151 g 
(p<0.01)  













Women with higher pre-pregnancy peripheral SBP and DBP 













DBP amplitude (extent of change within the day) is associated 
with increased odds to growth restricted newborns OR 1.7 
(95%CI 1.1–2.8), p=0.03; SBP amplitude and mean (SBP & 
DBP) not associated with growth restriction 
SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; OR, odds ratio; RR, risk ratio  
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There is evidence that the relation between maternal blood pressures and 
offspring’s birth weight were found to be stronger in Asian Indians than white 
or black women, 161 and was more evident in normal weight women than 
obese women.152 As the incidence of small for gestational age in Southeast 
Asian women is one of the highest in the world,70 examining inter-ethnic 
variation may enable specific and appropriate public health interventions.   
Therefore, we aimed to simultaneously examine both maternal peripheral 
and central blood pressures in relation to size at birth, and to explore the possible 
effect modification by maternal ethnicity or adiposity in pregnancy in a 
Southeast Asian birth cohort of pregnant Chinese, Malay and Indian women. 
 
5.2 Methods 
The present study sample was drawn from the Growing Up in Singapore 
Towards healthy Outcomes (GUSTO) study,85 a prospective early life cohort 
study comprising Chinese, Indian and Malay women. Between 2009 and 2010, 
a total of 1162 pregnant women without type 1 diabetes or using 
chemotherapy or psychotropic drugs were recruited from two tertiary hospitals 
in Singapore. We excluded 333 women (28.6%) women who did not attend 
the blood pressure measurements or had incomplete recordings around 27 
weeks, and 116 women who had incomplete demographic and pregnancy 
information, leaving a total of 713 women for the current analysis (Figure 5-
1). Women who were excluded from the analysis had similar demographic 
characteristics compared with those who were included, although they had 
shorter gestation duration and smaller offspring (Supplemental Table 5-1). The 
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GUSTO study was approved by the SingHealth Centralized Institutional 
Review Board (CIRB Ref: 2009/280/D) and National Health Group Domain 




Figure 5-1. Flow Chart of the GUSTO Study Sample Selected for Analysis                      
GUSTO Participants
(N=1162)
Women with  blood pressure 
measurements and 
evaluable radial pulse wave forms 
at  27 weeks gestation (n=829)
Women with information on size 
at birth: weight (n=795); length 
(n=794); head circumference 
(n=794); placenta  (n=779)
Available data for analysis
birth weight (N=713); 
length (N =711); 
head circumference (N=711); 
placenta (N=699)
Excluded due to missing covariates: 
age & ethnicity (n=12); education (n=9); 
maternal weight and height (n=17); parity, 
smoking history (n=23), coffee (n=1),Edinburgh Postnatal 
Depression Score (n=19), gestation  at delivery 
and babys gender (n=1); 
(total n=82)
Excluded due to missing 
birth weight
(n=34)
Excluded due to no blood pressure or radial pulse wave 
measurement at 27 weeks gestation (n=269) and 




At their enrolment visit prior to 14 weeks gestation, study participants 
were interviewed for baseline information on age, ethnicity, educational level, 
pre-pregnancy body weight, smoking history, coffee consumption and number 
of previous live-births. They were followed up at mid-pregnancy [median 
gestation of 27 weeks (interquartile range 26 to 29 weeks)] to measure 
maternal height and weight, as well as blood pressures using standard 
protocols 12. Depression status (defined as an overall score of 13 or greater 
from the self-administered Edinburgh Postnatal Depression Scale) and 
gestational diabetes (defined as fasting plasma glucose ≥7.0 mmol/L or 2-hour 
glucose ≥11.1 mmol/L)166  was also examined during this visit. Maternal body 
mass index (BMI)  before pregnancy and GUSTO mid-pregnancy follow-up 
visit were calculated as weight in kg divided by the square of height in meter, 
and categorised as normal weight for BMI <25.0 kg/m2, overweight as 25.0 to 
29.9 kg/m2 and obese as ≥30.0 kg/m2 according to the WHO international 
classification.105 Rate of weight gain was calculated as the weight difference 
before pregnancy and at GUSTO mid-pregnancy follow-up visit in kg divided 
by the length of gestation during mid-pregnancy in weeks. 
Study participants were rested for at least 10 minutes prior to the first 
blood pressure measurement. Peripheral systolic and diastolic blood pressures 
(SBP and DBP) were taken on the right brachial artery at the level of the heart. 
Using an oscillometric device (MC3100, HealthSTATS International Pte Ltd, 
Singapore), three blood pressure readings were taken consecutively at 30 to 60 
seconds apart to obtain the average reading of SBP and DBP. The A-pulse 
tonometer (BPro®, HealthSTATS International Pte Ltd, Singapore) was then 
applied on the radial artery of the same arm for continuous sampling of radial 
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artery waveforms for at least 60 seconds. Central SBP was estimated from the 
calibrated radial artery waveforms 12, and central pulse pressure (PP) was 
calculated as the difference between central SBP and peripheral DBP 62.  
Information on offspring size at birth (weight, length, head circumference 
and placental weight) were extracted from medical records, which were 
measured by midwives according to standard hospital protocols. Gestational age 
adjusted standard deviation (SD) scores for birth weight, length, head 
circumference and placental weight were constructed for the GUSTO cohort. 
The binary outcome of low birth weight was defined as weight at birth <2500 
g, and small for gestational age was defined as those who were below the 10th 
percentile for gestational age adjusted birth weight. 
Blood pressure values were converted into SD scores, whereby per 1-SD 
increase in peripheral SBP and DBP was equivalent to 11.1 and 8.3 mmHg, 
respectively, and central SBP and PP to 10.0 and 6.5 mmHg, respectively. 
Maternal characteristics were compared across blood pressures using analysis 
of variance. The relation between blood pressures and size at birth were 
examined using multiple linear and logistic regression models for continuous 
and binary birth size outcomes, respectively. All analyses were adjusted for 
baby’s sex, gestation age at delivery in weeks, maternal age, ethnicity, education, 
parity, smoking history, height, BMI around 27 weeks gestation, coffee 
consumption and depression. No adjustment was made for chronic hypertension 
as there were only 13 (1.8%) women with this condition. 
We further evaluated the potential effect modification by maternal ethnicity 
(Chinese, Indian, or Malay) and BMI categories (normal, overweight, or obese). 
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Multiplicative interaction terms with blood pressures as continuous variable and 
ethnicity or BMI as a categorical variable were added to the final model, and 
the likelihood ratio test was used to evaluate significance. We also reported the 
results stratified by maternal ethnicity (Chinese, Indian, or Malay) and BMI 
category (normal weight, overweight, or obese). 
We performed a series of sensitivity analyses to test the robustness of our 
results: (1) we additionally adjusted for gestational diabetes (n = 663 due to 50 
missing data for gestational diabetes status); (2) we examined a subgroup of 705 
women within normal range of blood pressures (peripheral SBP and DBP below 
140 and 90 mmHg, respectively); (3) we repeated our analysis using the imputed 
data (20 sets) for the missing information on blood pressures (imputed based on 
maternal age, ethnicity, education, parity, gestational diabetes, height and BMI 
around 27 weeks gestation, and the respective outcome variable); (4) we 
adjusted for pre-pregnancy BMI and rate of weight gain instead of BMI around 
27 weeks gestation (n = 678 due to 35 missing data for pre-pregnancy weight); 
(5) we used tertiles of BMI around 27 weeks gestation instead of the WHO 
classification to test for interaction between maternal adiposity and blood 
pressures; (6) lastly, we examined gestational age adjusted size at birth 
measures as the outcomes instead of actual values to better account for the effect 
of gestational duration on size at birth. All analyses were performed using Stata 
version 11.2 (Statacorp, College Station, Texas), with statistical significance at 




Of the 713 women studied, 339 (55.9%) were Chinese, 196 (27.5%) were 
Indians and 118 (16.6%) were Malays. The mean age at enrolment was 30.5 
(SD = 5.1) years. At the GUSTO study follow-up, 17.5% were obese at around 
27 weeks gestation (Tables 1 and Additional file 1: Table S1). Mean (SD) values 
for offspring’s birth weight, length, head circumference and placental weight 
were 3113.5 (435.0) g, 48.7 (2.2) cm, 33.4 (1.4) cm, and 585.3 (118.9) g, 
respectively. Women of Malay ethnicity, lower education levels and higher 
BMI categories were more likely to have higher peripheral and central blood 
pressures (p < 0.01, Table 5-2). 
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Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP DBP SBP PP 
Mean (SD) P Mean (SD) P Mean (SD) P Mean (SD) P 
Age at booking 
(years) 
  0.54  0.26  0.62  0.36 
1st quartile  
(18–26) 
162 (22.7) 110.2 (12.0)  66.5 (8.7)  96.5 (10.6)  30.0 (6.9)  
2nd quartile  
(27–29) 
148 (20.8) 109.6 (10.5)  67.1 (8.4)  96.3 (9.6)  29.3 (5.7)  
3rd quartile  
(30–33) 
204 (28.6) 108.7 (11.0)  65.8 (7.8)  96.4 (9.8)  30.5 (6.7)  
4th quartile  
(34–46) 
199 (27.9) 108.9 (10.7)  67.4 (7.9)  97.5 (9.8)  30.1 (6.4)  
Race   0.001  0.004  0.005  0.34 
    Chinese 399 (55.9) 108.4 (10.9)  66.3 (8.2)  95.9 (9.9)  29.7 (6.4)  
    Indian 118 (16.6) 108.3 (10.8)  65.4 (7.9)  95.9 (9.3)  30.4 (7.1)  
    Malay 196 (27.5) 111.8 (11.2)  68.2 (8.3)  98.7 (10.2)  30.4 (6.3)  
Education   0.005    0.001  0.84 
    Primary-
Secondary 
229 (32.1) 109.7 (11.5)  67.0 (8.4) <0.001 97.2 (10.4)  30.2 (6.5)  
    Post-Secondary 245 (34.4) 110.7 (11.4)  67.9 (8.2)  98.0 (10.0)  30.1 (6.7)  
    Tertiary 239 (33.5) 107.5 (10.2)  64.9 (7.8)  94.8 (9.2)  29.8 (6.3)  
Smoking Status   0.01  0.29  0.14  0.34 
    Never smoker 618 (86.7) 108.9 (10.9)  66.4 (8.4)  96.5 (9.8)  29.9 (6.4)  
    Ever smoker 95 (13.3) 111.9 (11.7)  67.5 (8.5)  98.1 (11.0)  30.6 (6.8)  
Coffee 
Consumption 
  0.80  0.45  0.39  0.73 
    No 369 (51.8) 109.2 (10.9)  66.5 (8.4)  96.4 (9.9)  29.9 (6.8)  
    Yes 344 (48.2) 109.4 (11.2)  66.9 (8.0)  97.0 (9.9)  30.1 (6.2)  
Parity   0.47  0.72  0.26  0.17 
    Nulliparous 311 (43.6) 109.1 (11.0)  66.6 (7.9)  96.2 (9.6)  29.6 (6.7)  
    Primiparous 246 (34.5) 108.9 (11.3)  66.4 (8.3)  96.6 (10.2)  30.2 (6.5)  
    Multiparous 156 (21.9) 110.3 (10.7)  67.1 (8.5)  97.8 (10.2)  30.7 (6.0)  
Gestational 
Diabetes** 
  0.10  0.02  0.02  0.40 
    No 540 (81.4) 109.1 (10.7)  66.4 (7.9)  96.3 (9.6)  29.9 (6.4)  
    Yes 123 (18.6) 110.9 (11.6)  68.2 (8.6)  98.7 (10.7)  30.5 (6.4)  
Pre-pregnancy 
BMI (kg/m2)*** 
  <0.001  <0.001  <0.001  0.29 
  <25.0 518 (76.4) 107.0 (10.3)  65.1 (7.6 )  94.7 (9.4)  29.7 (6.5 )  
    25.0-29.9 113 (16.7) 114 (9.7)  70.9 (8.3)  101.3 (8.8)  30.4 (6.4)  





Rate of weight 
gain at 27 weeks 
kg/week)*** 
  0.005  0.004  0.006  0.80 
1st tertile  
(−0.42 – 0.25) 
227 (33.5) 107.8 (11.0)  65.9 (8.6)  95.7 (10.1)  29.8 (6.6)  
2nd tertile  
(0.26 – 0.37) 
218 (32.2) 108.4 (10.2)  65.8 (8.1)  95.6 (9.1)  29.8 (6.6)  
3rd tertile  
(0.38 – 1.38) 
233 (34.5) 110.9 (11.2)  68.1 (7.7)  98.2 (10.0)  30.1 (6.3)  
Second trimester 
BMI (kg/m2) 
  <0.001  <0.001  <0.001  <0.001 
  <25.0 329 (46.2) 104.7 (9.9)  63.9 (7.7)  92.9 (9.3)  29.0 (6.2)  
    25.0-29.9 259 (36.3) 110.9 (9.8)  67.3 (7.4)  98.2 (8.7)  30.8 (6.5)  
    ≥30.0 125 (17.5) 117.9 (10.6)  72.8 (7.4)  103.8 (9.4)  31.0 (6.7)  
Depression   0.99  0.71  0.46  0.52 
    Not depressed 631 (88.5) 109.3 (11.2)  66.7 (8.1)  96.8 (10.1)  30.1 (6.5)  
    Depressed 82 (11.5) 109.3 (10.1)  66.4 (9.0)  95.9 (8.9)  29.6 (6.1)  
SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; PP, pulse pressure. 
*Data are represented as n (%) or mean (SD) where appropriate. P values were derived from 
analysis of variance. 
**There were 50 women with missing values for gestational diabetes. 
***There were 35 women with missing values for pre-pregnancy BMI and rate of weight gain. 
 
After adjusting for maternal and fetal covariates, central SBP was inversely 
associated with all birth measures, and peripheral SBP was inversely associated 
with birth weight (all p < 0.05; Table 5-3). For example, each 1-SD increase 
(10.0 mmHg) in central SBP was inversely associated with birth weight (−40.52 
g; 95% confidence interval [CI] -70.66 to −10.37), birth length (−0.19 cm; −0.36 
to −0.03), head circumference (−0.12 cm; −0.23 to −0.02) and placental weight 
(−11.16 cm; −20.85 to −1.47). One-SD (11.1 mmHg) increase in peripheral SBP 
was also associated with 35.56 g lower birth weight (95% CI −66.57 to −4.54). 
The relations between other blood pressure measures and offspring size at birth 
were in the same direction but not statistically significant. Results were also not 
materially different in various sensitivity analyses (Supplemental Table 5-2). 
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Table 5-3 Associations between Blood Pressures (Per 1-SD Increase) and Size at Birth* 
Measures of Size at Birth 
N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (g) 713 −35.56 (−66.57 to −4.54) −25.13 (−55.36 to 5.09) −40.52 (−70.66 to −10.37) −24.10 (−51.24 to 3.03) 
Length (cm)** 711 −0.16 (−0.32 to 0.01) −0.10 (−0.27 to 0.06) −0.19 (−0.36 to −0.03) −0.14 (−0.28 to 0.01) 
Head circumference (cm)** 711 −0.09 (−0.19 to 0.02) −0.08 (−0.18 to 0.02) −0.12 (−0.23 to −0.02) −0.07 (−0.16 to 0.02) 
Placental weight (g)*** 699 −8.78 (−18.74 to 1.19) −6.94 (−16.63 to 2.76) −11.16 (−20.85 to −1.47) −6.44 (−15.04 to 2.16) 
SD, standard deviation; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
* Multiple linear regression models were used with adjustment for baby’s sex, gestation at delivery, maternal age, ethnicity, education, parity, smoking 
history, height, BMI at 27 weeks gestation, coffee consumption and depression. 
** There were 2 women with missing information on length and head circumference. 
*** There were 14 women with missing information on placental weight. 
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We found no significant interactions between blood pressures and ethnicity 
in relation to size at birth (Table 5-4). Stratified results for different ethnic 
groups showed that the associations between blood pressures (peripheral SBP, 
DBP and central SBP) and birth weight were significant in Chinese women only, 
but not significant in Malay or Indian women. However, the 95% CIs were large 
and tended to overlap among the three ethnic groups. We detected significant 
interactions between blood pressures and maternal BMI categories in relation 
to offspring’s birth weight, length and head circumference, with stronger 
associations in normal weight women rather than overweight/obese women 
(Table 5-5). Similar interactions were observed when tertiles of maternal BMI 
around 27 weeks gestation were used (Supplemental Table 5-3).  
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Table 5-4 Associations between Blood Pressures (Per 1-SD Increase) and Size at Birth by Maternal Ethnicity* 
Maternal Ethnicity N Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (g)      
    Chinese 399 −49.10 (−89.63 to −8.56) −37.74 (−76.82 to 1.33) −52.12 (−91.19 to −13.11) −26.49 (−62.65 to 9.67) 
    Indian 118 −17.37 (−98.58 to 63.84) 0.17 (−76.87 to 77.22) −30.70 (−109.08 to 47.67) −29.87 (−91.32 to 32.15) 
    Malay 196 −4.88 (−70.38 to 60.62) −17.29 (−80.97 to 46.39) −17.00 (−80.93 to 46.93) −3.21 (−63.08 to 56.65) 
    P for interaction  0.96 0.78 0.98 0.96 
Length (cm)**      
    Chinese 398 −0.11 (−0.35 to 0.12) −0.14 (−0.37 to 0.08) −0.16 (−0.39 to 0.06) −0.05 (−0.26 to 0.16) 
    Indian 117 −0.14 (−0.54 to -.26) −0.07 (−0.44 to 0.31) −0.19 (−0.57 to 0.19) −0.13 (−0.43 to 0.18) 
    Malay 196 −0.24 (−0.57 to 0.08) 0.05 (−0.27 to 0.37) −0.24 (−0.56 to 0.08) −0.38 (−0.67 to −0.08) 
    P for interaction  0.16 0.96 0.29 0.09 
Head circumference 
(cm)** 
    
    Chinese 398 −0.13 (−0.28 to 0.01) −0.13 (−0.27 to 0.00) −0.17 (−0.31 to −0.04) −0.08 (−0.21 to 0.05) 
    Indian 117 −0.04 (−0.32 to 0.23) 0.10 (−0.15 to 0.36) −0.10 (−0.37 to 0.16) −0.18 (−0.39 to 0.02) 
    Malay 196 0.03 (−0.19 to 0.26) −0.09 (−0.31 to 0.13) −0.00 (−0.22 to 0.22) 0.09 (−0.11 to 0.30) 
    P for interaction  0.69 0.81 0.63 0.18 
Placenta weight (g)***     
    Chinese 392 −8.27 (−21.94 to 5.40) −6.28 (−19.47 to 6.92) −11.22 (−24.43 to 1.99) −7.43 (−19.37 to 4.51) 
    Indian 115 −11.15 (−37.06 to 14.76) −5.05 (−29.82 to 19.72) −13.62 (−38.69 to 11.44) −8.94 (−28.84 to 10.95) 
    Malay 192 −9.16 (−28.52 to 10.19) −12.83 (−31.39 to 5.73) −11.79 (−30.53 to 6.94) −1.13 (−18.65 to 16.39) 
    P for interaction  0.93 0.80 0.89 0.97 
SD, standard deviation; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
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* Multiple linear regression models were used with adjustment for baby’s sex, gestation at delivery, maternal age, education, parity, smoking history, height, 
BMI at 27 weeks gestation, coffee consumption and depression. 
** There were 2 women with missing information on length and head circumference. 





Table 5-5 Associations between Blood Pressures (Per 1-SD Increase) and Size at Birth by Maternal BMI* 
Maternal BMI According to 
WHO Classification 
N Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (g)      
    BMI <25.0 kg/m2 329 −74.50 (−117.92 to −31.08) −38.79 (−80.33 to 2.74) −81.36 (−122.36 to −40.32) −66.81 (−105.84 to −27.80) 
    BMI 25.0-29.9 kg/m2 259 −26.64 (−79.84 to 26.56) −60.87 (−111.65 to −10.10) −41.90 (−94.50 to 10.69) 13.56 (−31.22 to 58.35) 
    BMI ≥30.0 kg/m2 125 14.59 (−72.21 to 101.40) 80.71 (−8.57 to 170.01) 41.23 (−45.56 to 128.03) −24.39 (−99.09 to 50.31) 
    P for interaction  0.06 0.02 0.02 0.02 
Length (cm)**      
    BMI <25.0 kg/m2 327 −0.40 (−0.65 to −0.15) −0.18 (−0.42 to 0.05) −0.44 (−0.68 to −0.21) −0.40 (−0.63 to −0.18) 
    BMI 25.0-29.9 kg/m2 259 0.04 (−0.25 to 0.33) −0.29 (−0.56 to −0.01) −0.09 (−0.38 to 0.19) 0.18 (−0.06 to 0.42) 
    BMI ≥30.0 kg/m2 125 −0.07 (−0.48 to 0.34) 0.51 (0.09 to 0.93) 0.12 (−0.29 to 0.54) −0.31 (−0.66 to 0.04) 
    P for interaction  0.04 0.009 0.03 0.001 
Head circumference (cm)**    
    BMI <25.0 kg/m2 327 −0.19 (−0.35 to −0.04) −0.20 (−0.35 to −0.06) −0.22 (−0.37 to −0.07) −0.07 (−0.21 to 0.07) 
    BMI 25.0-29.9 kg/m2 259 −0.08 (−0.27 to 0.10) −0.10 (−0.28 to 0.08) −0.12 (−0.31 to 0.06) −0.03 (−0.19 to 0.12) 
    BMI ≥30.0 kg/m2 125 0.17 (−0.11 to 0.45) 0.31 (0.02 to 0.59) 0.13 (−0.15 to 0.42) −0.12 (−0.36 to 0.12) 
    P for interaction  0.04 0.004 0.05 0.87 
Placenta weight (g)***     
    BMI <25.0 kg/m2 323 −17.72 (−32.74 to −2.69) −11.45 (−25.67 to 2.76) −20.54 (−34.79 to −6.29) −14.05 (−27.27 to −0.83) 
    BMI 25.0-29.9 kg/m2 256 −5.85 (−21.75 to 10.06) −9.62 (−24.95 to 5.71) −10.14 (−25.91 to 5.62) −1.76 (−15.11 to 11.58) 
    BMI ≥30.0 kg/m2 120 −0.26 (−27.15 to 26.63) 4.16 (−23.54 to 31.87) 1.23 (−25.54 to 27.99) −2.27 (−25.05 to 20.51) 
    P for interaction  0.18 0.49 0.15 0.25 
SD, standard deviation; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
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* Multiple linear regression models were used with adjustment for baby’s sex, gestation at delivery, maternal age, ethnicity, education, parity, smoking history, 
height, BMI at 27 weeks gestation, coffee consumption and depression. 
** There were 2 women with missing information on length and head circumference. 
*** There were 14 women with missing information on placental weight. 
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To further account for the influence from gestational age, we used 
gestational age adjusted SD scores of size at birth as the outcomes, and similar 
findings were observed (Supplemental Tables 5-4 – 5-6). Using binary variables 
of birth weight, we found that higher peripheral and central blood pressures 
were associated with higher odds for low birth weight and small for gestational 
age infants (Table 5-6). Tests for interactions between maternal ethnicity and 
blood pressures were not significant (data not shown), whereas the interactions 
between maternal BMI category and blood pressures (peripheral SBP, central 
SBP and PP) were borderline significant for small for gestational age (p = 0.04 
to 0.06), and the interaction between maternal BMI category and central PP was 
significant for low birth weight (p = 0.01). Again, the odds ratios were generally 




Table 5-6. The Association between Maternal Blood Pressures (Per 1-SD Increase) and Low Birth Weight and Small  
for Gestational Age 
 
N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Low birth weight      
All women* 713 1.64 (1.12 to 2.41) 1.82 (1.27 to 2.61) 1.85 (1.29 to 2.67) 1.17 (0.85 to 1.62) 
BMI categories**      
    BMI <25.0 kg/m2 329 2.12 (1.27 to 3.53) 1.70 (1.06 to 2.72) 2.41 (1.45 to 3.99) 1.82 (1.15 to 2.88) 
    BMI ≥25.0 kg/m2 384 1.09 (0.60 to 1.99) 1.88 (1.09 to 3.24) 1.28 (0.73 to 2.24) 0.62 (0.34 to 1.13) 
    P for interaction  0.11 0.86 0.14 0.01 
Small for gestational age      
All women* 713 1.58 (1.16 to 2.14) 1.41 (1.06 to 1.89) 1.70 (1.27 to 2.28) 1.36 (1.05 to 1.76) 
BMI categories**      
    BMI <25.0 kg/m2 329 1.88 (1.24 to 2.86) 1.43 (0.97 to 2.09) 2.01 (1.35 to 3.00) 1.74 (1.19 to 2.53) 
    BMI ≥25.0 kg/m2 384 1.17 (0.72 to 1.92) 1.27 (0.79 to 2.03) 1.26 (0.79 to 2.03) 1.04 (0.69 to 1.55) 
    P for interaction  0.04 0.44 0.06 0.04 
SD, standard deviation; OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure;  
PP, pulse pressure. 
* Multiple logistic regression models were used with adjustment for baby’s sex, gestation at delivery, maternal age, ethnicity, 
education, parity, smoking history, height, BMI at 27 weeks gestation, coffee consumption and depression. In the analysis of small 
for gestational age, gestation weeks at delivery was not adjusted for. 
** Adjusted baby’s sex, gestation at delivery, maternal age, ethnicity, education, parity, smoking history, height, BMI at 27 weeks 
gestation, coffee consumption and depression. In the analysis for small for gestational age, gestation at delivery was not adjusted for. 





We found associations between higher maternal blood pressures and smaller 
offspring. Maternal adiposity modified the associations with stronger inverse 
associations in normal weight women than their overweight/obese counterparts. 
No significant effect modification by ethnicity were found, although Chinese 
women with higher blood pressures tended to have smaller offspring. 
Our finding of an inverse association between maternal blood pressures 
and offspring size at birth is consistent with previous studies.9, 150, 152-155, 159-163 
For example, Bakker et al.9 reported that per one-SD increase in SBP and DBP 
at mean gestation of 30.2 weeks (range 28.4 to 32.9 weeks) was associated 
with 16.9 g and 50.6 g lower birth weight, respectively. Among non-
hypertensive women, higher peripheral blood pressures (range of gestation 26 
to 39 weeks) were also associated with lower birth weight;155 and higher 
central blood pressures (range of gestation 22 to 39 weeks) were associated 
with lower birth weight.159, 160  
However, there are studies with conflicting results. For example, two 
previous studies measuring DBP from 34 weeks gestation onwards 158 and the 
average of SBP and DBP during pregnancy156 have described a u-shaped 
association with birth weight. In another perinatal cohort study, DBP 
measured between 15 to 24 weeks gestation were not found to be significantly 
associated with birth weight.157 These studies156, 158 were based on 
retrospective cohort design that utilized blood pressure information collected 
under clinical context whereas studies that reported inverse associations were 




study investigators. Furthermore, the DBP measures reported in these 
retrospective cohort studies 157, 158 were based on either Korotkoff phase IV or 
V from standard mercury sphygmomanometer compared to the automated 
oscillometric device used in other studies 9, 152 or Spacelabs blood pressure 
monitor.153, 154 Varying DBP measures arising from the different Korotkoff 
phases59 and blood pressure devices could have contributed to the conflicting 
results. 
Some studies have suggested that central blood pressures may be more 
relevant to size at birth than the conventional peripheral blood pressures, 
because blood pressure differences were more pronounced in central than 
peripheral measures.159, 160 However, in the current analysis, we found similar 
effect estimates between central and peripheral blood pressures, which is 
consistent with an earlier report by Elvan-Taspinar et al.155 Although central 
blood pressures may be better markers for arterial stiffness,30, 62 the role of 
central and peripheral blood pressures in relation to offspring birth size have 
yet to be ascertained due to the limited and divergent literature. 
The exact mechanisms linking higher maternal blood pressures and smaller 
offspring birth weight are unclear. Several studies have observed that women 
with preeclampsia and low birth weight offspring share a common link in 
placental dysfunction.167-170 But whether placental dysfunction precedes 
maternal hypertension, or that it arises from maternal hypertension as a 
consequence of pre-existing maternal predisposition to endothelial dysfunction, 
current literature is still controversial.152, 167, 168, 170 Although the exact 




by both endothelial dysfunction and placental dysfunction, as both entities are 
not mutually exclusive.169  
A previous study by Lydakis et al.161 found that the relation between 
higher maternal blood pressures and lower birth weight was stronger in Asian 
Indians than white or black women, but no studies have yet tested the ethnic 
differences within Asian women. Our study is the first in its kind in three 
Asian ethnicities, and we observed no significant ethnic differences in the 
association between blood pressures and birth outcomes. Our results of inverse 
associations were also supported by some studies in Asian women, where pre-
eclampsia was associated with increased risk to small for gestational age in 
Chinese women162 and lower birth weight in Indian women.163 However, we 
cannot exclude the possibility of ethnic differences due to the smaller 
subgroups of Indian and Malay women in our cohort and therefore was not 
powered to detect effect modification by maternal ethnicity. Our exploratory 
analysis on the ethnic differences in the relations between blood pressures and 
birth size were among the first few in literature and future studies are still 
needed to further explore the potential ethnic differences. 
Our finding on the effect modification by maternal obesity is consistent 
with literature that lean or normal weight women with higher blood pressures 
have smaller offspring compared to their obese counterparts.152 The effect 
modification by maternal obesity on fetal growth restriction, may be due to the 
higher fetal nutrient supply in obese women,171 and the overall effect of 
maternal obesity and blood pressures on birth weight may be dependent on the 




There are several strengths of our study. The prospective design enabled 
the evaluation of a comprehensive information on offspring size at birth and a 
wide range of potential confounding factors. Peripheral blood pressure and 
radial pulse wave were measured in a detailed and standardized approach, 
thereby minimizing inter-rater measurement errors. Various sensitivity 
analyses suggested that our results were robust. 
We are aware of several limitations. First, we excluded 38.6% of the 
GUSTO participants due to missing information on the exposures and 
covariates. However, we deemed that the selection bias was unlikely to change 
our results based on the sensitivity analysis using imputed data (Supplemental 
Table 5-2). Second, we did not have data on first and third trimester blood 
pressure, and thus were unable to assess trimester specific blood pressure 
changes during pregnancy in relation to size at birth. Thirdly, the use of 
maternal BMI at 27 weeks gestation may be affected by misclassification due 
to the growing fetus and fluid accumulation. We chose to use mid-pregnancy 
BMI instead of pre-pregnancy BMI because the latter measure was self-
reported and thus susceptible to information bias, and about 5% of the women 
did not report their pre-pregnancy weights. Due to the lack of pregnancy-
specific classification for obesity, we have used the WHO cut-offs for non-
pregnant adults in our study. However, our sensitivity analysis of using tertiles 
of BMI suggested that the interaction with BMI categories was robust. We did 
not measure maternal weight before delivery, and could not know whether the 
relation between blood pressures and birth size outcomes would be changed if 
total weight gain during pregnancy was adjusted in the model. Our results may 




reported, and unmeasured confounding factors, like diet and physical activity, 
are possible to explain our results. Lastly, the non-significant maternal blood 
pressures and offspring birth weight relations among the Malay and Indian 
populations in the study may be due to the smaller numbers of women in these 
ethnic subgroups 
In conclusion, our results provide further evidence that higher second 
trimester blood pressures are associated with smaller offspring, with a stronger 
association among normal weight women. Therefore, routine antenatal 
monitoring of maternal blood pressures are clinically relevant and important 
practice, and may have a positive impact on offspring size at birth, particularly 














Supplemental Table 5-1. Maternal Characteristics by Study Inclusion to the 
Present Study 
Maternal Characteristics 
Included in study Excluded from study 
P* 
n Mean (SD) or % n Mean (SD) or % 
Peripheral systolic blood 
pressure (mmHg) 
713 109.3 (11.1) 116 110.6 (11.7) 0.25 
Peripheral diastolic blood 
pressure (mmHg) 
713 66.7 (8.2) 116 67.4 (9.9) 0.38 
Central systolic blood pressure 
(mmHg) 
713 96.7 (9.9) 116 97.9 (10.9) 0.20 
Central pulse pressure (mmHg) 713 30.0 (6.5) 116 30.6 (6.8) 0.41 
Age at booking (years)     0.18 
   1st quartile (18-26)  162 22.7% 119 27.7%  
   2nd quartile (27-29)  148 20.8% 83 19.4%  
   3rd quartile (30-33)  204 28.6% 104 24.2%  
   4th quartile (34-46) 199 27.9% 123 28.7%  
Race     0.23 
   Chinese 399 55.9% 222 51.8%  
   Indian 118 16.6% 87 20.3%  
   Malay 196 27.5% 120 27.9%  
Education     0.37 
   Primary-Secondary 229 32.1% 138 32.8%  
   Post-Secondary 245 34.4% 158 37.5%  
   Tertiary 239 33.5% 125 29.7%  
Smoking Status     0.47 
   Never smoker 618 86.7% 290 85.0%  
   Ever smoker 95 13.3% 51 15.0%  
Coffee Consumption     0.42 
   No 369 51.8% 186 54.4%  
   Yes 344 48.2% 156 45.6%  
Parity      0.84 
   Nulliparous 311 43.6% 147 41.8%  
   Primiparous 246 34.5% 124 35.2%  
   Multiparous 156 21.9% 81 23.0%  
Gestational Diabetes      0.27 
   No  540 81.4% 304 84.2%  
   Yes 123 18.6% 57 15.8%  
Pre-pregnancy BMI (kg/m2)       0.58 
   <25.0  518 76.4% 243 73.4%  
   25.0-29.9  113 16.7% 62 18.7%  
   ≥30.0 47 6.9% 26 7.8%  
2nd trimester BMI (kg/m2)       0.19 
   <25.0  329 46.1% 180 49.2%  
   25.0-29.9  259 36.3% 113 30.9%  
   ≥30.0 125 17.5% 73 19.9%  
Rate of weight gain at 27 
weeks (kg/week) 
    0.46 
   1st tertile (-0.42 – 0.25)  227 33.5% 107 33.0%  
   2nd tertile (0.26 – 0.37) 218 32.2% 116 35.8%  




Maternal Depression      0.16 
   Not depressed   631 88.5% 300 85.5%  
   Depressed   82 11.5% 51 14.5%  
Gestation at delivery (weeks) 713 38.8 (1.4) 352 38.6 (1.8) 0.006 
Size at birth      
   Weight (g) 713 3113.5 (435.0) 350 3034.2 (478.2) 0.007 
   Length (cm) 711 48.7 (2.2) 351 48.2 (2.4) 0.001 
   Head circumference (cm) 711 33.4 (1.36) 350 33.2 (1.6) 0.006 
   Placenta weight (g) 699 585.3 (118.9) 346 561.5 (124.0) 0.003 
BMI, body mass index. 
Data are mean (standard deviation) or % as specified. 





Supplemental Table 5-2. Sensitivity Analysis for Per 1-SD Increase in Maternal Blood Pressures and Size at Birth 
 
N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (g)      
 Main Model  713 -35.56 (-66.57 to -4.54) -25.13 (-55.36 to 5.09) -40.52 (-70.66 to -10.37) -24.10 (-51.24 to 3.03) 
Main Model + GDM* 663 -34.47 (-66.93 to -1.99) -32.77 (-64.51 to -1.03) -41.72 (-73.05 to -10.38) -18.99 (-47.71 to 9.71) 
Main Model among non-
hypertensive women 
705 -36.25 (-68.02 to -4.47) -30.16 (-61.28 to 0.97) -42.63 (-73.65 to -11.61) -20.83 (-48.31 to 6.64) 
Main Model using 
multiple imputation 
922 -34.00 (-65.25 to -2.75) -24.37 (-53.15 to 4.41) -38.43 (-67.47 to -9.39) -21.09 (-48.67 to 6.49) 
Main Model with pre-
pregnancy BMI & rate of 
weight gain 
678 -35.05 (-66.66 to -3.43) -21.19 (-51.69 to 9.33) -40.14 (-70.79 to -9.49) -27.21 (-54.67 to 0.25) 
      
Length (cm)**      
 Main Model  711 -0.16 (-0.32 to 0.01) -0.10 (-0.27 to 0.06) -0.19 (-0.36 to -0.03) -0.14 (-0.28 to 0.01) 
Main Model + GDM* 661 -0.17 (-0.35 to 0.00) -0.14 (-0.31 to 0.04) -0.21 (-0.38 to -0.04) -0.13 (-0.28 to 0.03) 
Main Model among non-
hypertensive women 
703 -0.18 (-0.36 to -0.01) -0.14 (-0.31 to 0.02) -0.23 (-0.40 to -0.06) -0.13 (-0.28 to 0.02) 
Main Model using 
multiple imputation 
921 -0.16 (-0.32 to 0.01) -0.11 (-0.27 to 0.05) -0.21 (-0.37 to -0.06) -0.12 (-0.26 to 0.02) 
Main Model with pre-
pregnancy BMI & rate of 
weight gain 
676 -0.15 (-0.32 to 0.02) -0.10 (-0.27 to 0.06) -0.19 (-0.36 to -0.02) -0.12 (-0.28 to 0.02) 




 Main Model  711 -0.09 (-0.19 to 0.02) -0.08 (-0.18 to 0.02) -0.12 (-0.23 to -0.02) -0.07 (-0.16 to 0.02) 
Main Model + GDM* 661 -0.07 (-0.19 to 0.04) -0.07 (-0.18 to 0.04) -0.10 (-0.21 to 0.01) -0.05 (-0.15 to 0.05) 
Main Model among non-
hypertensive women 
703 -0.10 (-0.21 to 0.01) -0.10 (-0.21 to 0.01) -0.14 (-0.25 to -0.04) -0.07 (-0.17 to 0.02) 
Main Model using 
multiple imputation 
921 -0.08 (-0.20 to 0.03) -0.08 (-0.18 to 0.03) -0.12 (-0.22 to -0.01) -0.06 (-0.15 to 0.04) 
Main Model with pre-
pregnancy BMI & rate of 
weight gain 
676 -0.09 (-0.20 to 0.02) -0.08 (-0.18 to 0.03) -0.12 (-0.23 to -0.02) -0.07 (-0.17 to 0.02) 
      
Placenta weight (g)***      
 Main Model  699 -8.78 (-18.74 to 1.19) -6.94 (-16.63 to 2.76) -11.16 (-20.85 to -1.47) -6.44 (-15.04 to 2.16) 
Main Model + GDM* 650 -11.48 (-22.05 to -0.92) -9.19 (-19.51 to 1.13) -13.27 (-23.46 to -3.07) -7.12 (-16.32 to 2.08) 
Main Model among non-
hypertensive women 
691 -8.93 (-19.17 to 1.31) -7.70 (-17.72 to 2.32) -11.54 (-21.54 to -1.54) -5.92 (-14.65 to 2.80) 
Main Model using 
multiple imputation 
908 -8.04 (-18.21 to 2.13) -8.23 (-17.39 to 0.93) -11.23 (-21.31 to 1.14) -5.64 (-13.92 to 2.65) 
Main Model with pre-
pregnancy BMI & rate of 
weight gain 
666 -11.15 (-21.45 to -0.85) -7.79 (17.70 to 2.12) -13.01 (-22.99 to -3.02) -7.59 (-16.43 to 1.24) 
SD, standard deviation; CI, confidence interval; GDM, gestational diabetes; IOM, Institute of Medicine; SBP, systolic blood pressure;  
DBP, diastolic blood pressure; PP, pulse pressure. 
* There were 50 women with missing information on gestational diabetes  
** There were 2 women with missing information on length and head circumference. 




Main model was derived from multiple linear regression with adjustment for baby's sex, gestation at delivery, maternal age, ethnicity, education, parity, 
smoking history, maternal BMI at 27 weeks gestation, height, coffee consumption and depression.  
Main Model + GDM: adjusted for covariates in Main Model with additional adjustment for gestational diabetes.  
Main Model among non-hypertensive women: the analysis was done in women with peripheral systolic blood pressures less than 140 mmHg and diastolic 
blood pressures less than 90 mmHg.  
Main Model using multiple imputation: missing data in blood pressures were imputed from model with maternal age, ethnicity, education, parity, smoking 
history, BMI at 27 weeks gestation, height, gestational diabetes and the respective outcome variable.  
Main Model with pre-pregnancy BMI is adjusted for the same covariates in Main Model except for maternal BMI at 27 weeks gestation which was replaced 




Supplemental Table 5-3. Per 1-SD Increase in Maternal Blood Pressures and Size at Birth by Maternal BMI in Tertiles* 
 
 Maternal BMI in 
Tertiles 
N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP  
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (g)           
   1st Tertile  234 -89.57 (-142.41 to -36.73) -32.09 (-82.41 to 18.23) -95.6 (-145.66 to -45.54) -84.53 (-129.73 to -39.33) 
   2nd Tertile 244 -25.05 (-77.64 to 27.53) -53.05 (-103.05 to -3.05) -26.05 (-76.72 to 24.62) 24.38 (-21.83 to 70.59) 
   3rd Tertile 235 2.21 (-57.05 to 61.47) 14.56 (-44.92 to 74.04) -6.28 (-65.48 to 52.92) -21.13 (-72.20 to 29.93) 
   P for interaction  0.03 0.09 0.03 0.008 
Length (cm)**      
   1st Tertile  233 -0.54 (-0.85 to -0.22) -0.14 (-0.45 to 0.16) -0.58 (-0.88 to -0.28) -0.57 (-0.84 to -0.30) 
   2nd Tertile 243 0.08 (-0.21 to 0.37) -0.27 (-0.54 to 0.00) -0.01 (-0.29 to 0.26) 0.28 (0.03 to 0.53) 
   3rd Tertile 235 -0.03 (-0.33 to 0.27) 0.18 (-0.12 to 0.48) 0.00 (-0.30 to 0.30) -0.17 (-0.43 to 0.09) 
   P for interaction  0.02 0.06 0.006 0.0001 
Head circumference (cm)**       
   1st Tertile  233 -0.31 (-0.49 to -0.12) -0.22 (-0.40 to -0.05) -0.30 (-0.48 to -0.12) -0.13 (-0.29 to 0.03) 
   2nd Tertile 243 -0.06 (-0.24 to 0.13) -0.12 (-0.30 to 0.06) -0.10 (-0.28 to 0.08) 0.01 (-0.16 to 0.17) 
   3rd Tertile 235 0.08 (-0.12 to 0.28) 0.11 (-0.09 to 0.31) 0.01 (-0.19 to 0.21) -0.10 (-0.27 to 0.08) 
   P for interaction  0.005 0.009 0.02 0.64 
Placenta weight (g)***     
   1st Tertile  230 -28.89 (-47.19 to -10.59) -16.57 (-33.81 to 0.66) -29.41 (-46.89 to -11.93) -17.04 (-32.46 to -1.63) 
   2nd Tertile 240 6.60 (-9.09 to 22.29) -6.38 (-21.45 to 8.68) 0.12 (-15.04 to 15.28) 7.06 (-6.71 to 20.82) 
   3rd Tertile 229 -8.07 (-26.95 to 10.81) -1.07 (-19.94 to 17.81) -9.83 (-28.60 to 8.95) -10.18 (-26.30 to 5.94) 




SD, standard deviation; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
* Multiple linear regression models were used with adjustment for baby's sex, gestation at delivery, maternal age, ethnicity, education, parity, smoking 
history, height, BMI at 27 weeks gestation, coffee consumption and depression. 
** There were 2 women with missing information on length and head circumference. 




Supplemental Table 5-4. Per 1-SD Increase in Maternal Blood Pressures and Gestational Age Adjusted SD Scores of Birth Size Outcomes* 
Measures of Size at Birth N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (SD) 713 -0.08 (-0.17 to 0.00) -0.06 (-0.14 to 0.02) -0.10 (-0.18 to -0.02) -0.06 (-0.13 to 0.01) 
Length (SD)** 711 -0.07 (-0.15 to 0.02) -0.05 (-0.13 to 0.04) -0.08 (-0.17 to -0.003) -0.06 (-0.14 to 0.02) 
Head circumference (SD)** 711 -0.06 (-0.14 to 0.02) -0.05 (-0.13 to 0.03) -0.09 (-0.17 to -0.01) -0.06 (-0.13 to 0.01) 
Placental weight (SD)*** 699 -0.07 (-0.16 to 0.01) -0.06 (-0.14 to 0.02) -0.09 (-0.18 to -0.01) -0.05 (-0.12 to 0.02) 
SD, standard deviation; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
* Measures of size at birth were estimated as gestational age adjusted standard deviation scores. Multiple linear regression models were used with 
adjustment for baby's sex, maternal age, ethnicity, education, parity, smoking history, height, BMI at 27 weeks gestation, coffee consumption and 
depression.  
** There were 2 women with missing information on length and head circumference. 










Supplemental Table 5-5. Per 1-SD Increase in Maternal Blood Pressures and Gestational Age Adjusted SD Scores of Birth Size Outcomes by  
Maternal Ethnicity* 
Maternal Ethnicity N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (SD)       
   Chinese 399 -0.12 (-0.23 to -0.01) -0.10 (-0.21 to 0.001) -0.14 (-0.24 to -0.03) -0.07 (-0.17 to 0.03) 
   Indian 118 0.01 (-0.20 to 0.22) 0.02 (-0.18 to 0.22) -0.05 (-0.26 to 0.16) -0.06 (-0.23 to 0.09) 
   Malay 196 -0.02 (-0.19 to 0.15) -0.04 (-0.21 to 0.13) -0.05 (-0.22 to 0.12) -0.02 (-0.18 to 0.14) 
  P for interaction   0.90 0.80 0.96 0.98 
Length (SD)**       
   Chinese 398 -0.04 (-0.16 to 0.07) -0.07 (-0.19 to 0.04) -0.07 (-0.19 to 0.04) -0.02 (-0.12 to 0.09) 
   Indian 117 -0.03 (-0.23 to 0.16) -0.04 (-0.22 to 0.15) -0.08 (-0.27 to 0.11) -0.05 (-0.19 to 0.11) 
   Malay 196 -0.13 (-0.29 to 0.03) 0.03 (-0.13 to 0.19) -0.11 (-0.27 to 0.05) -0.18 (-0.33 to -0.03) 
   P for interaction   0.12 0.95 0.31 0.09 
Head circumference (SD)**    
   Chinese 398 -0.10 (-0.21 to 0.01) -0.10 (-0.21 to 0.004) -0.13 (-0.24 to -0.03) -0.06 (-0.16 to 0.04) 
   Indian 117 -0.01 (-0.21 to 0.19) 0.09 (-0.10 to 0.28) -0.06 (-0.26 to 0.13) -0.14 (-0.29 to 0.02) 
   Malay 196 0.02 (-0.14 to 0.19) -0.04 (-0.20 to 0.13) 0.01 (-0.16 to 0.17) 0.05 (-0.10 to 0.21) 
  P for interaction   0.71 0.76 0.61 0.24 
Placenta weight (SD)***     
   Chinese 392 -0.07 (-0.19 to 0.05) -0.06 (-0.17 to 0.05) -0.10 (-0.21 to 0.02) -0.06 (-0.16 to 0.04) 
   Indian 115 -0.07 (-0.28 to 0.13) -0.03 (-0.23 to 0.16) -0.09 (-0.29 to 0.10) -0.06 (-0.22 to 0.09) 
   Malay 192 -0.09 (-0.26 to 0.07) -0.11 (-0.27 to 0.05) -0.11 (-0.27 to 0.04) -0.02 (-0.17 to 0.12) 




SD, standard deviation; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
* Measures of size at birth were estimated as gestational age adjusted standard deviation scores. Multiple linear regression models were used with 
adjustment for baby's sex, maternal age, ethnicity, education, parity, smoking history, height, BMI at 27 weeks gestation, coffee consumption and 
depression  
 ** There were 2 women with missing information on length and head circumference 




Supplemental Table 5-6. Per 1-SD Increase in Maternal Blood Pressures and Gestational Age Adjusted SD Scores of Birth Size Outcomes by  
Maternal BMI According to WHO Classification* 
Maternal BMI According 
to WHO Classification 
N 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP 
(1 SD = 11.1 mmHg) 
DBP 
(1 SD = 8.3 mmHg) 
SBP 
(1 SD = 10.0 mmHg) 
PP 
(1 SD = 6.5 mmHg) 
ß (95% CI) ß (95% CI) ß (95% CI) ß (95% CI) 
Weight (SD)           
   BMI <25.0  kg/m2  329 -0.19 (-0.31 to -0.08) -0.09 (-0.21 to 0.01) -0.21 (-0.32 to -0.10) -0.18 (-0.28 to -0.08) 
   BMI 25.0-29.9  kg/m2 259 -0.06 (-0.19 to 0.09) -0.17 (-0.30 to -0.03) -0.11 (-0.24 to 0.04) 0.05 (-0.07 to 0.17) 
   BMI ≥30.0  kg/m2 125 0.05 (-0.18 to 0.29) 0.24 (-0.00 to 0.48) 0.13 (-0.10 to 0.37) -0.06 (-0.26 to 0.14) 
   P for interaction  0.05 0.01 0.02 0.009 
Length (SD)**      
   BMI <25.0  kg/m2  327 -0.18 (-0.31 to -0.06) 0.08 (-0.19 to 0.04) -0.21 (-0.33 to -0.09) -0.19 (-0.31 to -0.08) 
   BMI 25.0-29.9  kg/m2 259 0.02 (-0.12 to 0.17) -0.15 (-0.29 to -0.01) -0.04 (-0.18 to 0.11) 0.11 (-0.01 to 0.23) 
   BMI ≥30.0  kg/m2 125 -0.02 (-0.23 to 0.49) 0.28 (0.06 to 0.49) 0.08 (-0.14 to 0.29) -0.16 (-0.33 to 0.02) 
     P for interaction  0.04 0.005 0.03 <0.001 
Head circumference (SD)**       
   BMI <25.0  kg/m2  327 -0.15 (-0.326 to -0.03) -0.15 (-0.26 to -0.04) -0.18 (-0.29 to -0.06) -0.06 (-0.17 to 0.04) 
   BMI 25.0-29.9  kg/m2 259 -0.05 (-0.19 to 0.09) -0.06 (-0.19 to 0.08) -0.08 (-0.22 to 0.06) -0.03 (-0.15 to 0.09) 
   BMI ≥30.0  kg/m2 125 0.14 (-0.07 to 0.36) 0.26 (0.04 to 0.48) 0.13 (-0.09 to 0.34) -0.08 (-0.27 to 0.10) 
    P for interaction  0.04 0.002 0.03 0.88 
Placenta weight (SD)***     
   BMI <25.0  kg/m2  323 -0.16 (-0.28 to -0.03) -0.10 (-0.23 to 0.02) -0.18 (-0.30 to -0.06) -0.12 (-0.24 to -0.01) 
   BMI 25.0-29.9  kg/m2 256 -0.03 (-0.17 to 0.09) -0.08 (-0.21 to 0.05) -0.08 (-0.21 to 0.05) -0.01 (-0.12 to 0.10) 
   BMI ≥30.0  kg/m2 120 0.01 (-0.21 ti 0.24) 0.07 (-0.17 to 0.30) 0.04 (-0.19 to 0.26) -0.02 (-0.21 to 0.18) 




SD, standard deviation; CI, confidence interval; BMI, body mass index; WHO, World Health Organization. 
* Measures of size at birth were estimated as gestational age adjusted standard deviation scores. Multiple linear regression models were used with adjustment 
for baby's sex, maternal age, ethnicity, education, parity, smoking history, height, BMI at 27 weeks gestation, coffee consumption and depression. 
** There were 2 women with missing information on length and head circumference. 
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Studies have consistently showed that in-utero exposure to preeclampsia is 
associated with higher blood pressures and an increased risk to hypertension 
and cardiovascular complications later in life.172-190 For example, a meta-
analyses of observational studies has reported a 2 mmHg and 1 mmHg higher 
systolic (SBP) and diastolic (DBP) blood pressures, respectively, in the 
offspring exposed to maternal preeclampsia.183, 184 This inter-generational 
transmission of higher levels of blood pressure may indicate shared 
mechanisms which include genetic 82 or non-genetic factors such as shared 
environmental or lifestyle factors.74 
However, most of the literature on maternal-offspring blood pressures is 
based on maternal hypertension which included preeclampsia or gestational 
hypertension,172, 176, 177, 179, 180, 182, 185-189 and few have examined the peripheral 
and central components and quantitative nature of blood pressures (Table 6-
1).190 Moreover, examining maternal hypertension based on prevailing blood 
pressure cut-offs may be suboptimal as blood pressure is a biological variable 
that has a unimodal distribution in the population.191 The effects from the 
stable and pulsatile hemodynamic blood pressure components, which include 
SBP, DBP, and pulse pressure (PP) during pregnancy, has also rarely been 
studied. Lastly, as hypertension is increasingly prevalent in Asian 
populations,71, 72 examining the influence of maternal blood pressures on early 
offspring blood pressures may lead to the early preventive strategies and 




Therefore in the present study, we aimed to examine the relation between 
maternal blood pressures during pregnancy and offspring blood pressures 
during early childhood in a prospective mother-offspring cohort of Southeast 





Table 6-1. Evidence Table for the Associations Between Maternal Hypertension and Offspring Blood Pressures 
























15 to 17 years 
old 
PE or GH SBP and DBP were higher in offspring of mother with GH 
or PE than those without. 
GH 
SBP: 2.06 (95%CI 1.28-2.84)mmHg 
DBP: 1.11 (95%CI 0.54-1.69)mmHg 
PE 
SBP: 1.12 (95%CI -0.80 -3.12)mmHg 
DBP: 1.71 (95%CI 0.23-3.17)mmHg 
2 Miettola et 
al/2013 
Prospective 
cohort   
5573/Finland 16 years old PE 
GH 
Normal pregnancy: GH : PE 
 
SBP: 114 vs 119 mmHg (p<0.001) vs 116 mmHg (p=0.15) 
DBP: 67 vs 70 mmHg (p<0.001) vs 68 mmHg  (p=0.06) 












Preterm offspring with hypertension compared to 
normotensive pregnancies : 
- Have lower pulse wave velocity 
- Have lower flow mediated dilation 
- Have higher common carotid intima thickness 
 
Preterm PE: Preterm Normal: Term normal 




Peripheral DBP: 71.8 (7.4):71.6 (6.5): 66.1 (7.0) mmHg 
Peripheral PP: 48.4(10.6): 48.9 (8.5): 47.9 (8.2) mmHg 
Central  SBP: 115.9 (10.9): 115.8 (10.6): 96.7 (9.9) mmHg 
Central DBP: 69.4 (6.3): 68.5 (9.8): 66 (7.4) mmHg 
Central PP: 46.6 (8.6): 46.9 (10.3): 30.7 (4.8) mmHg 












9 years old PE or GH SBP and DBP were higher in offspring of mother with GH 
or PE than those without. 
 
GH 
SBP: 2.04 (95%CI 1.42-2.67) mmHg 
DBP: 1.07 (95%CI 0.60-1.54) mmHg 
 
PE 
SBP: 2.05 (95%CI 0.72-3.38) mmHg 
DBP: 1.00 (95%CI -0.01-2.10) mmHg 
5 Kvehaugen et 
al/ 2010  
Prospective 
cohort   
63/Norway 5-8 years old PE 
  
Control vs PE (median) 
SBP: 115 vs 119 mmHg (p=0.03) 
DBP: 70 vs 70 mmHg  (p=0.17) 
6 Oglaend et 
al/ 2009  
Prospective 
cohort  
537/ Norway 10.8 to 11.8 
years old 
PE Crude SBP were significantly different between offspring of 
women with preeclampsia and normal pregnancies 
113.5 vs 115.3 mmHg (diff 1.8 [0.2-3.5]mmHg) 
However, association were no longer significant after 
adjusting for maternal BMI and SBP 
 
Offspring DBP not significant different between women 








57/Finland 12 years of age PE Daytime SBP; PE: non-PE (122.0 vs 108.3 mmHg, p<0.001) 
Nightime SBP; (117.8 vs 105.9 mmHg, p<0.001_ 
Daytime DBP:73.5 vs 59.1 mmHg, p<0.001) 
Nightime DBP: (69.7 vs 56.6 mmHg, p<0.001) 
 
Subgroup analysis between preterm and term PE – no 
significant difference 




120/Finland 12 years of age PE SBP; PE: Non PE (116.4 vs 113.2 mmHg, p=0.02) 
DBP; 73.9 vs 70.3 mmHg, p=0.02) 
 
Highest SBP and DBP in SGA PE offspring (SBP=120 
mmHg; DBP=76.3 mmHg)  
9 Kajantie et 
al/ 2009  
Prospective 
cohort 
13345/Finland Mean age at 
follow-up 30 
(SD 2.9) for 
28.8 (SD8.8) 
years 
PE or GH Stroke:  
GH: HR 1.4 (95%CI 1.0-1.8)  
PE; HR 1.9 (95%CI 1.2-3.0)  
 
Offspring hypertension:  
GH: RR 1.3 (95%CI 1.1-1.5)  
Non-severe PE: RR 0.9 (95%CI 0.6-1.5)  
Severe PE: RR1.5 (95%CI 1.1-2.3)    




188/Israel 6 years old 
  
PE  PE : non PE 
SBP; 101.3 vs 99.8 mmHg, NS 
 DBP; 66.2 vs 63.9 mmHg, p=0.03 




33545/Israel 17 years PE High SBP; 
Female: OR 2.3 (95%CI 1.80 – 4.46) 




























Parent offspring associations of BP are similar between 
fathers and mothers. 
 
Maternal-offspring correlation for SBP is stronger than 
paternal-offspring (-0.21 95%CI -0.04, -0.004; p=0.02) 
 
No difference for DBP 






The Growing Up in Singapore Towards healthy Outcomes (GUSTO) study is 
a prospective mother-offspring cohort study where 1162 pregnant women less 
than 14 weeks gestation were recruited at two public tertiary hospitals with 
maternity care in Singapore from 2009 to 2010.192 Women who were enrolled 
into the GUSTO study were free of type 1 diabetes and were not on 
chemotherapy treatment or on psychotropic drugs. From the GUSTO study 
cohort, 829 women had mid-pregnancy blood pressure measurements and 
were eligible for the present study. Among the offspring of these women, 567 
had blood pressure measurements at age 3 years and these 567 maternal-
offspring pairs with complete blood pressure information were included in the 
present study (Figure 6-1).  The women included in the analysis tended to be 
older, had higher education and were less likely to smoke and consume 
alcohol compared to the 262 women excluded. Maternal blood pressures 
during pregnancy and offspring blood pressures at 3 years old were similar 
between women who were included and excluded in the analysis 
(Supplemental Table 6-1). The study was approved by the SingHealth 
Centralised Institutional Review Board and National Healthcare Group 
Domain Specific Review Board. Written informed consent was obtained from 





          
 Figure 6-1. Flow Chart of the GUSTO Study Sample Selected for 
Analysis     
     
Blood pressure Measurements 
Based on a standardized protocol, maternal blood pressures were taken by 
trained research coordinators during the GUSTO mid-pregnancy follow-up 
visits at a median gestation of 27 weeks (interquartile range 26 to 29 weeks). 
GUSTO participants 
(N=1162)
Women with  blood pressure 
measurements and evaluable radial  pulse 
wave forms at  27 weeks gestation 
(n=829)
Women-offspring pars with 
complete blood pressure 
information 
(n=567)
Excluded women whose 
offspring blood pressure 
information were missing at 3 
years old (n=262)
Excluded due to no blood pressure or 
radial pulse wave measurement at 27 






Mothers were rested for at least 10 minutes prior to blood pressure 
measurement, and the peripheral SBP and DBP were measured thrice from the 
brachial arm at 30-60 second intervals with an oscillometric device MC3100 
(HealthSTATS International Pte Ltd, Singapore). An average of these three 
readings was calculated if the difference between readings was less than 10 
mmHg; otherwise, measurements were repeated. Central blood pressures were 
determined by the radial artery pressure waveforms measured from the A-
pulse tonometer (BPro®, HealthSTATS International Pte Ltd, Singapore), 
having calibrated with the average of peripheral SBP and DBP, respectively. 
Central SBP were then estimated from the calibrated radial artery pressure 
waveforms using the N-point moving average.12 Peripheral and central pulse 
pressure (PP) was calculated as the difference between peripheral or central 
SBP and peripheral DBP.  
Offspring Blood Pressure Outcomes 
At the age of 3 years old, offspring blood pressure outcomes were measured 
by trained research personnel at the outpatient clinics. Prior to blood pressure 
taking, the child was required to seat with the mother for at least 5 minutes in 
a quiet room. Peripheral SBPs and DBPs were taken twice from the right 
brachial arm using a Dynamap CARESCAPETM V100 (GE Healthcare, 
Milwaukee, WI, USA) with the arm resting at the chest level. An average of 
the two blood pressure readings was calculated if the difference between 
readings were less than 10 mmHg; otherwise, a third reading was taken and an 






Information on maternal age, ethnicity and education level, smoking status, 
alcohol and coffee consumption and physical activity during pregnancy, 
family history of hypertension, number of living children and pre-pregnancy 
weight were obtained via questionnaires and maternal height was measured by 
trained research coordinators at GUSTO mid-pregnancy follow-up. Maternal 
pre-pregnancy BMI was calculated as weight (kg) divided by the square of 
height (m2). Information on the offspring’s sex and gestation at birth were 
retrieved from medical records and their subsequent weight and height at 3 
years old were measured at the same time of their blood pressure 
measurements. 
Statistical Analysis 
Comparisons between characteristics of eligible mother-offspring pairs that 
were included and excluded from the current analysis were done using 
Student’s t-test and Chi-square test for continuous and categorical variables, 
respectively. Partial correlations between maternal and offspring blood 
pressures were performed using Pearson correlations, adjusted for offspring 
sex and ethnicity. Associations between continuous variables of maternal 
blood pressures (peripheral SBP, DBP, PP, central SBP and PP) and offspring 
blood pressures (peripheral SBP, DBP and PP) were examined using multiple 
linear regression with adjustments for maternal age, education level, parity, 
smoking status, alcohol consumption and physical activity during pregnancy, 
and pre-pregnancy BMI; offspring characteristics (including sex, ethnicity, 




women with hypertension during pregnancy (17 with gestational hypertension, 
9 with preeclampsia and 4 with chronic hypertension), we did not include 
maternal hypertension as a covariate in our analysis. Instead, we repeated our 
analysis in women without hypertension in pregnancy (n=537).  
We further evaluated the relation of binary variables of maternal blood 
pressures with offspring blood pressures. The continuous variables of maternal 
blood pressures were categorized into binary variables with 85th percentile 
higher maternal blood pressures based on >120 mmHg for peripheral SBP as 
prehypertension,60  >75 mmHg for peripheral DBP, >50 mmHg for peripheral 
PP, >106 mmHg for central SBP and >35 mmHg for central PP. 
Exploratory analysis on effect modifications by offspring sex (male, 
female) and ethnicity (Chinese, Malay, or Indian) were evaluated from the 
multiplicative interaction terms between continuous blood pressure variables 
and the effect modifier added to the main effect model. Ethnicity and sex 
stratified analysis was performed, respectively, and likelihood ratio test was 
used to test for interaction effects. All analysis were performed using Stata 
version 11.2 (Statacorp, College Station, Texas) was used for analysis; and 
two tailed P value of less than 0.05 was considered statistically significant.  
 
6.3 Results 
Of the 567 mother-offspring pairs followed-up in the present study, 310 
(54.7%) were of Chinese, 157 (27.7%) Malay and 100 (17.6%) Indian 




higher maternal blood pressures were observed in women of Malay ethnicity, 
lower education, who smoked before, had no or light physical activity during 
pregnancy, or higher pre-pregnancy BMI (Table 6-2). Maternal blood 
pressures also tended to be higher in hypertensive women, but offspring blood 
pressures were similar in the children of hypertensive and normotensive 






Table 6-2.Distribution of Maternal Blood Pressures by Maternal and Offspring’s Characteristics* 
Characteristics Overall 
Peripheral Blood Pressures (mmHg) Central Blood Pressures (mmHg) 
SBP P DBP P PP P SBP P PP P 
   Age, years   0.71  0.26  0.28  0.35  0.35 
      1st quartile (18–26) 106 (18.7%) 110.2 ± 11.6  66.3 ± 8.4  43.9 ± 8.5  96.7 ± 10.1  30.4 ± 6.6  
      2nd quartile (27–29) 132 (23.3%) 109.6 ± 10.7  67.2 ± 8.5  42.3 ± 7.8  96.6 ± 10.0  29.4 ± 6.1  
      3rd quartile  (30–33) 151 (26.6%) 108.6 ± 10.9  65.8 ± 8.1  42.8 ± 8.2  96.4 ± 10.1  30.5 ± 6.8  
      4th quartile (34–46) 178 (31.4%) 109.5 ± 11.2  67.4 ± 8.2  42.0 ± 8.2  98.1 ± 10.1  30.7 ± 6.6  
   Race   <0.001  0.003  0.09  <0.001  0.33 
      Chinese 310 (54.7%) 110.9 ± 11.1  65.9 ± 8.1  42.1 ± 8.2  95.9 ± 10.0  29.9 ± 6.5  
      Malay 157 (27.7%) 112.8 ± 11.2  69.0 ± 8.4  43.8 ± 7.8  99.8 ± 10.2  30.8 ± 6.1  
      Indian 100 (17.6%) 108.4 ± 10.3  65.6 ± 8.2  42.7 ± 8.6  96.2 ± 9.3  30.6 ± 7.5  
   Education   0.006  0.001  0.80  0.002  0.72 
      Primary to Secondary 171 (30.3%) 110.2 ± 11.1  67.5 ± 8.4  42.7 ± 7.5  98.0 ± 10.0  30.5 ± 6.1  
      GCE/Vocational/ 
      Polytechnic 
194 (34.4%) 
110.8 ± 11.7  67.9 ± 8.3 
 
42.9 ± 8.9 
 
98.3 ± 10.5 
 
30.3 ± 6.9 
 
      Tertiary and above 199 (35.3%) 107.5 ± 10.3  65.1 ± 8.0  42.3 ± 8.1  95.1 ± 9.5  29.9 ± 6.6  
   Alcohol intake   0.92  0.29  0.36  0.61  0.04 
      None 372 (67.6%) 109.2 ± 11.0  66.3 ± 8.2  42.8 ± 8.2  97.0 ± 10.2  30.6 ± 6.7  
      Yes 178 (32.4%) 109.3 ± 11.2  67.1 ± 8.4  42.2 ± 8.4  96.5 ± 9.8  29.4 ± 6.3  
   Smoking status   0.02  0.10  0.11  0.04  0.29 
      Non-smoker 497 (88.0%) 109.0 ± 10.9  66.5 ± 8.2  42.4 ± 8.3  96.7 ± 9.8  30.1 ± 6.6  
      Ever-smoker 68 (12.0%) 112.4 ± 12.0  68.2 ± 9.0  44.2 ± 7.4  99.3 ± 11.6  31.1 ± 6.5  
    Parity   0.77  0.81  0.87  0.33  0.24 
      Nulliparous 234 (41.3%) 109.3 ± 11.4  66.6 ± 7.9  42.6 ± 8.6  96.5 ± 10.0  29.9 ± 6.8  
      Multiparous 333 (58.7%) 109.5 ± 10.8  66.8 ± 8.6  42.7 ± 7.9  97.4 ± 10.1  30.5 ± 6.4  
   Physical activity    0.21  0.02  0.55  0.01  0.42 
      None to Light 404 (71.2%) 109.8 ± 11.1  67.2 ± 8.3  42.5 ± 8.1  97.7 ± 10.2  30.4 ± 6.7  




   Pre-pregnancy  BMI, kg/m2    <0.001  <0.001  0.02  <0.001  0.39 
       BMI <25.0   387 (74.1%) 107.0 ± 10.3  65.0 ± 7.5  42.0 ± 8.0  94.9 ± 9.5  29.9 ± 6.5  
       BMI 25.0-29.9   93 (17.8%) 113.9 ± 9.8  70.9 ± 8.6  42.9 ± 7.9  101.4 ± 8.9  30.5 ± 6.1  
       BMI ≥30.0  42 (8.05%) 119.9 ± 10.7  74.1 ± 7.8  45.7 ± 9.3  105.3 ± 9.1  31.2 ± 6.7  
   Offspring Sex   0.13  0.03  0.85  0.27  0.27 
      Male 437 (53.8%) 108.7 ± 11.2  66.0 ± 8.0  42.7 ± 8.2  96.6 ± 10.0  30.5 ± 6.3  
      Female 375 (46.2%) 110.2 ± 10.9  67.5 ± 8.6  42.6 ± 8.2  97.5 ± 10.1  29.9 ± 6.8  
BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure 
Data are presented as column percentages (%) or in mean ± SD  
A total of 567 women and their offspring were included in analysis, women with missing information for education (n=3), alcohol intake (17), smoking status 




Table 6-3. Maternal and Offspring Blood Pressures by Maternal Hypertension 










Maternal  Measures     
   Peripheral SBP 109.5 ± 11.1 108.8 ± 10.8 120.7 ± 10.9 <0.001 
   Peripheral DBP 66. ± 8 8.3 66.3 ± 8.1 75.4 ±7.5 <0.001 
   Peripheral PP 42.7 ± 8.2 42.6 ± 8.1 45.3 ± 10.0 0.08 
   Central SBP 97.1 ± 10.1 96.5 ± 9.8 107.7 ± 9.5 <0.001 
   Central PP 30.3 ± 6.6 30.2 ± 6.6 32.3 ± 6.3 0.08 
     
Offspring Measures     
   Peripheral SBP 98.4 ± 9.8 98.3 ± 9.9 99.6 ± 8.9 0.49 
   Peripheral DBP 58.3 ± 6.6 58.3 ± 6.6 58.9 ± 6.6 0.65 
   Peripheral PP 40.0 ± 7.0 40.0 ± 7.0 40.7 ± 7.1 0.60 
SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
P values were derived from Student’s t test. 
*Maternal hypertension included women with chronic or gestational hypertension or 
preeclampsia 
 
After accounting for offspring sex and ethnicity, maternal blood pressures 
were weakly correlated with offspring peripheral SBP and PP (adjusted r ranged 
from 0.05 to 0.11), but not with offspring peripheral DBP. Weak correlations 
were also observed between offspring blood pressures, BMI and height (r ranged 
from 0.11 to 0.25; Supplemental Table 6-2).  
In the multiple linear regression models, positive maternal-offspring blood 
pressure relations were observed for the blood pressure measures of SBP and PP 
(Table 6-4) but not for DBP. Each 1-mmHg increase in maternal central SBP was 
associated with 0.08 (95% confidence interval [CI] 0.00 to 0.17; p=0.06) mmHg 




PP was associated with 0.10 (95% CI 0.01 to 0.18; p=0.03) mmHg higher 
offspring PP. All other maternal-offspring blood pressure relations were not 
statistically significant, except for the relations between maternal SBP and 
offspring PP. Estimated increases in offspring peripheral SBP and PP were 
consistently greater for maternal central blood pressures than for the relations 
with maternal peripheral blood pressures. Findings were not significantly 
modified by offspring ethnicity and sex (Supplemental Tables 6-3 and 6-4).   
Table 6-4. Estimated Increases in Offspring Peripheral Blood Pressures, Each 1-mmHg Increase 




Offspring Blood Pressure Outcomes (mmHg) 
Peripheral SBP Peripheral DBP Peripheral PP 
ß (95% CI) P ß (95% CI) P ß (95% CI) P 
Peripheral SBP 
0.05 (-0.03 to 0.13) 0.21 -0.02 (-0.07 to 0.04) 0.52 0.07 (0.01 to 0.13) 0.02 
Peripheral DBP 
0.09 (-0.01 to 0.20) 0.09 0.03 (-0.04 to 0.10) 0.35 0.06 (-0.02 to 0.13) 0.14 
Peripheral PP 
0.00 (-0.10 to 0.09) 0.96 -0.06 (-0.12 to 0.01) 0.09 0.05 (-0.02 to 0.13) 0.14 
Central SBP 
0.08 (0.00 to 0.17) 0.06 0.00 (-0.06 to 0.05) 0.88 0.09 (0.02 to 0.15) 0.006 
Central PP 
0.04 (-0.08 to 0.16) 0.50 -0.05 (-0.14 to 0.03) 0.19 0.10 (0.01 to 0.18) 0.03 
CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse 
pressure. 
*A total of 567 women and their offspring were included in analysis. 
All analysis were performed using multiple linear regressions with adjustments for maternal 
age, education level, parity, smoking status, alcohol consumption and physical activity during 






 BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse 
pressure 
 
Figure 6-2. Each 1-mmHg increase in Maternal Blood Pressures at 26 – 28 Weeks 
Gestation and Offspring Blood Pressures  
 
 
Among the 567 women included in the analysis, 537 (94.7%) were 
normotensive during pregnancy and only 30 (5.3%) were hypertensive during 
pregnancy. The maternal-offspring blood pressure relations in the subgroup of 
women who were normotensive during pregnancy were qualitatively the same 
with the main cohort (Figure 6-2; Supplemental Table 6-5). Further analysis of 
binary variables of maternal blood pressure ≥85th percentile showed similar 
positive associations with offspring blood pressure (Figure 6-3; Supplemental 
Table 6-6). For example, weak trends were observed between offspring SBP and 
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maternal peripheral and central SBP at ≥85th percentile, at a mean differences of 
2.16 mmHg and 1.81 mmHg respectively. 
 
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure;  
PP,   pulse pressure 
  
Figure 6-3. Maternal blood pressures at 85
th
 percentile or higher at 26 – 28 Weeks 




Previous studies have shown higher blood pressures in young children and adult, 
who are offspring of women with pregnancy-related hypertension than offspring 
of women with normal pregnancy.172-184 The present study builds on that 
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knowledge by demonstrating that higher maternal central blood pressures in 
pregnancy were associated with higher pulsatile blood pressure components (SBP 
and PP) in the offspring. Importantly, the positive associations of mother-
offspring blood pressures persisted in normotensive women who were free of 
hypertension during pregnancy. 
Positive maternal-offspring blood pressure relations have been reported 
previously in several studies that measured peripheral blood pressures190, 193 and 
maternal hypertension in non-pregnant194, 195 and pregnant women.172-184 In the 
HUNT Study of Norwegians, positive correlations were reported between mother-
offspring SBP (r=0.15) and DBP (r=0.14).190 In a study of Dutch families with 
children aged 5-19 years,  each mmHg increase in maternal peripheral SBP was 
associated with a 0.09 mmHg increase in offspring SBP; for DBP relation the 
corresponding mother-offspring increase was 0.04 mmHg.193 Compared to these 
findings, we found qualitatively similar maternal-offspring blood pressure 
correlations in our cohort of Southeast Asian Chinese, Malay and Indian women. 
In our study, each 1mmHg increase in maternal peripheral and central SBP was 
associated with 0.05 mmHg and 0.08 mmHg increases in offspring SBP, although 
the former was not statistically significant. 
Our observation of stronger associations of maternal central than peripheral 
blood pressures with offspring blood pressures is supported by two studies that 
suggest central blood pressures may be better markers for arterial compliance than 
peripheral blood pressures.30, 196 Although two recent meta-analysis have 




and outcomes in pregnant197 and non-pregnant 198 populations, evidence for its 
stronger role compared with peripheral blood pressures was demonstrated only in 
non-pregnant populations.64 Therefore, further studies examining maternal blood 
pressures during pregnancy incorporating both central and peripheral measures 
are needed. 
In line with the present literature on the positive associations between 
pregnancy hypertension and offspring blood pressures,172-184 our study extend 
these findings by suggesting that maternal blood pressures during pregnancy are 
an important determinant of offspring blood pressures, even in normotensive 
pregnant women. Indirect evidence came from studies examining the influence of 
maternal blood pressures in normotensive pregnancies, whereby higher maternal 
blood pressures have been found to be associated with smaller offspring9, 10 and 
preterm delivery.10 Therefore, it is plausible that maternal blood pressures, even 
within normal range, have a graded relation with offspring blood pressures. 
The positive association of mother and offspring blood pressures, as early as 
3 years old in the present cohort, suggests that the higher blood pressures in 
offspring of women with higher pregnancy blood pressures occur early in life. 
And, as blood pressure tracks in life,199 the higher blood pressure in the offspring 
of women with higher pregnancy blood pressures are also likely to persist in life. 
This has been demonstrated in studies that examined maternal hypertension in 
pregnant172-184 and non-pregnant women194, 195 in relation to blood pressures in 




The higher early childhood SBP and PP in offspring of women with higher 
blood pressures are likely to persist through adulthood and may have significant 
impact on cardiovascular health in later life. SBP and PP, being indicators of 
arterial stiffening,200, 201 are associated with increased risk of cardiovascular 
morbidity and mortality,201 While this raises the possibility that optimal blood 
pressure compliance through antenatal monitoring and primary health prevention 
strategies could have long term benefits for offspring health this hypothesis can 
only be addressed in randomized trials.   
Overall, the results in the present study are congruent with earlier studies that 
the blood pressure phenotype clusters in family, and this may be explained by the 
shared environmental,74, 202 epigenetic and/or genetic factors.203-205  Moreover, 
findings from animal and in-utero studies have found changes in the cardiac and 
vascular structures 204, 205 as well as sympatho-adrenal and renal dysfunction in 
the offspring exposed to maternal hypertension during pregnancy.203 
The findings of this study should be interpreted in consideration of its 
strengths and limitations. Strengths of this study include the prospectively 
measured maternal and offspring blood pressures, performed according to a 
standard protocol by trained research personnel and the ability to measure and 
account for various maternal and offspring factors in our analysis. However, there 
are several limitations to our study. First, 262 (31.4%) mother-offspring pairs 
were excluded from the present analysis due to missing offspring blood pressure 
information at the GUSTO 3rd year follow-up. However, our findings are unlikely 




was similar between those who were included and excluded from analysis. As 
maternal blood pressures were measured only once during pregnancy, we were 
unable to examine the blood pressure changes during pregnancy in relation to 
blood pressures in the offspring. Our effect estimates may be affected by residual 
confounding, for example, from self-reported measures of maternal pre-pregnancy 
BMI and from lack of adjustment for dietary intake (like salt).74, 206, 207 As salt 
intake is an important determinant for offspring blood pressures, this may have 
limited the interpretation of our study findings. However, the maternal-offspring 
blood pressure relations are likely to persist as findings from the Avon 
Longitudinal Study of Parents and Children had demonstrated persistent positive 
maternal hypertension and offspring blood pressure relations even after 
adjustment for salt intake.176 Measuring blood pressures in young children at the 
age of 3 years old have practical difficulties, for example having the child seated 
comfortably and taking repeated measurements in the same position, and 
therefore, greater variation and measurement errors are likely to occur. Lastly, the 
non-significant effect modification by ethnicity may be constrained by the smaller 
ethnic subgroups of Chinese, Malay and Indian women. Further studies in Asian 
women are needed to explore their ethnic contributions to the maternal-offspring 
blood pressure relations. 
 In conclusion, our findings suggest that higher maternal blood pressures 
during pregnancy are associated with higher offspring blood pressures. As the 




pregnant women, ensuring optimal blood pressure compliance during pregnancy 






Supplemental Table 6-1. Characteristics of Women and Their Offspring, Comparing 







n 829 (100%) 567 (68.4%) 262 (31.6%)  
Maternal Characteristics     
   Age, years 30.4 ± 5.2 31.0 ± 5.1 29.1 ± 5.03 <0.001 
   Race    0.53 
      Chinese 451 (54.4%) 310 (54.7%) 141 (53.8%)  
      Malay 238 (28.7%) 157 (27.7%) 81 (30.9%)  
      Indian 140 (16.9%) 100 (17.6%) 40 (15.3%)  
   Education    0.01 
      Primary to Secondary 267 (32.6%) 171 (30.3%) 96 (37.5%)  
      GCE/Vocational/Polytechnic 289 (35.2%) 194 (34.4%) 95 (37.1%)  
      Tertiary and above 264 (32.2%) 199 (35.3%) 65 (25.4%)  
   Alcohol intake    0.03 
      None 526 (65.2%) 372 (67.6%) 154 (59.9%)  
      Yes 281 (34.8%) 178 (32.4%) 103 (40.1%)  
   Smoking status    0.03 
      Non-smoker 710 (86.2%) 497 (88.0%) 213 (82.2%)  
      Ever-smoker 114 (13.8%) 68 (12.0%) 46 (17.8%)  
    Parity    0.11 
      Nulliparous 350 (43.1%) 234 (41.3%) 116 (47.4%)  
      Multiparous 462 (56.9%) 333 (58.7%) 129 (52.6%)  
   Physical activity     0.02 
      None to Light 609 (73.7%) 404 (71.2%) 205 (79.2%)  
      Moderate to Strenuous 217 (26.3%) 163 (28.8%) 54 (20.8%)  
   Maternal Hypertension    0.11 
      None 787 (94.9%) 537 (94.7%) 250 (95.4%)  
      Chronic Hypertension 5 (0.4%) 4 (0.7%) 1 (0.2%)  
      Gestational Hypertension 25 (2.2%) 17 (3.0%) 8 (1.3%)  
      Preeclampsia 21 (1.8%) 9 (1.6%) 12 (2.0%)  
   Pre-pregnancy BMI, kg/m2 22.8 ± 4.4 22.8 ± 4.4 22.6 ± 4.4 0.59 
   Peripheral SBP, mmHg 109.49 ± 11.16 109.47 ± 11.12 109.53 ±11.27 0.94 
   Peripheral DBP, mmHg 66.78 ±8.46 66.77 ± 8.35 66.80 ± 8.73 0.95 
   Peripheral PP, mmHg 42.71 ±8.27 42.70 ± 8.24 42.73 ± 8.34 0.97 
   Central SBP, mmHg 96.89 ± 10.09 97.06 ± 10.10 96.5 ± 10.06 0.45 
   Central PP, mmHg 30.11 ± 6.54 30.29 ± 6.59 29.69 ± 6.42 0.22 
Offspring Characteristics     
   Sex    0.21 
      Male 437 (53.8%) 297 (52.4%) 140 (57.1%)  
      Female 375 (46.2%) 270 (47.6%) 105 (42.9%)  
   BMI, kg/m2 15.8 ± 1.6 15.8 ± 1.6 15.9 ± 1.9 0.54 
   Height, cm 94.8 ± 3.8 94.8 ± 3.8 94.9 ± 4.0 0.78 
   Peripheral SBP, mmHg - 98.4 ± 9.8 -  
   Peripheral DBP, mmHg - 58.3 ± 6.6 -  
   Pulse pressure, mmHg - 40.0 ± 7.0 -  
BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse 
pressure 
Data are presented as mean ± SD or in column percentages (%) 
A total of 567 women and their offspring were included in analysis, women with missing information 
for education (n=3), alcohol intake (17), smoking status (n=2) and maternal pre-pregnancy BMI (n=45) 




Supplemental Table 6-2. Partial Correlations between Maternal and Offspring’s 
Anthropometry and Blood Pressure Measures 
  Offspring Blood Pressure Outcomes (mmHg) 
  Peripheral SBP Peripheral DBP Peripheral PP 
 r P r P r P 
Maternal  Measures       
   Peripheral SBP, mmHg 0.07 0.08 0.01 0.78 0.09 0.03 
   Peripheral DBP, mmHg 0.07 0.08 0.05 0.19 0.05 0.21 
   Peripheral PP, mmHg 0.02 0.58 -0.04 0.34 0.07 0.09 
   Central SBP, mmHg 0.09 0.04 0.02 0.69 0.11 0.01 
   Central PP, mmHg 0.04 0.35 -0.04 0.30 0.10 0.02 
   Pre-pregnancy BMI, kg/m2 0.05 0.29 0.06 0.15 0.01 0.89 
       
Offspring Measures       
   BMI at 3 years old, kg/m2  0.25 <0.001 0.23 <0.001 0.14 <0.001 
   Height at 3 years old, cm 0.18 <0.001 0.11 0.007 0.14 <0.001 
BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; PP, pulse pressure. 





Supplementary Table 6-3. Estimated Increases in Offspring Peripheral Blood Pressures, 





Offspring Blood Pressure Outcomes (mmHg) 
Peripheral SBP Peripheral DBP Peripheral PP 
ß (95% CI) P ß (95% CI) P ß (95% CI) P 
Peripheral SBP       
   All women 0.05 (-0.03 to 0.13) 0.21 -0.02 (-0.07 to 0.04) 0.52 0.07 (0.01 to 0.13) 0.02 
   Chinese 0.12 (0.02 to 0.22) 0.02 0.01 (-0.05 to 0.08) 0.72 0.11 (0.03 to 0.18) 0.005 
   Malay 0.01 (-0.18 to 0.20) 0.91 -0.01 (-0.12 to 0.10) 0.85 0.02 (-0.10 to 0.15) 0.73 
   Indian -0.05 (-0.25 to 0.14) 0.58 -0.13 (-0.30 to 0.04) 0.14 0.07 (-0.08 to 0.23) 0.35 
   P for interaction  0.45 0.76 0.38 
Peripheral DBP       
   All women 0.09 (-0.01 to 0.20) 0.09 0.03 (-0.04 to 0.10) 0.35 0.06 (-0.02 to 0.13) 0.14 
   Chinese 0.15 (0.02 to 0.28) 0.02 0.06 (-0.02 to 0.15) 0.15 0.09 (-0.01 to 0.19) 0.08 
   Malay 0.15 (-0.12 to 0.41) 0.27 -0.02 (-0.18 to 0.14) 0.82 0.17 (-0.01 to 0.35) 0.07 
   Indian -0.07 (-0.29 to 0.16) 0.57 0.09 (-0.11 to 0.29) 0.39 -0.15 (-0.33 to 0.03) 0.09 
   P for interaction  0.57 0.51 0.12 
Peripheral PP       
   All women 0.00 (-0.10 to 0.09) 0.96 -0.06 (-0.12 to 0.01) 0.09 0.05 (-0.02 to 0.13) 0.14 
   Chinese 0.05 (-0.08 to 0.17) 0.44 -0.04 (-0.12 to 0.04) 0.36 0.09 (-0.01 to 0.18) 0.07 
   Malay -0.11 (-0.35 to 0.14) 0.39 0.00 (-0.15 to 0.14) 0.97 -0.10 (-0.27 to 0.06) 0.22 
   Indian -0.01 (-0.23 to 0.21) 0.94 -0.25 (-0.43 to -0.06) 0.01 0.24 (0.07 to 0.41) 0.006 
   P for interaction  0.59 0.23 0.05 
Central SBP       
   All women 0.08 (0.00 to 0.17) 0.06 0.00 (-0.06 to 0.05) 0.88 0.09 (0.02 to 0.15) 0.006 
   Chinese 0.14 (0.04 to 0.25) 0.006 0.02 (-0.05 to 0.09) 0.53 0.12 (0.04 to 0.20) 0.004 
   Malay 0.09 (-0.13 to 0.31) 0.41 0.01 (-0.12 to 0.13) 0.93 0.08 (-0.06 to 0.23) 0.25 
   Indian -0.01 (-0.21 to 0.19) 0.90 -0.06 (-0.24 to 0.11) 0.48 0.05 (-0.11 to 0.21) 0.53 
   P for interaction  0.54 0.85 0.59 
Central PP       
   All women 0.04 (-0.08 to 0.16) 0.50 -0.05 (-0.14 to 0.03) 0.19 0.10 (0.01 to 0.18) 0.03 
   Chinese 0.09 (-0.07 to 0.24) 0.26 -0.04 (-0.14 to 0.06) 0.44 0.13 (0.01 to 0.25) 0.03 
   Malay -0.02 (-0.34 to 0.30) 0.92 0.04 (-0.15 to 0.23) 0.69 -0.05 (-0.27 to 0.16) 0.62 
   Indian 0.06 (-0.19 to 0.30) 0.65 -0.2 (-0.41 to 0.02) 0.07 0.25 (0.07 to 0.44) 0.009 
   P for interaction  0.76 0.33 0.18 
CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, 
pulse pressure. 
 All analysis were performed using multiple linear regressions with adjustments for 
maternal age, education level, smoking status, alcohol consumption and physical activity 
during pregnancy, pre-pregnancy BMI; and offspring sex, BMI and height at 3 years of age. 






Supplementary Table 6-4. Estimated Increases in Offspring Peripheral Blood Pressures, 




Offspring Blood Pressure Outcomes (mmHg) 
Peripheral SBP Peripheral DBP Peripheral PP 
ß (95% CI) P ß (95% CI) P ß (95% CI) P 
Peripheral SBP       
   All offspring 0.05 (-0.03 to 0.13) 0.21 -0.02 (-0.07 to 0.04) 0.52 0.07 (0.01 to 0.13) 0.02 
   Males 0.03 (-0.08 to 0.14) 0.58 -0.01 (-0.08 to 0.05) 0.69 0.04 (-0.04 to 0.12) 0.28 
   Females 0.07 (-0.05 to 0.19) 0.26 -0.03 (-0.11 to 0.06) 0.55 0.09 (0.01 to 0.18) 0.03 
   P for interaction  0.74 0.76 0.47 
Peripheral DBP       
   All offspring 0.09 (-0.01 to 0.20) 0.09 0.03 (-0.04 to 0.10) 0.35 0.06 (-0.02 to 0.13) 0.14 
   Males 0.04 (-0.11 to 0.19) 0.59 0.05 (-0.04 to 0.15) 0.27 -0.01 (-0.12 to 0.10) 0.83 
   Females 0.15 (0.00 to 0.30) 0.06 0.01 (-0.10 to 0.12) 0.82 0.13 (0.03 to 0.24) 0.01 
   P for interaction  0.56 0.46 0.15  
Peripheral PP       
   All offspring 0.00 (-0.10 to 0.09) 0.96 -0.06 (-0.12 to 0.01) 0.09 0.05 (-0.02 to 0.13) 0.14 
   Males 0.01 (-0.12 to 0.15) 0.84 -0.07 (-0.15 to 0.02) 0.13 0.08 (-0.02 to 0.18) 0.12 
   Females -0.03 (-0.17 to 0.11) 0.67 -0.05 (-0.15 to 0.05) 0.35 0.02 (-0.08 to 0.12) 0.73 
   P for interaction  0.78 0.73 0.48 
Central SBP       
   All offspring 0.08 (0.00 to 0.17) 0.06 0.00 (-0.06 to 0.05) 0.88 0.09 (0.02 to 0.15) 0.006 
   Males 0.07 (-0.05 to 0.19) 0.26 0.02 (-0.05 to 0.10) 0.58 0.05 (-0.04 to 0.14) 0.30 
   Females 0.09 (-0.03 to 0.22) 0.16 -0.04 (-0.13 to 0.06) 0.44 0.13 (0.04 to 0.22) 0.01 
   P for interaction  0.94 0.29 0.28 
Central PP       
   All offspring 0.04 (-0.08 to 0.16) 0.50 -0.05 (-0.14 to 0.03) 0.19 0.10 (0.01 to 0.18) 0.03 
   Males 0.09 (-0.08 to 0.26) 0.31 -0.03 (-0.14 to 0.08) 0.63 0.12 (-0.01 to 0.25) 0.08 
   Females -0.02 (-0.19 to 0.15) 0.81 -0.08 (-0.21 to 0.04) 0.20 0.06 (-0.06 to 0.18) 0.33 
   P for interaction  0.43 0.54 0.61 
CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, 
pulse pressure. 
All analysis were performed using multiple linear regressions with adjustments for 
maternal age, education level, smoking status, alcohol consumption and physical activity 
during pregnancy, pre-pregnancy BMI; and offspring ethnicity, BMI and height at 3 years 
of age. 





Supplemental Table 6-5. Estimated Increases in Offspring Peripheral Blood Pressures, 






 Offspring Blood Pressure Outcomes (mmHg) 
 Peripheral SBP Peripheral DBP Peripheral PP 
N 
ß (95% CI) P ß (95% CI) P ß (95% CI) P 
Peripheral SBP       




0.06 (-0.02 to 0.14) 0.16 -0.01 (-0.06 to 0.05) 0.86 0.07 (0.01 to 0.13) 0.03 
        
Peripheral DBP       




0.10 (-0.01 to 0.21) 0.07 0.04 (-0.03 to 0.12) 0.24 0.06 (-0.02 to 0.14) 0.15 
        
Peripheral PP        




0.00 (-0.10 to 0.10) 0.98 -0.05 (-0.12 to 0.02) 0.19 0.05 (-0.03 to 0.12) 0.21 
        
Central SBP        




0.10 (0.00 to 0.19) 0.04 0.01 (-0.05 to 0.07) 0.76 0.09 (0.02 to 0.15) 0.01 
        
Central PP        




0.05 (-0.08 to 0.17) 0.46 -0.04 (-0.12 to 0.05) 0.36 0.09 (0.00 to 0.18) 0.06 
CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse 
pressure.  
Normotensive women referred to women without chronic or gestational hypertension or 
preeclampsia 
All analysis were performed using multiple linear regressions with adjustments for maternal 
age, education level, parity, smoking status, alcohol consumption and physical activity during 






Supplemental Table 6-6. Estimated Mean Difference in Offspring Peripheral Blood Pressures, 
Maternal Blood Pressures at 85
th





 Offspring Blood Pressure Outcomes 
 Peripheral SBP Peripheral DBP Peripheral PP 
 ß (95% CI) P ß (95% CI) P ß (95% CI) P 
Peripheral SBP       




537 2.71 (0.24 to 5.18) 0.03 0.54 (-1.13 to 2.21) 0.53 2.17 (0.38 to 3.96) 0.02 
      
Peripheral DBP       




537 2.03 (-0.36 to 4.41) 0.10 0.59 (-1.02 to 2.20) 0.47 1.44 (-0.29 to 3.16) 0.10 
       
Peripheral PP        




537 0.85 (-1.40 to 3.10) 0.46 -0.18 (-1.70 to 1.34) 0.82 1.03 (-0.6 to 2.66) 0.22 
      
Central SBP        




537 2.05 (-0.37 to 4.47) 0.10 -0.02 (-1.65 to 1.61) 0.98 2.07 (0.32 to 3.82) 0.02 
      
Central PP        




537 0.50 (-1.58 to 2.58) 0.64 -0.01 (-1.41 to 1.39) 0.99 0.51 (-1.00 to 2.02) 0.51 
SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 
* 85th percentile higher maternal peripheral SBP is > 120 mmHg, peripheral DBP > 75 mmHg, 
peripheral PP > 510 mmHg, central SBP > 106 mmHg and central PP > 35 mmHg. 
Non-hypertensive women referred to women without chronic or gestational hypertension or 
preeclampsia  
All analysis were performed using multiple linear regressions with adjustments for maternal 
age, education level, smoking status, alcohol consumption and physical activity during 
























Blood pressure is an independent arterial marker for hypertension and 
cardiovascular outcomes.50, 60, 62-64 Data from several large observational 
studies have demonstrated a direct relation between higher maternal blood 
pressures and adverse pregnancy outcomes in the women and their offspring.9, 
10, 63, 157, 158 As the vast majority of literature examined maternal hypertension 
and few have comprehensively examined maternal blood pressures, the 
specific influences from the quantitative nature and components of blood 
pressures are not well elucidated. 
Therefore the role of maternal lifestyle factors (obesity and n-3 PUFA) on 
maternal blood pressures, and the influence of maternal blood pressures on 
offspring outcomes were examined accordingly in this thesis. The following 
sections of this chapter provides a summary of findings, linking the evidence 
together. A general discussion on the methodological approach is also 
provided.  
 
7.2 Summary of Findings 
Based on a birth cohort of a Southeast Asian cohort of Chinese, Malay and 
Indian women residing in Singapore, the two main aims of the study on 
maternal life-style determinants and offspring consequences of maternal blood 
pressures during pregnancy were examined. The findings were summarized 




Firstly, on the lifestyle factors of maternal blood pressures, a cross-
sectional analysis of maternal adiposity and blood pressures measured at 26 – 
28 weeks gestation, showed positive associations between maternal adiposity 
(measured by BMI and sum of skinfold thickness) and peripheral and central 
blood pressures. Effect modifications by maternal ethnicity and gestational 
diabetes were observed. The maternal adiposity-BP relations tended to be 
stronger Chinese women and women with gestational diabetes. Particularly, 
greater adiposity was associated with higher blood pressures among Chinese 
women with gestational diabetes.   
Secondly, on the cross-sectional analysis of maternal plasma PC n-3 and 6 
PUFA levels and blood pressures measured at 26 – 28 weeks gestation, total 
and long chain n-3 PUFAs and n-3/n-6 ratio were inversely associated with 
peripheral SBP and central SBP and PP, whereas dihomo-ƴ-linolenic acid was 
marginally positively associated with peripheral and central SBP. Higher n-3 
PUFAs were also associated with lower odds of pregnancy associated 
hypertension [OR 0.76 (95% CI 0.60 to 0.97) in total n-3 PUFA and OR 0.77 
(95%CI 0.60 to 0.98) in long chain n-3 PUFAs. Maternal ethnicity modified 
the relation between plasma PC PUFAs and blood pressures, with stronger 
inverse associations for n-3 PUFAs in Chinese women, and stronger but 
positive associations for n-6 PUFAs in Indian women. 
Thirdly, on the consequences of maternal blood pressures on offspring 
outcomes, analysis of data from women with complete blood pressure 
information and offspring size at birth, showed that higher maternal blood 




offspring at birth. Maternal adiposity modified the relation between maternal 
blood pressures and offspring size at birth, with stronger inverse associations 
in normal weight women than overweight/obese women. Although the effect 
modification by maternal ethnicity was not statistically significant, Chinese 
women with higher blood pressures tended to have smaller offspring 
compared to Malay or Indian women. 
Lastly, analysis of data from maternal-offspring pairs with complete blood 
pressure information, showed that higher maternal blood pressures in 
pregnancy were associated with higher pulsatile components (SBP and PP) of 
blood pressures in the offspring, with larger estimated increases for maternal 
central blood pressures than peripheral blood pressures. When stratified by 
maternal hypertension, the positive mother-offspring blood pressures persisted 
in normotensive women who were free of hypertension during pregnancy. 
Effect modification by maternal ethnicity was not statistically significant. 
 
7.3 Synthesis of Findings 
From the studies included in this thesis, our findings suggest that maternal 
blood pressure is an important marker for haemodynamic adaptation during 
pregnancy. As pregnancy is associated with marked cardiovascular changes,6, 
29, 30 maternal lifestyle factors during pregnancy leading to higher pregnancy 
BMI may impair the mechanism involved in blood pressure control. And in 
turn, maladaptation in maternal blood pressures may lead to unfavourable in-
utero environment for fetal growth and development,75, 76 and thereby, 




We also postulate that there are two important incidental findings spanning 
across the four different studies. The first incidental finding was based on the 
ethnic differences observed in our study findings. Although the ethnic varying 
effect on blood pressure relations may have a genetic basis,208-210 migratory 
studies have shown that between population blood pressure differences are 
strongly associated with environmental factors.65, 211-213 This requires further 
study of gene-environment interaction in other settings, for example, to 
examine ethnic differences among south-east Asian women who live in rural 
areas and of various epidemiological study designs such as case-control or 
genetic linkage studies. 
Secondly, we also postulate that maternal blood pressures, even in non-
hypertensive women, are associated with health outcomes in the offspring. 
There is evidence suggesting that higher blood pressures in normotensive 
pregnant women are associated with preterm birth9, 10 and smaller offspring.9 
This may be explained by the nature of blood pressure which has a Gaussian 
distribution in the population, and has a graded relation with cardiovascular 
outcomes.19, 214, 215 Therefore, stratification of women into hypertensive or 
non-hypertensive groups may be inadequate to identify women at risk to 
having adverse outcomes in their offspring.  
The other consideration of interest is the inclusion of central blood 
pressures measured using radial applanation tonometry. Although our findings 
do not suggest the superiority of central blood pressures over peripheral 
(brachial) blood pressures, there is some evidence suggesting its role over and 




central and peripheral blood pressures indirectly, as they were strongly 
correlated with each other and thereby a methodological constraint in 
statistical analysis. 64, 217 At present, central blood pressure remains to be an 
arterial marker for research but not for clinical purposes.17, 218 
 
7.4 Methodological Considerations 
In this thesis, all the data used were drawn from the GUSTO birth cohort study 
and therefore, the findings should be interpreted in consideration of its 
methodological strengths and weaknesses. A general discussion on the 
methodological considerations involving study design, associations due to 
chance, confounding and bias would be described in the following. 
Study Design 
The GUSTO birth cohort study is prospective cohort study that was 
designed to examine early life factors that may be associated with metabolic 
compromise and altered body composition in the offspring. Therefore, the 
study measures that were incorporated into the GUSTO study were primarily 
observational in nature, and they were collected over the course of the 
GUSTO study follow-up (Chapter 2). Therefore, the four studies that were 
included in this thesis were similarly observational in nature.  
A cross-sectional design was employed to examine the role of maternal 
adiposity, plasma PUFA on maternal blood pressures. The primary limitation 
associated with cross-sectional study is the difficulty to establish the temporal 




outcome (blood pressures) as they are simultaneously measured.219, 220 
However, it is noteworthy that the relation between maternal adiposity and 
blood pressures have been reported previously in other cohort studies in 
pregnant women.30, 77, 88-92 Similarly for the PUFA and blood pressure 
relations, the hypotensive effect from n-3 PUFA supplementation has been 
shown in systematic reviews of randomized clinical trials in adult non-
pregnant79, 122, 123, 221, 222 and pregnant population,147 although data in pregnant 
population has been limited. There is also evidence that weight loss combined 
with increased PUFAs intake have an addictive hypotensive effect compared 
to either effect alone,223, 224 as shown in two randomized trials involving 
hypertensive223 and non-hypertensive populations.224 Therefore, although 
reverse causation may not be excluded, the significant associations observed 
between maternal adiposity, plasma PUFAs and blood pressures in this thesis 
are likely to be valid observations as they are consistent with reports from 
systematic reviews of randomized trials or prospective studies.223, 224 
A prospective cohort design was employed to examine the role of maternal 
blood pressures on health outcomes on the offspring (size at birth and blood 
pressures at 3 years old). As cohort studies enable the establishment of the 
temporal sequence between the exposure and outcome, they are often regarded 
as the best for non-interventional epidemiological studies.219, 220 Moreover, the 
prospective nature of the GUSTO cohort study has enabled the blood 
pressures in the women and their offspring to be measured systematically 





Associations due to chance  
By convention, the assessment of the role of chance in epidemiological studies 
involves statistical analysis in estimation of p value and confidence intervals. 
In this regard, the test for significance in all the statistical testing was set at 
0.05 so as to reduce the probability of committing type I error.219, 220 Although 
multiple analysis of peripheral and central blood pressure measures were 
performed, Bonferroni correction was not applied in the analysis as the blood 
pressure measures were highly correlated and that the tests were planned at the 
start of the study. 225, 226  Applying the Bonferroni correction, in this instance, 
will be counter-productive as it will lead to the problem of over-correction and 
thereby increasing the probability of type II error in the study findings. As 
there is active on-going research on central blood pressures, future reports will 
be useful in validating the findings presented in this thesis. 
Confounding 
Confounding is an inherent issue in all epidemiological studies. It occurs when 
the association between an exposure and outcome is distorted due to a third 
variable that is associated with both the exposure and outcome. 219, 220 This 
third variable however does not lie between the causal pathway between the 
exposure and outcome. For the maternal blood pressure associations, various 
strategies involving restriction, stratification and multivariate analysis were 
employed to control for confounding. Selection of confounders (maternal or 
offspring) were based on their biological importance or known confounding 
from the literature. For example, maternal age, ethnicity, BMI, were 




and smoking status were considered as known confounders. Other known 
confounders that were included in the adjustment were based on literature 
review and they were specific to the blood pressure relations examined. For 
example, fish oil supplementation is an important confounder for the maternal 
blood pressures and plasma PUFAs relations; and maternal coffee intake and 
depression for the maternal blood pressure and offspring size at birth relations.  
Although there were some variations in the covariates selected for adjustment 
in the maternal blood pressure relations, for example maternal intake of 
alcohol and physical activity; the lack of adjustment for these variables are not 
likely alter the study findings as they are likely to only weaken the blood 
pressure associations to the null from residual confounding. 
Residual confounding occur as a result of unmeasured or inaccurately 
measured, misclassified or poorly categorized variables such as maternal 
weight, physical activity and diet. Key covariates, such as maternal adiposity 
and salt intake,65, 77, 202, 227 may have greater contribution to residual 
confounding, compared to others, due to their strong relationships with blood 
pressures across all ages of life.65 Although maternal pre-pregnancy or 
pregnancy BMI have been widely used as an indication of adiposity during 
pregnancy, it is affected by measurement errors from the self-reported 
measures for pre-pregnancy BMI; and from fluid accumulation,  fetal and 
placental weight which contributes to pregnancy BMI.  Compared to maternal 
adiposity, measurement of salt intake from diet or urine is time consuming and 
often under-estimated due to difficulties in quantifying the sodium levels in 




Selection and Information Bias 
Selection bias may occur when subjects identified for study participation are 
dependent on the outcome of interest.219 Therefore selection bias is a particular 
problem in case-control and retrospective cohort study designs where both 
study exposure and outcome have already occurred. 219, 220 But for the GUSTO 
study, selection bias due to non-participation is unlikely to occur as at the time 
of study enrolment, as the outcomes of interest have yet to be ascertained. 
Moreover, examination of data in women included and excluded from the 4 
studies in this thesis, showed that there were no significant differences 
between exposure status between women who were included and excluded 
from the study.  
However, selection bias due to loss to follow-up or attrition bias may be an 
issue in the examination of maternal blood pressures on offspring outcomes. 
Among GUSTO participants that had complete blood pressure information 
and were followed-up, a total of 116 (14.0%) were lost to follow-up due to 
missing information on the birth measures in the offspring (Chapter 5), and 
262 (31.6%) due to missing blood pressure information in the offspring. 
Again, as the maternal measures of blood pressures were similar between 
women who were included in the study and those who were lost to follow-up, 
it is likely that the loss to follow-up occurred at random. Therefore, this may 
have affected the power, but not the internal validity of the study.  
Another major source of bias in cohort studies arises from information 
bias. It relates to systematic difference in the measurement of exposure or 




study, misclassification bias arising from inaccuracies or errors in recording or 
reporting exposure and outcome status are likely to be random and therefore 
would weaken the strength of the blood pressure associations to the null.  
Although random misclassification of maternal blood pressures and offspring 
outcomes may occur, the GUSTO study has built in strategies to reduce 
information bias through careful construction of the data collection form and 
rigorous training to its research personnel following standardized protocol. 
Moreover, maternal blood pressures were measured prior to offspring health 
outcomes, and the research personnel involved in the collection of outcome 
information in the offspring were unaware of the status of maternal blood 
pressures at the time of blood pressure measurements. Therefore, the impact of 
random misclassification of maternal blood pressures and offspring outcomes 
are likely to be minimized. 


















In conclusion, findings from the studies included in this thesis that were based 
on the GUSTO cohort, indicated that maternal adiposity, n-3 and 6 PUFA 
levels are associated with maternal blood pressures at 26-28 weeks gestation. 
In our cohort of Southeast Asian Chinese, Malay and Indian women, 
associations between maternal characteristics (adiposity, gestational diabetes 
and n-3 PUFA levels) and blood pressures were stronger in Chinese women. 
In addition, our findings also suggest that higher maternal blood pressures 
during pregnancy are associated with smaller offspring size at birth and higher 
early childhood blood pressures. 
Overall, the study findings included in this thesis are relevant to clinical 
practice and the pregnant woman. For example, a one percent increase in total 
n-3 PUFAs is associated with 0,5 mmHg decrease in peripheral SBP and a 23 
percent reduction in odds to pregnancy hypertension; and likewise, a one 
mmHg increase in peripheral SBP is associated with a 35.6 g reduction in 
offspring weight at birth and 64 percent increase in odds to low birth weight.  
Although the effect estimates from quantitative assessment of maternal blood 
pressures, at per-mmHg, are small, they are relevant to clinical practice on two 
basis. First, the lower blood pressures levels during pregnancy from higher n-3 
PUFAs if maintained over time, may reduce the risk to hypertension and 
cardiovascular diseases later on in life as women with pregnancy hypertension 
have a twofold increased risk to cardiovascular outcomes.2  Second, the 
persistent maternal blood pressures and offspring outcomes in normotensive 




were not at hypertensive range. Therefore, at the population level, maintaining 
lower blood pressures during pregnancy will shift the average mean to lower 
levels, and this may have an impact on the population’s risk to hypertension 
during pregnancy and later on in life.229  
The observations on maternal blood pressures in the GUSTO cohort are in 
agreement with findings in the current literature indicating that maternal blood 
pressures during pregnancy may have long term consequences on offspring 
health outcomes. Therefore, preventive strategies that focus on prevention and 
detection of hypertension should be instituted early in pregnancy. Strategies 
that incorporate appropriate weight gain during pregnancy according to pre-
pregnancy BMI and fish oil supplementation or fatty fish intake may be useful 
adjuncts to promoting good blood pressures control during pregnancy. This 
approach has been shown to be effective in improving metabolic syndrome 
features223, 224  and reducing the risk of cardiovascular in women through the 
anti-inflammatory and immune regulatory effects from long chain PUFAs in 
fish oil.230, 231 Due to the long term implications of maternal blood pressures 
during pregnancy on maternal and offspring’s cardiovascular health, 
institution of preventive strategies early in pregnancy may be a good start for 
the pregnant woman and her family.   
 
8.2 Future Directions 
Hypertension in pregnancy is a multi-factorial disorder that has been shown to 
be associated with environmental and genetic risk factors.20, 45, 67 Although the 




down-regulation of vasodilators and up-regulation of vasoconstrictors,21, 45 has 
been proposed as one the key pathophysiological mechanism leading to higher 
maternal blood pressures. Other mechanisms involved were increased shear 
stress from hyperdynamic circulation, decrease in renin-angiotensin-
aldosterone activities, increased cytokine-mediated oxidative stress, immune 
mediated altered inflammation and genetic factors.20, 44  
While these mechanisms may explain the associations between maternal 
obesity, plasma PUFAs and blood pressures; how these mechanisms occur and 
interact at various levels of function, for example from genetic inheritance to 
expression is not well understood. As such, research in various ‘omics’ 
techniques may be an important complement to current epidemiological 
research.232 Epigenomics research holds promise to many chronic diseases that 
are associated with genetic and environmental factors, such as hypertension 
and diabetes, as it not only provides the mechanisms underlying 
transcriptional regulation across developmental time-frames, but also the 
linkage between genotype and phenotype associations.233 
In the GUSTO study, there is an on-going collection of offspring’s bio-
specimens for epigenetic markers from birth onwards. And the combination of 
epidemiological, genetic and epigenetic information from this cohort, and 
from other studies, will be useful to clarify the genetic-phenotype disease 
interactions. 
In consideration of the methodological constraints in the studies described 
in this thesis, there are several areas of future research worth mentioning. 




maternal blood pressures measured only once at 26 – 28 weeks gestation. 
Therefore, incorporation of maternal blood pressures measured repeatedly 
during the three pregnancy trimesters would provide two important levels of 
information in understanding the maternal blood pressure adaptation and 
status during pregnancy. They include trimester specific blood pressure 
information as well as the changes that occur during pregnancy. 
Second, the associations between maternal adiposity and PUFA on 
maternal blood pressures suggest that these lifestyle factors may be important 
strategies in blood pressure control during pregnancy. However, as these 
findings were based on observational designs, they need to be tested further in 
randomised clinical trial design. Moreover, as adiposity and diet are closely 
related, concurrent assessment of these two determinants would facilitate the 
understanding on their independent and collective roles in blood pressure 
control strategies. 
Third, as the observation on ethnic modifying effects on the maternal 
adiposity and PUFA levels in relation to blood pressures were novel findings, 
it requires confirmation in larger cohort studies.  Future studies examining 
ethnic differences in the present target population of Southeast Asian Chinese, 
Malay and Indian women would need to ensure adequate power for interaction 
analysis. This could be achieved by oversampling of the Malay and Indian 
ethnic minorities. Collection of both genetic and dietary information would 
enable the assessment of gene-environment-interaction which may elucidate 




Fourth, on the positive maternal-offspring blood pressure relations during 
pregnancy, the duration of follow-up in the offspring should be lengthened or 
until overt hypertension or cardiovascular disease occurs. The inclusion of 
parental (maternal and paternal) blood pressures to be examined to further 
elucidate and compare in-utero and ex-utero exposure to parental blood 
pressures. By examining the offspring early exposures to parental blood 
pressures, early targeted preventions may be instituted in the women or the 
family as a whole. 
In summary, the proposed areas for future research may lead to 
improvement in antenatal care to ensuring optimal in-utero milieu for fetal 
growth and development and eventually lead to better health outcomes for 
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Study ID : _____________________ Date of interview : _____________________
Interviewer code : _____________________ Interview start time : _____________________
 
1. DEMOGRAPHY 
I would like to start by asking you some questions about yourself.  
 
1.1.  How old were you when you left long term full time education?  
(enter current age if still studying)   years 
 
1.2.  What is the highest level of education that you have attained?  
  1: None 
  2: Primary (PSLE) 
  3: Secondary (GCE ‘O’/ ‘N’ levels) 
  4: ITE/NTC 
  5: GCE ‘A’ levels/Polytechnic/diploma 
  6: University 
  7: Others, specify:_________________________________ 
 
1.3.  What is your marital status?  
  1: Single and living with the baby’s father  
  2: Single and not living with the baby’s father  
  3: Married (living with husband)  
  4: Married but not living with husband 
  5: Separated 
  6: Divorced 
  7: Widowed  
  8: Others, specify:______________________________________ 
 
1.4.  What is your religion?  
  1: No religion 
  2: Buddhism  
  3: Christianity 
  4: Islam 
  5: Taoism 
  6: Hinduism 
  7: Others, specify:______________________________________ 
 
1.5.  Where were you born?  
  1: Singapore               go to question 2.1 
  2: Malaysia 
  3: China 
  4: India  
  5: Others, specify:______________________________________ 
Appendix 1
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1.6.  When did you move to Singapore?  
 M M  Y Y Y Y 
        
2. OCCUPATION   
2.1.  What is your current job?  
    1:   Legislator/senior official 
    2:   Professional 
    3:   Technician & associated professional 
    4:   Clerical worker 
    5:   Service worker 
    6:   Agricultural worker 
    7:   Production craftsman 
    8:   Plant and machine operator 
    9:   Homemaker  
  10:   Retired  
  11:   Student  
  12:   Unemployed 
  13:   Others, specify:_______________________________ 
  14:   Refused 
3. HOUSING AND HOUSEHOLD COMPOSITION  
3.1.  What type of accommodation do you live in? 
  1: 1-2 room HDB flat 
  2: 3 room HDB flat 
  3: 4-5 room HDB flat 
  4: HUDC/executive flat 
  5: Condominium 
  6: Landed property 
  7: Others, specify:_________________________________ 
 
3.2.  Does anyone else live together with you? 
  0: No           go to question 4.1 
  1: Yes         please specify in the following table (next page) 
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For each person living in the household (apart from the woman herself), complete one line. 
A household is defined as a group of people who share a living room or eat together for at least one 
meal a day. 
CHILDREN 
For all children, record date of birth (or age if D.O.B. not available). 
For the woman’s own children, give the child’s birth weight. 
 
S/N Relationship to 
woman 




(Specify in gm 
or lb.oz) 
M F DD MM YYYY 
1         
2         
3         
4         
5         
ADULT 
S/N Relationship to 
woman 




No=0) M F 
6      
7      
8      
9      
10      
4. CHILDCARE ARRANGEMENTS  
4.1.  Do you have your own child or children at home under the age of 12 years? 
  0: No, go to question 5 
  1: Yes 
4.1.1 If yes, you are: 
  1: Working part time, go to question 4.2 
  2: Working full time, go to question 4.2 
  3: Stay home mother, go to question 5 
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4.2. Which of the following best describes the way you arrange for your child/children aged 12 or 
under to be looked after while you are at work? 
Please fill in numbers of relevant choices in boxes on right. You can select up to 3 choices. 
 
1: I work only while they are at school. 1st choice    
2: They look after themselves until I get home.    
3: I work from home. 2nd choice    No further choices 
4: My husband/partner looks after them.    
5: A nanny/grandparent/relative looks after them at home 3rd choice    No further choices 
6: They go to a workplace nursery.    
7: They go to a day nursery.    
8: They go to a child minder.    
9: A relative looks after them.    
10: A friend or neighbour looks after them.    
11: Others, specify___________________________    
5. PERSONAL HEALTH   
Now, I would like to ask you about your personal health and about the stress level you face.  
5.1. How is your health in general? Would you say it is: 
  1: Very good 
  2: Good 
  3: Fair 
  4: Bad 
  5: Very bad 
 
5.2. Do you have any long term illness or disability? By long term, I mean anything that has troubled 
you over a period of time? 
  0: No                go to question 5.4 
  1: Yes 
 
5.3. What is the illness/disability? _____________________________________________________ 
______________________________________________________________________________ 
(Do not record headaches, indigestion, aches and pains. We are interested in major problems 
such as diabetes, multiple sclerosis, rheumatoid arthritis, muscular dystrophy – anything which 
might affect growth or body composition.) 
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5.4. To what extent do you feel that the stress or pressure you have experience in your life has 
affected your health? 
  1: None 
  2: Slightly 
  3: Moderately 
  4: Quite a lot 
  5: Extremely  
  
5.5. In general, how much stress or pressure have you experienced in your daily living in the last 
4 weeks? 
  1: None  
  2: Just a little 
  3: A good bit 
  4: Quite a lot 
  5: A great deal 
 
5.6. Were you part of a multiple birth (twins, triplets etc.)? 
  0: No  
  1: Yes 
 
5.7. Were you born early, late or when your maternal mother was expecting you?  
  1: Early 
  2: When expected, go to question 5.9 
  3: Late 
  99: Don’t know, go to question 5.9 
 
 
5.8. How early/late were you?  
   Wks  Days  99: Don’t know 
5.9. How many children did your mother have before you were born? (including stillbirths)   
     99: Don’t know 
 
5.10. Approximately what was your weight before this pregnancy? 
     kg  99: Don’t know 
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6. ASTHMA  
6.1. Have you ever suffered from asthma, either as a child or an adult?  
  0: No        go to question 6.3          
  1: Yes      
  99: Don’t know   go to question 6.3 
 
6.1.1. If yes, was this confirmed by a doctor? 
  0: No 
  1: Yes 
  99:  Don’t know 
 
6.2. How many attacks of wheezing have you had in the last 12 months? 
  0: None  
  1: 1-3 
  2: 4-12 
  3: More than 12 
 
6.3. Did you suffer from eczema (recurrent itchy skin) in childhood?  
  0: No           go to question 6.5        
  1: Yes 
  99: Don’t know 
 
6.4. Have you had eczema (recurrent itchy skin) affecting the creases of your elbows or knees in 
the last year?  
  0: No                  
  1: Yes 
 
6.5. Have you ever had a problem with sneezing, or a runny, or blocked nose when you did not 
have a cold or flu? 
  0: No                 go to question 6.7 
  1: Yes 
  99: Don’t know   go to question 6.7 
 
6.5.1.  If “YES”, is the nose problem usually accompanied by itchy-watery eyes? 
  0: No                 
  1: Yes 
  2: Sometimes 
  99: Don’t know 
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6.6. In the last 12 months, have you had a problem with sneezing, or a runny, or blocked nose 
when you did not have a cold or the flu?  
  0: No                  
  1: Yes 
 
6.7. In the last 12 months, have you used any medicines to treat hay fever, rhinitis, or any other 
nasal problems, at any time (including sprays, solutions, pills, capsules or tablets)?  
  0: No        
  1: Yes 
7. HIGH BLOOD PRESSURE (HYPERTENSION)  
7.1. Has a doctor, a nurse or other healthcare professional ever told you that you have high blood 
pressure?  
  0: No                 go to question 8.1 
  1: Yes 
 
7.2. At what age were you diagnosed to have high blood pressure?  (Fill in one of the options 
below)  
Age   (or) Year       99: Don’t know 
8. DIABETES MELLITUS  
8.1. Has a doctor ever told you that you have diabetes?  
  0: No                 go to question 9.1 
  1: Yes 
 
8.2. How old were you when the doctor first told you that you had diabetes?  (Fill in one of the 
options below)  
Age   (or) Year       99: Don’t know 
9. MYOPIA   
9.1. Have you ever been told by a doctor or an optometrist that you need to wear glasses or 
contact lenses? 
  0: No                 go to question 10.1 
  1: Yes 
 
9.2. Did you get the glasses / contact lenses?  
  0: No                 go to question 10.1 
  1: Yes 
 
9.3. When did you first begin wearing glasses or contact lenses?  
Age   (or) Year       99: Don’t know 
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9.4. What is the purpose for the glasses / contact lenses? 
  1: Seeing far ± Astigmatism 
  2: Seeing near ± Astigmatism 
  3: Seeing both far and near 
  4: Astigmatism only 
  99: Don’t know 
10. FAMILY HISTORY 
10.1. Do you have a history of one of the following diseases in your first degree biological relatives 
(immediate family members)? 
  0: No, go to question 11 
  1: Yes, specify in the following table. 
 
Code  First degree relatives  Code Site of cancer 
1: Father  1: Breast  
2: Mother  2: Ovarian 
10-19: Sisters  3: Colorectal 
20-29: Brothers  4: Others, specify ___________ 
30-39: Sons   ________________________ 
40-49: Daughters  99: Don’t know 
 
Please use multiple rows if multiple diseases per individual 
Pre-eclampsia = high blood pressure in pregnancy 
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11. MENSTRUAL CYCLES AND PREGNANCIES  
11.1. Is your usual cycle regular, or has it varied by more than 5 days between periods in the last 6 
months? 
  1: Regular    go to question 11.2 
  2: Varied by more than 5 days   go to question 11.3 
  3: Don’t know                            go to question 11.3 
 
11.2. How long is your usual menstrual cycle between the start of one period and the start of the next 
period? 
  days  99: Don’t know 
 
11.3. How old were you when you had your first period? 
  years  99: Don’t know 
 
11.4. IF THIS IS YOUR FIRST PREGNANCY, PLEASE GO TO QUESTION 12.1 
Next, would you please tell me the ending date(s) and outcome(s) of each of your pregnancy in 
sequence? 
1: Live birth – Normal vaginal delivery 7: Premature birth – Normal vaginal delivery 
2: Live birth – Assisted delivery (Forceps/vacuum) 8: Premature birth – Assisted delivery 
3: Live birth – Caesarean section 9: Premature birth – Caesarean section 
4: Abortion 10: Ectopic pregnancies 
5: Miscarriage 11: Others, please specify: 


























































1                 
2                 
3                 
4                 
5                 
                 
 
11.5. Were you anaemic after the birth of any of your previous babies? 
  0: No 
  1: Yes 
  99: Don’t know 
 RECRUITMENT VISIT 
 1ST CLINIC VISIT QUESTIONNAIRE
 
 
NOTE TO RECRUITERS WHEN FILLING IN QUESTIONNAIRE SETS:  
(1) PLEASE USE THE CAPITAL LETTER.  
(2) PLEASE WRITE CLEARLY. 
 
CONFIDENTIAL 
GUSTO-1stClinicVisitQuestionnairefinal_12_11_09.doc Page 10 of 11 
 
12. MEDICATION 
The questions below ask about REGULAR consumption of medications, supplements and traditional 
medicine in the past year BEFORE THIS PREGNANCY. 
 Regular refers to more than once a week for at least 1 month in past1 year. 
12.1. Have you been taking any medications regularly before this pregnancy? 
  0: No    go to question 12.2 
  1: Yes, please specify in table below 
 







12.2. Have you been taking folic acid supplement before your current pregnancy? 
  0: No    go to question 12.3 
  1: Yes 
12.2.1. How many weeks before pregnancy have you been taking folic acid supplement? 
   weeks 
 
12.3. Are you still taking folic acid supplement NOW? 
  0: No 
  1: Yes 
12.4. Have you been taking any fortified milk supplement (e.g. Anlene, Anmum) regularly before this 
pregnancy? 
  0: No     
  1: Yes 
 
12.5. Have you been taking any probiotics (e.g. Yakult, Vitagen, Yoghurt) regularly before this 
pregnancy? 
  0: No     
  1: Yes 
 
12.6. Have you been taking any other vitamins or supplements regularly before this pregnancy? 
  0: No     
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12.7. Have you been taking any traditional medicines regularly before this pregnancy? 
  0: No     
  1: Yes 
 
 
13. INCOME  
13.1.  What is your personal monthly income? 
  1: $0 - $999 
  2: $1000 - $1999 
  3: $2000 - $3999 
  4: $4000 - $5999 
  5: more than $6000 
  6: Refuse to answer 
  99: Don’t know 
 
13.2.  What is the monthly income of your household?   
  1: $0 - $999 
  2: $1000 - $1999 
  3: $2000 - $3999 
  4: $4000 - $5999 
  5: more than $6000 
  6: Refuse to answer 
  99: Don’t know 
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Study ID: _______________________         Date of interview: _________________ 




Have you changed your address or telephone number since you were seen in early 
pregnancy? 
 
  0: No                 
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1. OCCUPATIONAL ACTIVITY 
 
1.1. Have you had any jobs at any time since you became pregnant? 
  0: No                go to Section 2 
  1: Yes 
 
1.2. Would you please tell me your jobs during pregnancy and the weeks of your pregnancy 
in which you have done them? 
If started before pregnancy, week started = 0 
If job is still ongoing, week finished = 88  
 
Occupation Week started Week finished 
1.   
2.   
3   
4.   
 
1.3. How many hours in total did you work during an average week? 
 
    .    hrs (round to nearest 0.5 hr) 
 
1.4.Did this include working night shifts?  
Night shift means “working at least once a week or more from 12 midnight to 6:00am” 
  0: No 
  1: Yes 
 
1.5. At around this time, did your paid work involve any of the following activities in an 
average day at work? 
i) Standing or walking for more than four hours in total? 
  0: No                 
  1: Yes 
 
ii) Kneeling or squatting for more than an hour in total? 
 
  0: No 
  1: Yes 
iii) Standing or sitting with your trunk bent forward for more than an hour in total? 
 
  0: No 
  1: Yes 
 
iv) Lifting or carrying weight of 25kg (56lbs) or more by hand (equivalent to a sack of 
potatoes, a nine year old child, a very heavy suitcase) 
  0: No 
  1: Yes 
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1.6. Have you at any time during your pregnancy left a job or changed the type of work that 
you were doing because of a health problem?  
  0: No 
  1: Yes 
 
           1.6a. If yes, give details of health problems__________________________________  
                      ________________________________________________________________ 
           1.6b. and the stage of pregnancy                                weeks 
 
2. ACTIVITY AND EXERCISE– BEFORE THIS PREGNANCY 
 
Now I’m going to ask you about your activity and exercise patterns during the 1 year before 
your pregnancy. We would like you to divide up a “typical” day into three types of activities. 
These are:  
(1) sleeping or lying,            (2) sitting,  (3) standing or walking. 
 
2.1. Over a typical 24 hour day, how many hours do you generally spend sleeping or 
lying with your feet up? 
(ask what  time she usually goes to bed & wakes up, including any at work!)  
   .  hrs (round to nearest 0.5 hr) 
 
2.2. How many hours on a typical day do you spend sitting down? 
(e.g. includes sitting at work, mealtimes, driving, reading, watching TV)  
   .  hrs (round to nearest 0.5 hr) 
 
2.3. This would mean that you spend about xx hours a day on your feet.  
       Does this sound about right?   
   .  hrs (round to nearest 0.5 hr) 
 
Sum of hours reported in Q2.1, 2.2 and 2.3 should total up to 24 hours 
 
Total hours: ___________________________ 
Checked and signed: ____________________ 
 
 
2.4. Out of these xx hours spent on your feet, about how much of the time are you 
actively on the move (rather than standing fairly still)?  
 
  1: Very little  10% 
  2: Some 30% 
  3: About half 50% 
  4: Most 70% 
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2.5. During the 1 year before your pregnancy, how often have you done the following 
kind of exercises or activities?  
a) Strenuous exercise which normally makes your heart beats rapidly AND leaves you 
breathless e.g. jogging, vigorous swimming or cycling, aerobics 
  1: Never 
   2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
b) Moderate exercise which normally leaves you exhausted but not breathless, e.g. 
brisk walking, dancing, easy swimming or cycling, badminton, sailing.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
c) Gentle exercise which normally leaves you tired but not exhausted, e.g. walking, 
driving, housework (including washing windows and polishing), gardening, DIY, golf.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
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2.6.On a typical day, how many hours do you generally spend watching television?  
  1:  More than 5 hours 
  2:   4-5 hours 
  3:   3-4 hours 
  4:   2-3 hours 
  5:   1-2 hours 
  6:   Less than one hour 
  7:    None 
 
2.7. Which of the following best describes your walking speed?  
  1: Very slow 
  2: Stroll at an easy pace  
  3: Normal speed 
  4: Fairly brisk 
  5: Fast 
 
3. ACTIVITY AND EXERCISE –DURING THIS PREGNACY 
 
Can I now ask you about your activity and exercise patterns over the last 6 months?   
As before, we would like you to divide up a “typical” day into three types of activities.  
These are:  
(1) sleeping or lying,    (2) sitting,  (3) standing or walking. 
 
3.1. Over a typical 24 hour day, how many hours do you generally spend sleeping or 
lying with your feet up? 
(ask what time she usually goes to bed & wakes up, including any at work!)  
   .  hrs (round to nearest 0.5 hr) 
 
3.2. How many on a typical day do you spend sitting down? 
(e.g. includes sitting at work, mealtimes, driving, reading, watching TV)  
   .  hrs (round to nearest 0.5 hr) 
 
3.3. This would mean that you spend about xx hours a day on your feet.  
       Does this sound about right?  
   .  hrs (round to nearest 0.5 hr) 
 
Sum of hours reported in Q3.1, 3.2 and 3.3 should total up to 24 hours 
 
Total hours: ___________________________ 
Checked and signed: ____________________ 
 
3.4. Out of these xx hours spent on your feet, about how much of the time are you 
actively on the move (rather than standing fairly still)?  
  1: Very little  10% 
  2: Some 30% 
  3: About half 50% 
  4: Most 70% 
  5: Almost all 90% 
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3.5. During the past six months, how often have you done the following kinds of exercise 
or activities?  
 
a) Strenuous exercise which normally makes your heart beat rapidly AND leaves you 
breathless e.g. jogging, vigorous swimming or cycling, aerobics 
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
b) Moderate exercise which normally leaves you exhausted but not breathless, e.g. 
brisk walking, dancing, easy swimming or cycling, badminton, sailing.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
c) Gentle exercise which normally leaves you tired but not exhausted, e.g. walking, 
driving, housework (including washing windows and polishing), gardening, DIY, golf.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
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3.7. Which of the following best describes your walking speed?  
  1: Very slow 
  2: Stroll at an easy pace  
  3: Normal speed 
  4: Fairly brisk 




4.1.How many weeks pregnant were you when you first found out that you were pregnant? 
   wks 
4.2.Was this pregnancy planned? 
  0: No    Go to question 4.4 
  1: Yes: Go to question 4.3 
 
4.3 If YES, did you change your diet when you were planning to be pregnant? 
  0: No    Go to question 5.1 
  1: Yes   Go to question 5.1 
  
4.4.If NO, this pregnancy is due to 
  1: No contraception: Go to question 5.1 
  2: Failure of contraceptive methods 
 
4.5.If NO, which was the main contraceptive method used which failed?  
  1. Safe period 
  2. Barrier e.g. condom, diaphragm 





  4. Intrauterine contraceptive device 
  5. Withdrawal  





3.6.On a typical day, how many hours do you generally spend watching television?  
  1: More than 5 hours 
  2: 4-5 hours 
  3: 3-4 hours 
  4: 2-3 hours 
  5: 1-2 hours 
  6: Less than one hour 
  7: None 
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5. DIET DURING PREGNANCY  
 
5.1 Are you following any special diet? 
  0: No    go to question 5.3 
  1: Yes 
 
5.2 If yes, what is your special diet? 
  1: Vegetarian (Eggs and milk allowed) 
  2: Vegan (No eggs or milk allowed) 
  3. Diabetic diet 
  4. Low fat diet 
  5. Others, specify ________________ 
 
5.3 How often do you eat eggs? 
  1: More than one egg a day 
  2: One egg a day 
  3. 4 to 6 eggs a week 
  4. 1 to 3 eggs a week 
  5. Less than one egg a week 
  6. Do not eat eggs at all 
 
5.4 How often do you eat liver (any type e.g. chicken, beef, pork)? 
  1: Every day 
  2: 4 to 6 times a week 
  3. 1 to 3 times a week 
  4. Less than once a week but more than once a month 
  5. Less than once a month 
  6. Do not eat liver at all 
 
5.5 How often do you eat out or purchase take-away foods? 
  1: Two meals a day or more 
  2: One meal a day 
  3. 4 to 6 meals a week 
  4. 1 to 3 meals a week 
  5. Less than once a week 
  6. Never/ rarely 
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5.6  I would like to find out more about your diet during pregnancy compared to what you usually ate 
before you were pregnant. I will be asking you about your eating habit for a list of foods during 
pregnancy. Please tell me if you ate more, less or similar amount of the food during pregnancy 
compared to your usual diet. 
 
 Types of Food Change in 
amount  
 
1.  Chicken  Key 
2.  Fish  1: More 
3.  Meat (beef / mutton / pork)  2: Less 
4.  Organ meats  
(e.g. liver, kidney, heart, brain) 
 3. Same as before 
9. Don’t usually eat 
5.  Seafood  
(e.g. prawn, crab, mussels, clams) 
  
6.  Egg   
7.  Vegetables (all types)   
8.  Fruits (all types)   
9.  Red, orange, yellow fruits and 
vegetables (e.g. carrots, papaya) 
  
10.  Rice, noodles, breads    
11.  Cheese, yogurt   
12.  Chocolates, sweets, biscuits, cakes   
13.  Milk   
14.  Chocolate drinks (Milo, Ovaltine)   
15.  Soft drinks  
(e.g. Coke, sprite, 7-up, Pepsi)  
  
16.  Tea   
17.  Coffee   
18.  Wine/alcohol (including tonic wine)   
 
6.   APPETITE AND NAUSEA DURING PREGNANCY  
6.1. Have you experienced any nausea or sickness since becoming pregnant? 
  0: No     go to question 6.5            
  1: Yes 
 
6.2. If yes, has this been: 
  1: Mild (nausea only) 
  2: Moderate (sometimes sick, vomiting) 
  3: Severe (regularly sick, vomiting, can’t retain meals) 
 
6.3. If yes, were you admitted to the hospital because of nausea? 
  0: No     go to question 6.5 
  1: Yes 
 
6.4. If yes, how were you treated? 
  1: Fasting, then slowly introducing food 
  2: Intravenous fluid treatment 
  3: Medication (Note: Refer to medical records/CPSS) 
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6.5. Compared with BEFORE you were pregnant, are you eating: 
  1: More                           go to question 6.5a 
  2: The same                    go to question 7.1 
  3: Less in amount           go to question 6.5b 
  99: Don’t know 
 
      6.5a. If more, is this: 
  1: Because you feel more hungry 
  2: To prevent from feeling sick 
  3: Because you feel it is best for the baby 
  4: Other reasons; specify: _________________________________ 
 
      6.5b. If less, is this: 
  1: Because you feel less hungry 
  2: Because of nausea/sickness 
  3: Don’t want to put on too much weight 
  4: Other reasons; specify: _________________________________ 
 
7. DIETING  
 
7.1  Which of the following describes you best? 
 
  1: I have NEVER been on a diet to lose weight. 
  2: I have ONLY ONCE been on a diet to lose weight. 
  3: I USED TO diet REGULARLY to lose weight but NOT ANYMORE 
  4: I go on a diet to lose weight EVERY NOW AND AGAIN. 
  5: I am USUALLY on a diet to lose weight. 
   
If answered 2, 4, 5, please ask question 7.2; otherwise go to next section. 
 
7.2     Are you currently trying to lose weight by dieting? 
 
  0: No 
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8.  ALCOHOL CONSUMPTION – BEFORE THIS PREGNANCY 
I’d like to ask you a few questions about your drinking and smoking habits. 
 
8.1  Did you ever drink alcohol before this pregnancy? 
  0: No                go to section 9 
  1: Yes 
  99: Don’t know 
 
8.2 How often did you drink the following alcoholic beverages in the 1 year before you 
became pregnant? Please select the category that best describes how often and how much 
you drank during the past year.  
Alcoholic 
beverages 
Average consumption in past year  Usual serving size 
 
Beer 
1. Never or hardly ever 
2. Once a month 
3. 2-3 times a month 
4. Once a week 
5. 2-3 times a week 
6. 4-6 times a week 
7. Once a day 
8. 2 or more times a day 
1. One small bottle 
(375ml) or less 
2. One large bottle 
(750ml) 
3. Two large bottles 




(eg. red wine) 
 1. One wine glass         
      (118ml) or less  
2. Two wine glasses  
3. Three wine glasses 
4. Four wine glasses or 




 1. One wine cup 
(30ml) or less  
2. Two wine cups  
3. Three wine cups  
4.    Four wine cups or 
more 
Hard liquor 
(eg. brandy)  
 1. One drink (30ml) 
or less  
2. Two drinks 
3. Three drinks 
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9 ALCOHOL CONSUMPTION – DURING THIS PREGNANCY 
 Did you ever drink alcohol during this pregnancy?    
  0: No                go to section 10 
  1: Yes 
  2: Refuse to answer 
 
9.1 During the past 6 months, how often did you drink the following alcoholic beverages? 
Please select the category that best describes how often and how much you drank. 
Alcoholic 
beverages 
Average consumption past 6 mth  Usual serving size 
 
Beer 
1. Never or hardly ever 
2. Once a month 
3. 2-3 times a month 
4. Once a week 
5. 2-3 times a week 
6. 4-6 times a week 
7. Once a day 
8. 2 or more times a day 
1. One small bottle (375ml) 
or less 
2. One large bottle (750ml) 
3. Two large bottles 




(eg. red wine) 
 1. One wine glass         
      (118ml) or less  
2. Two wine glasses  
3. Three wine glasses 
4. Four wine glasses or 




 1. One wine cup  
     (30ml) or less 
2. Two wine cups  
3. Three wine cups  
4.  Four wine cups or more 
Hard liquor 
(eg. brandy)  
 1. One drink (30ml) or less  
2. Two drinks 
3. Three drinks 
4. Four drinks or more 
 
10. PERSONAL VIEWS ON BREAST FEEDING 
 
10.1 Have you breastfed before? 
  0: No, go to question 10.3                  
  1: Yes 
  
                   10.1.1 If “YES”, how many children have you breastfed before? 
    Number of children 
 
                   10.1.2 If YES, please describe your type of breastfeeding for your last child: 
   1. Exclusive breastfed (Only breast milk with no water) 
   2. Predominant breastfed (Breast milk and liquids (including water) other than formula) 
   3. Partial breastfed (Breast milk, formula and liquids) 
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               10.1.3 How long did you breastfeed your last child? 
  Year   Months    weeks 
 
10.2 Are you still breastfeeding during this pregnancy? 
   0: No 
   1: Yes but I stopped at   weeks of pregnancy 
   2: Yes, I am still continuing breastfeeding 
 
10.3 Do you know people who have successfully breastfed their babies? 
 0: No 
 1: Yes 
 
10.4 Did you receive advice from family or friends about breastfeeding? 
 0: No 
 1: Yes 
 
 
10.5 Have you read books or watched programs on breastfeeding? 
 0: No 
 1: Yes 
 
10.6 Are you currently attending antenatal classes? 
 0: No 
 1: Yes 
 
10.7 Do you plan to breastfeed? 
   0: No 
   1: Yes, for how long   months , go to question 10.8 
             99: Don’t know 
 
               10.7.1 If No, please specify reason 
   1: Underlying medical problems 
   2: Painful 
 th     3: Troublesome 
   4: Inconvenient 
   5: Formula more nutritious 
   6: No reason 
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10.8 Who will be the main person helping you with the baby after delivery? 
   1. Confinement nanny 
   2. Mother / Mother-in-law 
   3. Husband 
   4. Other relatives 
   5. Others, specify__________________ 
 
11. SMOKING – BEFORE THIS PREGNANCY  
 
11.1 Have you ever smoked regularly (at least once a day for a year or more)?  
  0: No                go to question 11.5 
  1: Yes 
  2: Refuse to answer 
 
11.2 How old were you when you first smoked regularly? 
   yrs 
 
11.3 Did you smoke during the 1 year before you became pregnant? 
  0: No                go to question 11.5  
  1: Yes 
 
11.4 If yes, how many sticks per day? Record maximum stated. 
    
 
Note to interviewer: You may want to explain to the participant that even though she does not 
smoke, there is some evidence of health implications from second-hand smoke exposure. The 
following questions are to capture information on second-hand smoke exposure, i.e. where 
the participant was close enough to the smoker(s) to smell the smoke. 
 
11.5 Did anyone living in your home smoke at home on a daily basis for 6 months or longer?   
  0: No                go to question 11.7  
  1: Yes 
 
11.6 For how many years did at least 1 person living in your home smoke daily at home? 
  1:   1 year or less 
  2:   2-5 years 
  3:   5-14 years 
  4:   15-24 years 
  5.   25+ years 
 
11.7  Have you ever had a job in which, on a daily basis, you were exposed to cigarette 
smoke from others?   
  0: No                 
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12. SMOKING – DURING THIS PREGNANCY 
 
12.1  Are you currently smoking?  
  0: No                go to question 12.3 
  1: Yes 
 
12.2 If yes, how many sticks per day? Record maximum stated.  
    
 
12.3  During your pregnancy, did anyone living in your home smoke at home on a daily      
         basis?   
  0: No                 
  1: Yes 
 
12.4 During your pregnancy, have you ever had a job in which, on a daily basis, you were 
exposed to cigarette smoke from others?   
  0: No                go to section 13 
  1: Yes 
 
12.5 On average, how many hours were you exposed to cigarette smoke at work? 
  1:   1 hour or less 
  2:   1-3 hours 
  3:   More than 3 hours 
 
12.6 Are you currently exposed to cigarette smoke at work on a daily basis? 
  0: No                 
  1: Yes 
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13. MEDICATION 
 
13.1 Are you taking any medications / supplements / traditional medicine regularly DURING this 
pregnancy? 
         Regular refers to more than once a week 
  0: No    END OF QUESTIONNAIRE 
  1: Yes, please specify in table below 
 






















THANK YOU VERY MUCH FOR YOUR HELP! 
 
Interview end time: ________________ 
 
 1 source: Cox JL, Holden JM and Sagovsky R. 1987. Detection of postnatal depression: Development of 
the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150: 782 -786. 
 
Users may reproduce the scale without further permission providing they respect copyright by quoting 
the names of the authors, the title and the source of the paper in all reproduced copies. 
Edinburgh Postnatal Depression Scale1 (EPDS) 
Study ID: _______________________         Date: _________________ 
 
As you are pregnant or have recently had a baby, we would like to know how you are feeling. Please 
check the answer that comes closest to how you felt IN THE PAST 7 DAYS, not just how you feel today. 
 
Here is an example, already completed. 
 
I have felt happy: 
 
 1. Yes, all the time 
2. Yes most of the time 
3. No, not very often 





This would mean: “I have felt happy most of the time” during the past week. Please complete the other 
questions in the same way. 
 
In the past 7 days: 
 
1. I have been able to laugh and see the funny side of things 
 
 1. As much as I always could 
2. Not quite so much now 
3. Definitely not so much now 





2. I have looked forward with enjoyment to things 
 
 1. As much as I ever did 
2. Rather less than I used to 
3. Definitely less than I used to 





3. I have blamed myself unnecessarily when things went wrong 
 
 1. Yes, most of the time 
2. Yes, some of the time 
3. No, not very often 







 1 source: Cox JL, Holden JM and Sagovsky R. 1987. Detection of postnatal depression: Development of 
the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150: 782 -786. 
 
Users may reproduce the scale without further permission providing they respect copyright by quoting 
the names of the authors, the title and the source of the paper in all reproduced copies. 
 
4. I have been anxious or worried for no good reason 
 
 1. No, not at all 
2. Hardly ever 
3. Yes, sometimes 





5. I have felt scared or panicky for no very good reason 
 
 1. Yes, quite a lot 
2. Yes, sometimes 
3. No, not much 





6. Things have been getting on top of me 
 
 1. Yes, most of the time I haven’t been able to cope at all 
2. Yes, sometimes I haven’t been coping as well as usual 
3. No, most of the time I have coped quite well 





7. I have been so unhappy that I have had difficulty sleeping 
 
 1. Yes, most of the time 
2. Yes, sometimes  
3. Not very much 





8. I have felt sad or miserable 
 
 1. Yes, most of the time 
2. Yes, quite often 
3. Not very often 





9. I  have been so unhappy that I have been crying 
 
 1. Yes, most of the time 
2. Yes, quite often 
3. Only occasionally 






 1 source: Cox JL, Holden JM and Sagovsky R. 1987. Detection of postnatal depression: Development of 
the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150: 782 -786. 
 
Users may reproduce the scale without further permission providing they respect copyright by quoting 
the names of the authors, the title and the source of the paper in all reproduced copies. 
 
10. The thought of harming myself has occurred to me 
 
 1. Yes, quite often 
2. Sometimes 
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Anthropometric measurements for participants 
(Parents and children) 
General	note:	
 
Length, height, circumferences, and skinfolds are to be recorded to the nearest unit 
specified for each measure. 
 
Arm circumference and skinfold measurements are taken on the right side of the 




 The measurements are taken in duplicate.  
 A third measurement should be taken if the first two measurements differed 
by >1.0 cm.  
Note: If it is necessary to take a third measurement, the two closest measurements 
are averaged. Should the third measurement fall equally between the first two 
measurements, all three should be averaged. 
 A SECA infant mat is used for measurement of recumbent length. The mat has a 
fixed headpiece, horizontal backboard, and movable foot piece.  
 Ask the parent or guardian to remove the child’s clothes except for a diaper or 
underpants and t-shirt. 
 Position the child on the infant mat with the feet positioned against the foot piece 
and the head against the headpiece.  
 Note: Children often cry when placed on the infantometer, so ask the parent or 
guardian to stand beside the examiner, make eye contact, and reassure the child. 
 One person supports the child’s head and ensures that the head is positioned in 
the Frankfort horizontal plane. To do this, apply gentle traction to bring the top of 
the head in contact with the fixed headpiece. Secure the child’s head in the 
proper alignment by lightly cupping the palms of your hands over the ears. 
 A second person can align the child’s legs by placing one hand gently but with 
mild pressure over the knees. With the other hand, slide the foot piece to rest 
firmly against the soles of the feet. The toes should point upward with both soles 
of the feet flexed perpendicular against the acrylic foot piece. To encourage the 
child to flex the feet, run the tip of your finger down the inside of the foot. 
Appendix 4
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Height	
 Standing height is measured from the top of the participant’s head to his or her 
heels. 
 Remove shoes, hair ornaments and undo braids and buns.  
Note: Adjustments for shoes and hair:  
When participants cannot remove hair braids, buns, and headwear that interferes with the 
stature measurement, measure the distance from the scalp to the top of the hair with a 
small ruler to the nearest 0.1 cm.  
If shoes are worn, measure the height of the shoe heel to the nearest 0.1 cm. A corrected 
height value can be calculated by subtracting these distances from the original stature 
measurement, thus yielding an adjusted stature value 
 Ask the participant to stand erect against the backboard with the body weight 
evenly distributed and both feet flat on the stadiometer platform. 
 Keep the legs straight.  
 The participant’s feet should be positioned with the heels together and toes 
pointed slightly outward at approximately a 60 degree angle.  
 Check to be sure that the back of the head, upper back between shoulder blades, 
buttocks, and heels touching the vertical stand/board of the stadiometer.  
Note:  
Depending on the overall body conformation of the individual, all four contact points - 
head, shoulders, buttocks, and heels - may or may not touch the stadiometer backboard. 
In such instances it is important to obtain the best measurement possible.  
 The observer should get to a face-to-face level with the subject and positioned 
her head so that a horizontal line drawn from the ear canal to the lower edge of 
the eye socket, running parallel to the baseboard (i.e., the Frankfort plane 
positioned horizontally).  
 The headboard is pulled down to rest firmly on top of the head and compressed 
the hair.  
 A gentle push applied to the tummy can help the subject stand to full height.  
 Instruct the survey participant to stand as tall as possible, take a deep breath, 
and hold this position.  
Note: The act of taking a deep breath helps straighten the spine to yield a more 
consistent and reproducible stature measurement. Notice that the inhalation will 
cause the headpiece to rise slightly.  
 As soon as the participant inhales, record the measurement. The reading is taken 
to the nearest 1 mm.Measurements are taken in duplicate. A third measurement 
should be taken if the first two measurements differed by >1.0 cm.  
Note: If it is necessary to take a third measurement, the two closest measurements 
are averaged. Should the third measurement fall equally between the first two 
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Weight	
 Measurements are taken in duplicate.  
 A third measurement should be taken if the first two measurements differ by >200 
grams.  
Note: If it is necessary to take a third measurement, the two closest measurements 
are averaged. Should the third measurement fall equally between the first two 
measurements, all three should be averaged. 
Participants are asked to remove objects such as cell phones, wallets, and toys 
from their pockets.   
 In light clothings and without shoes, the participant to stand in the center of the 
scale platform with hands at their sides and looking straight ahead.  
 Measure to last 0.1 kg. 
 
Head	circumference	
The child may need to be held by the parent or a health professional while the 
examiner uses a tape measure to measure the child’s head.  
 The measurements are taken in duplicate.  
 A third measurement should be taken if the first two measurements differed 
by >1.0 cm. If it is necessary to take a third measurement, the two closest 
measurements are averaged. Should the third measurement fall equally between 
the first two measurements, all three should be averaged. 
 The circumference of the head is measured on children from birth through 36 
months of age.  
 Follow the steps below to obtain the head circumference measurement: 
1. Position of the study participant: Instruct the parent (or guardian) to stand 
holding the child over the parent’s left shoulder or else sit with the child in the 
parent’s lap. Ask the parent to remove hair ornaments or braids that might 
interfere with the measurement. 
2. Taking the measurement: Place the head circumference tape around the 
child’s head so that the tape lies: across the frontal bones of the skull; slightly 
above the eyebrows; perpendicular to the long axis of the face; above the ears; 
and over the occipital prominence at the back of the head. Move the tape up and 
down over the back of the head to locate the maximal circumference. Tighten the 
insertion tape so that it fits snugly around the head and compresses the hair and 
underlying soft tissues. Measure the circumference to the nearest 0.1 cm. 




 The mid-upper-arm point is half the distance between the acromion process (the 
most lateral bony protuberance of the back of the shoulder) and the olecranon 
(the bony structure that stands out when the elbow is bent).  
 The midpoint was located for measurement of the mid-upper-arm circumference 
(MUAC) and triceps skinfold thickness.  
 Direct the participant to turn away from you.  
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 Ask participant to stand upright with his/her weight evenly distributed on both feet, 
the right arm bent 90 degrees at the elbow, and the right palm facing up.  
 The observer palpates the shoulder to find the acromion. Locate the end of the 
spine of the right scapula by following the scapula out to the arm until it makes a 
sharp V-turn to the front of the body.  
 Using the cosmetic pencil/pen, make a horizontal line on the uppermost edge of 
the posterior border of the spine extending from the acromion process.  
 The observer placed the zero point of the tape on the mark over the acromion 
process and runs it downward along the back of the arm to the tip of the 
olecranon process, the bony part of the elbow.  
 The tape must be centered on the posterior surface of the arm.  
 The midpoint on the posterior aspect of the arm is marked.  
 Finally, tell the participant to relax the right arm.  
 Proceed to the arm circumference measurement.  
 For measurement of the MUAC, the arm hangs in a relaxed position or is held in 
the extended position; care should be taken not to flex or tighten the muscles 
which will yield an inaccurate measurement.  
 The tape is then wrapped around the arm over the marked midpoint. Position the 
tape perpendicular to the long axis of the upper arm and make sure the tape is 
level around the circumference. The tape has to lie flat around the arm.  
 Pull the two ends of the overlapping tape together so that the zero end sits below 
the measurement value and the result lies on the lateral aspect of the arm (not 
the posterior surface).  
 Check that the tape fits snug around the arm but does not compress the skin. 




(National Health and Nutrition Examination Survey [NHANES])  
 
 Locate the top of the right iliac crest.  
 With the cosmetic pencil/pen, draw a horizontal line just above the uppermost 
lateral border of the right iliac crest.  
 Cross this mark at the midaxillary line, which extends from the armpit down the 
side of the torso.  
 Repeat the same process on the participant’s left side.  
 Make sure the participant does not inhale while his/her waist circumference is 
being measured (at expiration) and that the tape is not twisted.  
 Wrap the tape measure around the individual’s waist as you would a belt, making 
sure that the zero end of the measure is at the beginning of the circumference.  
 Be sure to position the tape in a horizontal plane at the level of the measurement 
mark.  
 Check the horizontal alignment of the tape before taking the measurement and 
make sure the tape lies snug but does not compress the skin. 
 Note: If another person is available, the person can be positioned on the opposite 
side of the participant and should check that the tape sits parallel to the floor and 
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lies snug but does not compress the skin. Always position the zero end of the 
tape below the section containing the measurement value.  
 Take the measurement to the nearest 0.1 cm at the end of the participant’s 
normal expiration. Measurements are taken in duplicate.  
 A third measurement should be taken if the first two measurements differed 
by >1.0 cm for parents or > 0.5 cm for children up to 11 yrs 
 If it is necessary to take a third measurement, the two closest measurements are 
averaged. Should the third measurement fall equally between the first two 




 Participant should be wearing an examination gown or in thin underwear when 
this measure is taken.  
 The hip girth measurement should be made on the participant’s right side (rather 
than in front) with the patient’s feet together.  
 Hip girth is measured at the level of the symphysis pubis anteriorly and 
posteriorly at the level of the maximal protrusion of the gluteal muscles (Exhibit 1). 
This level usually is the greatest circumference of the hips, around the greater 
trochanter (but not always).  
 Mark the level of greater trochanter. (Marking may not be possible if the mothers 
do not agree to lower the garment. However this should be the exception and not 
the rule) 
 Keep the anthropometric tape horizontal at this level and record the 
measurement to the nearest 0.1 cm. 
 Measurements are taken in duplicate.  
 A third measurement should be taken if the first two measurements differed 
by >1.0 cm for parents or > 0.5 cm for children up to 11 years.  
 If it is necessary to take a third measurement, the two closest measurements are 
averaged.  
 Should the third measurement fall equally between the first two measurements, 
all three should be averaged. 
 




 Measurements are to be taken in triplicates and record to last completed 0.2 
mm.  
 If repeated tests vary by more than 1mm, repeat the measurement.  
 The final value recorded should be the average of the three that seems to best 
represent the skinfold site. 
 
Biceps‐		
 Mark the anterior surface of the biceps midway between the anterior auxiliary fold 
and the antecubital fossa (anterior auxiliary line is the crease where the top of the 
arm, when hanging down, meets the chest).  
 Grasp a vertical fold 1 cm above the mark with arm relaxed and hanging by side, 
straight. 
 The caliper jaws were applied at right angles to the “neck” of the fold just below 
the finger and thumb over the midpoint mark.  
 While maintaining a grip on the skinfold, the observer gently released the caliper 
handles and allowed the jaws to close on the fat fold for two seconds before 
taking the reading to the last completed 0.2 mm. 
 
Triceps-  
 Along the midline on the back of the triceps of the right arm, determine the 
midpoint located between the top of the acromial process (top of the shoulder) to 
the bottom of the olecranon process of the ulna (elbow). (This midpoint has 
already been marked before measurement of mid upper arm circumference). 
 The elbow should be extended and the arm relaxed.  
 Pinch the skin so that the fold is running vertically.  
 Picked up the skinfold about 1 cm above the midpoint mark over the triceps 
muscle, with the fold running downward along the midline of the back upper arm.  
 The caliper jaws were applied at right angles to the “neck” of the fold just below 
the finger and thumb over the midpoint mark.  
 While maintaining a grip on the skinfold, the observer gently released the caliper 
handles and allowed the jaws to close on the fat fold for two seconds before 
taking the reading to the last completed 0.2 mm  
 
Subscapular‐  
 The measurement point for the subscapular skinfold located immediately below 
the inferior angle of the scapula was identified by palpating and marking the 
inferior angle of the scapula.  
 The subject stands or sits with shoulders relaxed or gently held down to prevent 
movement of the scapula.  
 The skinfold was picked up 1 cm above and medial to the subscapular mark, 
where the fold is taken on the diagonal line coming from the vertebral border to 
between 1 and 2 cm from the inferior angle of the scapulae, so that the fold ran 
diagonally down toward the left elbow.  
 The caliper was applied to the “neck” of the fold over the mark  
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Suprailiac-  
 A diagonal fold above the crest of the ilium at the spot where an imaginary line 
would come down from the anterior auxiliary line.  
 Determine the anterior auxiliary line and palpate for the iliac crest (top of the hip 
bone).  
 Grasp the skin that follows the natural fold which will follow a line of 
approximately from the suprailiac to just below the umbilicus (bellybutton), an 
angle of approximately 30 degrees.  
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MANUAL OF PROCEDURES 
Procedures for using BPro and A-PULSE CASP 
 
Aim: To derive the central aortic systolic pressure, radial augmentation index (rAI) and a 
range of other pulse wave indices from the radial pulse. 
 
Applicability:  
All ground staff involved in clinic activities of GUSTO study 
 
Location: 




1) Launching A-PULSE CASP 
Open the start menu and select All Programs. Select A-PULSE CASP and click to launch the 
program. Alternatively, you can click the shortcut on the desktop for quick access. 
 





• You must configure the COM port of the BPro USB data cable in order for A-PULSE 
CASP to communicate with the BPro. 
• You may need to reconfigure the COM port of the BPro USB data cable once you exit 
A-PULSE CASP. 
 
3) Activating BPro for use with A-PULSE CASP 
 
1. Click the start button (first button) on the A-PULSE CASP startup screen to open the 
pulse wave window.  
1. Click Settings on the A-PULSE CASP startup 
screen to open the Settings dialog box. 
2. Click the drop-down button for Com to see the 
initial port number present. 
3. Plug the USB connector of the BPro data cable 
into the USB port of the computer. Click 
Settings on the A-PULSE CASP startup screen 
to open the Settings dialog box. 
4. Click the drop-down button for Com to select 
the NEW port number that is different from the 
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2.  Press and hold the Mode/Set (MODE) and +/Std by (FORWARD) buttons (top right 
& bottom left button simultaneously) on the BPro until POS AdJ appears.  
3. The activation is now complete. Try tapping the BPro to see waveforms on the 
window. The BPro is ready to capture pulse waveforms for display by A-PULSE 
CASP.  
 
4) Taking calibration readings 
 
1.  Have the patient sit comfortably with the blood pressure cuff on the patient arm. The 
green marker of the cuff should be centered over the brachial artery on the inside of 
the arm, and the bottom edge should be about 2 to 3 cm above the elbow. 
2.  Rest the patient’s arm on the table such that the cuff is at the same level as the heart. 
3.  Ask the patient to relax for at least 10 minutes before taking the first blood pressure 
measurements. 
4. Take 3 blood pressure measurements on the same arm, with an interval of 30 to 60 
seconds between measurements, and record the systolic and diastolic readings. 
5. If any of the readings for systolic or diastolic pressure differ by more than 10 mmHg, 
take more measurements until the last 3 consecutive readings for each pressure do not 
differ from each other by more than 10 mmHg. 
6. Average the 3 readings for each pressure and use the average systolic and diastolic 
readings for calibration. 
 
5) Entering patient data (while measuring brachial pressure) 
 
1. Click Patient on the toolbar of the A-PULSE CASP startup screen to open the Patient 
dialog box. 
                                                  
 
2. Enter all the necessary data e.g. ID No. (as GUSTO study ID), date of birth, gender 
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6) Calibrating and capturing arterial pulse waveform 
 
1. Using the plunger positioning marker (white vertical line) as a guide, place the 
plunger of the BPro over the radial artery where the strongest pulse is felt. 
Note: This should be the same arm used for measuring brachial pressure earlier 
 
2. Hold the plunger in place and fasten the BPro firmly to the wrist. 
3. Once there’s a constant waveform, click Calibrate on the toolbar to open the Calibrate 
dialog box. 
                                                
 
 
7. The calibration is now in progress. 
Note: 
• Ask the patient to continue keeping his or her arm as still as possible throughout 
the whole process of calibrating and capturing the arterial pulse waveform. 
• After clicking Calibrate, the arterial pulse waveform will appear in the plot area. 
A-PULSE CASP will begin the calibration process and complete it in about 10 seconds, and 
save the waveform data on the computer.  
 
8. The calibration readings will appear in the CALIBRATION pane. The ONLINE > 
PLAY > CALIBRATED > SAVING … message will appear on the status bar to indicate that 
the waveform is being saved to the specified location. 
 
9. Calibrated readings will appear in the READINGS pane about 20 seconds later. 
 
4. Click Browse in the 
Calibrate dialog box. A 
Save As dialog box will 
appear. Save the file.  
 
5. In the Calibrate dialog 
box, enter the average 
systolic reading in the 
Systolic blood pressure 
(SBP) and the average 
diastolic reading in the 
Diastolic blood pressure 
(DBP).  
 
6. Ask the patient to keep 
his or her arm as still as 
possible, and then click 
Calibrate. 




10. Continue reading the waveform for another 40 seconds (4 rounds).  
 
11. To stop saving the data, click the stop icon. 
 
7) Managing A-PULSE CASP reports 
 
1. Click the Report icon on the toolbar of the A-PULSE CASP startup screen to open the 
average arterial pulse waveform window. 
 
2. Click Browse to open the Open dialog box. 
 
3. Click to select the correct subject’s file and click Open to open the file. A list of 
waveform blocks will appear in the Select Waveform Block window. 
 
4. Click the block of waveform you want to display. The selected block of waveform 
and an average arterial pulse waveform will be displayed in the respective plot areas. 
 




5. Click the Preview button to view the report. To print the report after previewing, click 
Print in the PRINT PREVIEW window 
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MOP for measuring Blood Pressure by Dynamap CARESCAPETM V100 
General Instruction for both Mother and Child 
 The measurement has to be done on the right side of the upper arm. 
 Have the mother/child sits quietly for a period of five minutes before the first BP is taken. 
 Ensure the subject is seated, legs uncrossed, in a quiet room, with the elbow and forearm resting 
comfortably on the armrest of the chair or table, with the palm of the hand turned upward.  
 The area to which the cuff is to be applied must be bare (free of clothing). 
 Accuracy of measurement depends on the use of appropriate cuff size (GE CRITIKON BP cuffs) (Fig 1 
and Table 1).  
Figure 1 Table 1 
 
 
 Wrap the cuff snuggly around the subject’s upper arm allowing a finger between the child’s arm and 
the cuff. Do not apply cuff to areas when skin is not intact or tissue is injured. (Figure 2) 
 The palm of the subject’s hand should turn upwards, making sure the long edges of the cuff lie on 
top of each other as the cuff is wrapped around. 
Figure 2 
 The dotted index line and the solid range line on the cuff for easier and accurate placement. (Figure 
3A and 3B) 
  





 The dotted index line needs to fall within the solid range line. If the index line goes beyond the solid 
line, use a larger cuff. If the index line stops before the solid range line, use a smaller cuff.  
 
Taking the blood pressure measurement 
 To get started turn on the monitor by pressing ON/OFF button (Figure 4). 
Figure 4 
 Apply the blood pressure cuff to the subject’s upper arm.  
 Connect the cuff to the air hose.  
 Press INFLATE/STOP button on the monitor and wait for the output (Figure 5). 
 Figure 5 
 Dynamap takes systolic and diastolic pressure, mean arterial pressure (MAP) and Pulse Rate of the 
Subject. 
 Record the measurements in the case report form (CRF) 
 Repeat the measurement second time and record in the CRF accordingly.  
 Wait 25 to 30 seconds between each measurement. 
 If either systolic or diastolic BP of the second measurement varies by more than 10mmHg, repeat 
the third measurement and record in CRF. 
 FOR THE MOTHER - If the readings are abnormal i.e. >130/80mmHg, please ask the MOTHER to rest 
for 10 minutes before taking the 3rd measurement. 
 
